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The idea of this book emerged within the discussion of the implementation and 
resources of a Europe-funded project (IManage), especially regarding the utiliza-
tion of an eHealth platform. eHealth is regarded as a fundamental resource for care 
nowadays, to the point that a growing number of scientific publications involve 
some form of web-based and/or immersive technologies devoted to improve patient 
adherence to treatment and healthy activities, patient education, and even the moni-
toring of mental health outcomes such as stress, emotions, as well as biases poten-
tially affecting health-related decision-making.
However, by analyzing the literature on these topics, we realized that eHealth 
evolution still tends mostly to the implementation and exploitation of technological 
advancement, but the consideration of behavioral, psychological, and emotional 
aspects often remains on the background. Some years ago, the first editor of this 
book proposed the concept of P5 medicine, by adding one-fifth requirement for the 
evolution of medicine to the original ones in the well-known P4 approach. This last 
P was related to psycho-cognitive characteristics of patients; specifically, besides 
being preventive, personalized, predictive, and participatory, medicine should 
become able to:
 1. Engage patients in personalized treatment as well as management plans: patients 
should become competent, active, responsible managers of their own health
 2. Analyze and improve quality of life not as a secondary but as a primary objective 
of the care process
In order to achieve such aims, medicine should turn to psychology and cognitive 
sciences in order to understand how patients interpret and use information on their 
own healthcare and also how they do develop intentions and behavior which could 
be more or less useful toward their health and wellness improvement. Also, health-
care should develop and master its own techniques and psychometric instruments to 
be included in care practices to account for these aspects.
Originally, the P5 approach as described here was not explicitly related to tech-
nology, but of course, eHealth constitutes an unprecedented opportunity to pursue 
all the five Ps within the healthcare process. In light of this concept, the present 
vi
book is aimed to give examples, guidelines, suggestions, and methods to achieve the 
development of health technologies able not only to support health management but 
also to capture and exploit the personologic uniqueness of each individual.
In the contemporary scenario, where the main challenge faced by the healthcare 
systems worldwide is not to cure a specific disease but to support the management 
of incurable, chronic conditions and to guarantee long-term care to patients and 
survivors, such approach could be crucial to ensure that health technologies will be 
used and demonstrate their utility in the long term.
In this book, each one of the 5 Ps will be explained in depth by the authors with 
a specific expertise, with a focus on how they could be achieved through the use of 
specific health technologies; secondarily, other contributions will explore important 
aspects of eHealth design, implementation, and management.
Chapter 1, written by the editors of this book, will present the P5 approach and 
link it to eHealth, along with a short resume of health technologies themselves and 
considerations about their present and future.
Chapter 2 will present the IManage project and its technologies, in order to elab-
orate on them as an example of eHealth platform that has been designed and will be 
improved exactly on the basis of the P5 approach.
Chapter 3 will explore the first P, namely, prevention: the opportunities of new 
technologies for the forecast of future diseases and health issues will be described.
Chapter 4 will explore the concept of personalized medicine and will show that 
digital media can be used by patients both to express themselves and to communi-
cate with health providers and by health providers to better comprehend patients’ 
personal experience.
Chapter 5 will be focused on computational model and approaches to analyze 
and interpret data in order to predict future state of patients and illnesses; according 
to recent studies, this could be done not only with genetic and anatomical data but 
also with psychological and behavioral information.
Chapter 6 will present and comment on examples of specific technological fea-
tures (coming from IManage technologies again and from other digital solutions) 
that could be used effectively to promote the active participation of patients to their 
own care, in order to advance toward activation and engagement.
Chapter 7 will explore the psycho-cognitive characteristics of patients, by 
remarking upon the importance of them in diagnosis and intervention; secondarily, 
persuasive technologies will be presented as one possible resource toward the 
implementation of behavioral and cognitive strategies within the technologies them-
selves, in order to promote positive behavioral change in patients.
Chapter 8 will present innovative technologies used in oncology and cancer care; 
indeed, also, diagnostic and research technologies should be taken into consider-
ation when considering health technologies.
Chapter 9 will provide a brief history of the disciplines related to technology 
evaluation (e.g., ergonomics, usability, user experience), in order to promote the 




Chapter 10 will explore ethical issues related to the adoption of different health 
technologies (e.g., privacy) and suggest ways to effectively deal with them at an 
organizational level.
In the end, the objective of the present book is to set the grounds for the further 
development of P5 as a concept able to guide the growth of medicine, as well as the 
virtuous utilization of technological tools with the aim of improving human health 
and well-being.
Milan, Italy  Gabriella Pravettoni 




Part I  Foundations for P5 eHealth
 1  A “P5” Approach to Healthcare and Health Technology  . . . . . . . . . .    3
Gabriella Pravettoni and Stefano Triberti
 2  The Development of iManageCancer: The Experience  
of a Personalised eHealth Platform for Cancer Patients’  
Empowerment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   19
Chiara Crico and Chiara Renzi
Part II  The 5 Ps and eHealth
 3  The Prevention of Chronic Diseases Through eHealth:  
A Practical Overview  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   33
Dario Monzani and Silvia Francesca Maria Pizzoli
 4  An Introduction to Personalized eHealth . . . . . . . . . . . . . . . . . . . . . . .   53
Valeria Sebri and Lucrezia Savioni
 5  Predictive Precision Medicine: Towards the Computational  
Challenge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   71
Cosimo Tuena, Michelle Semonella, Javier Fernández-Álvarez, 
Desirée Colombo, and Pietro Cipresso
 6  Participatory Aspects of ICT Infrastructures for Cancer  
Management  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   87
Haridimos Kondylakis, Lefteris Koumakis, Ketti Mazzocco,  
Manolis Tsiknakis, and Kostas Marias
 7  Psycho-cognitive Factors Orienting eHealth Development  
and Evaluation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  109
Alessandra Gorini, Enrico Gianluca Caiani, and Gabriella Pravettoni
x
Part III  Important Aspects for P5 Technologies Development  
and Utilization
 8  Role of Next-Generation Sequencing Technologies  
in Personalized Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  125
Stefania Morganti, Paolo Tarantino, Emanuela Ferraro,  
Paolo D’Amico, Giulia Viale, Dario Trapani,  
Bruno Achutti Duso, and Giuseppe Curigliano
 9  User-Centered Design Approaches and Methods for P5 eHealth . . . .  155
Stefano Triberti and Eleonora Brivio
 10  Data Protection and Ethical Issues in European P5 eHealth . . . . . . .  173




Gabriella Pravettoni, Ph.D. is Full Professor of Psychology of Decision-Making 
and Director of the Department of Oncology and Hemato-oncology (DIPO) at the 
University of Milan, Italy. She is also Director of the Applied Research Division for 
Cognitive and Psychological Science at the European Institute of Oncology (IEO) 
IRCCS and Coordinator of the doctorate course “FOLSATEC” (Foundations of the 
Life Sciences and Their Ethical Consequences) at SEMM (European School of 
Molecular Medicine), Milan, Italy. Her main research activities focus on medical 
humanities, in particular on patient empowerment and wellbeing, cognitive pro-
cesses, decisions in medicine, errors prevention, and eHealth. She has authored 
more than 260 scientific publications to date on these topics.
Stefano Triberti holds a Ph.D. in Psychology. He is a Researcher at the Department 
of Oncology and Hemato-oncology of the University of Milan, Italy, and collabo-
rates with the Applied Research Division for Cognitive and Psychological Science, 
European Institute of Oncology IRCCS, Milan, Italy. His research activities focus 
mainly on ergonomics and user experience of new technologies for medicine and 
healthcare (eHealth) and the usage of innovative resources to promote health and 
well-being. He has authored around 70 scientific publications on these topics.
Part I
Foundations for P5 eHealth
3© The Author(s) 2020 
G. Pravettoni, S. Triberti (eds.), P5 eHealth: An Agenda for the Health 
Technologies of the Future, https://doi.org/10.1007/978-3-030-27994-3_1
Chapter 1




The main challenge faced by healthcare systems worldwide is not the cure of spe-
cific diseases but the management of chronic illness emerging from diseases that are 
treatable but incurable. This scenario requires the health providers to maintain long- 
term relationship with the patient, who has to learn how to manage symptoms, orga-
nize treatment adherence (e.g., taking medications regularly), and cope with stress 
and negative emotions as well.
The literature agrees that patients themselves should not be seen as passive recip-
ients of care, but rather they should become “active” (Hibbard et al. 2007; Remmers 
et  al. 2009), “empowered” (Anderson and Funnell 2010; Pravettoni 2016; Renzi 
et al. 2017), or “engaged” (Barello et al. 2012; Graffigna et al. 2016) in their own 
care in order to recover a positive approach to everyday life issues and to the man-
agement of illness and the treatment as well.
This theoretical approach to healthcare lays its own roots in the patient-centered 
approach to medicine. Patient-centered medicine emphasizes the limitations of a 
disease-centered approach to medicine, namely, the idea according to which health 
practitioners should focus their activity on the recognition and treatment of the 
symptoms only. On the contrary, patient-centered medicine attributes importance to 
the recognition and appreciation of patients’ values, desires, expectations, personal 
objectives, and lived experience in general.
On this basis, patients deserve to be made active participants in the decisions 
related to their own care plan. Historically, patient-centered medicine emerged dur-
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ing the second half of the 1900s (Balint et al. 1970); Levenstein (1984) elaborated 
some of the most important theoretical principles of the approach, namely, the belief 
that both physician’s and patient’s agendas should be recognized and integrated in 
medical care. Specifically, the patient’s agenda could be described in terms of three 
main domains:
 1. The cognitive sphere or the patient’s ideas about his/her own condition and the 
“folk models” about health and illness.
 2. The emotional sphere or patient’s feeling, emotions, and affective reactions to 
illness and care.
 3. The expectation sphere or patients’ objectives and desires about the processes 
and the outcomes of care.
Today, patient-centered medicine is worldwide recognized as a fundamental com-
ponent of the healthcare system or better as the correct, desirable, and more ethical 
approach to healthcare; however, there is still uncertainty around the actual meaning 
of “patient centeredness” for health practitioners, patients, and health organizations 
(Bardes 2012; Hanyok et al. 2012; Miller et al. 2015). According to Liberati and 
colleagues (Liberati et al. 2015), a review of patient-centered interventions high-
lights at least two main approaches, namely, the dyadic and the organizational ones.
The dyadic approach to patient-centered medicine includes those interventions 
focused on strengthening and empowering patient-doctor communication or in 
other words those interventions that focus on individual experience of illness, ther-
apy administration, and treatment management, for example, basing on a “narrative 
medicine” approach (Fioretti et al. 2016). Dyadic studies are usually centered on 
clinical encounters and individual interactions/communications; they explore inno-
vative ways of creating a positive alliance between the patient and the health pro-
vider, and they report outcomes showing how the interventions influence (or not) 
therapy effectiveness and well-being outcomes.
On the other hand, organizational interventions move the focus of inquiry from 
clinical encounters to the overall healthcare context; in other words, they intervene 
at the level of procedures, practices, policies, organizational boundaries, and roles 
and the communication of the medical offer in order to improve patient centered-
ness at the level of organizations and their services.
Both these approaches have specular strengths and limitations. Dyadic patient- 
centered approaches may fail to recognize organizational factors that influence 
patients’ well-being and/or effectiveness of illness management independently of 
the quality of the communication with the health provider (e.g., complex time 
schedules in the care facility), and also they do not consider additional important 
figures (e.g., caregivers); on the other hand, organizational patient-centered 
approaches do not address how practitioners carry out care in their local context nor 
do they capture what patients perceive as actually significant along their care path.
On this basis, it appears evident that a mature approach to patient-centered medi-
cine should encompass both dyadic and organizational aspects; probably, this could 
be done by adopting a different stance, not focused on the specific type of interven-
tion but rather on general features healthcare interventions should have in order to 
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promote patient centeredness. The P5 approach to medicine does exactly that and 
will guide the contributions featured in this book.
2  P5 Medicine
The approach to medicine that is taken as a main guideline for theory and practice 
in the present book lies its roots in the evolution of medicine as a scientific activity. 
Professor Leeroy Hood, a pioneer in systems biology, theorized that modern medi-
cine was evolving from P0 to P4 medicine (Hood and Galas 2008; Hood 2009, 
2013); from a biological point of view, P0 medicine or the traditional approach was 
focused on individual analysis of “one cell or one protein,” while the availability of 
technology-conveyed data around diseases and patients allows researchers and 
health providers to adopt a systems, holistic approach to diagnosis and treatment. 
Hood thought that future medicine would become more and more predictive, per-
sonalized, preventive, and participatory. Already in Hood’s writings, but also in sub-
sequent studies on the topic, these concepts transcended systems biology to embrace 
multiple disciplines and approaches involved in promoting healthcare (Cesario et al. 
2014; Pulciani et al. 2017).
The preventive (cfr. Chap. 3) property of medicine refers to its ability to proac-
tively (not only reactively) address diseases. According to Hood, by knowing the 
molecular picture of the patient and by using a systemic approach to its condition, 
it is possible to anticipate diseases as well as relapses or other modifications to over-
all health status. In the P5 approach, such characteristic extends to environmental, 
social, and psychological aspects of patients’ experience; indeed, not only biologi-
cal events can be anticipated but also changes in environment or psychological sta-
tus (e.g., onset of depression, emotional reactions to the diagnosis, etc.), so to 
project therapy interventions that address pathology and issues before they actually 
manifest themselves.
Personalized medicine (cfr. Chap. 4) was originally proposed in the field of 
genetics, in the sense that by the application of nanogenomics and nanoproteomics, 
it is possible to tailor medical interventions to the specific molecular picture of the 
individual (Eisen et al. 1998; Nicolini et al. 2012); also this concept has evolved 
toward a consideration of the patient as a whole, so that “tailoring interventions” on 
people means designing them by taking into considerations patients’ abilities, con-
texts, needs, and decision-making priorities (Cutica et al. 2014; Renzi et al. 2016).
Medicine should become more and more predictive (cfr. Chap. 5) which means 
it will employ the information arising from genome sequences and longitudinal 
molecular, cellular, and phenotypic measurements to provide baseline values that 
can be defined as health/wellness and then used to identify subsequent transitions to 
disease. Consistently with its original formulation in terms of systems biology, it 
should be highlighted that predictive medicine is necessarily evidence-based 
(Domenighetti et al. 1998; Hood and Flores 2012), and it is typically characterized 
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by the usage of equations, formulas, and models to elaborate multiple variables in 
order to approximately describe future health-relevant events.
Medicine is participatory (cfr. Chap. 6) in that it does not operate in a social 
vacuum. Despite this, traditional medicine was perceived as an activity abstracted 
from the everyday social life of the patient, such as patient, doctor, and the disease 
interacted among themselves only (Gorini and Pravettoni 2011; Kabat-Zinn 2000). 
On the contrary, the process of care involves a number of additional stakeholders 
and influencers, such as caregivers, other patients, and different types of health pro-
viders (Gorini et al. 2018). This aspect of health should not only be made explicit 
but exploited, in that an effective alliance between the multiple actors of the care 
process is expected to strengthen its effectiveness.
As explained above, the 4 Ps in Leeroy Hood’s model emerged from a concep-
tion rooted in systems biology and were then extended to social and ethical aspects. 
Doing so, the original model could not ignore another aspect which very much 
deserves to be included among its main pillars as well.
On this basis, recently Pravettoni and Gorini (Gorini and Pravettoni 2011; 
Pravettoni and Gorini 2011) proposed to add a fifth P to the model, namely, the 
psychocognitive one. Psychocognitive medicine (cfr. Chap. 7) emphasizes that the 
patient, considered as a person and not only as a recipient of care, is characterized 
by emotions, attitudes, and cognitive processes which have specific relations with 
his/her own care process. By embracing the fifth P, this approach has a conception 
of value in healthcare that goes beyond the evidence-based medicine approach 
(Marzorati and Pravettoni 2017; Riva and Pravettoni 2016); while evidence-based 
medicine is regarded as the results of clinical trials to identify the most desirable 
medical procedures and interventions, P5 considers the impact on quality of life as 
an additional fundamental marker of effectiveness.
Moreover, the fifth P has important methodological consequences for healthcare: 
future medicine should be able to design a psychological and cognitive profile of the 
patient, instead of a mere diagnostic classification; in this sense, P5 medicine leads 
to an assessment with psychometric tools that include cognitive, decision-making, 
and mental aspects, as well as clinical ones.
Specifically, to sum up, the fifth P proposes some activities to be considered 
fundamental in healthcare interventions (Pravettoni and Gorini 2011):
• Development and testing of new psychometric instruments, devoted to provide a 
complete medical profile of the patient.
• Promotion of the active patient’s decision-making about therapy and healthcare 
process as a whole.
• The right for the patient to develop an empathic relationship with the physician.
• Assessment of quality of life and its inclusion among the criteria necessary to 
perform evaluation of clinical procedures and practices (value-based medicine).
For the sake of completeness, we could report that also a sixth P was proposed in 
the literature, namely, public; Bragazzi (2013) analyzed the famous case of 
Salvatore Iaconesi, a patient diagnosed with cancer who made his medical records 
available on the Internet and social media, inviting “everyone” to find a cure for his 
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disease (not only in medical but also in emotional and spiritual terms). This case is 
interesting in that, according to Bragazzi, it shows how healthcare is evolving from 
a private and dyadic, paternalistic relationship between patient and physician to a 
public issue that extends the therapeutic alliance to multiple actors within the social 
context.
Anyway, this highlights again the importance of considering the patient as a 
whole person, not only a passive recipient of medical care but an active individual 
looking for meaning and personal actualization. Although some aspects of human 
experience (e.g., happiness, self-fulfillment, spirituality) should probably not be 
considered objectives of medicine, healthcare providers should take into account 
that patients with a chronic disease are not only combating a physical illness but 
also they are engaged in a personal journey whose final objective is the pursuit of 
happiness and fulfillment besides or independently of the presence of a chronic 
health condition.
Starting from these premises, healthcare providers of the future should be able to 
design, develop, and implement care projects and tools that, as first, do not prevent 
people to chase their own personal objectives but also, when possible, include affor-
dances and opportunities to actively pursue them. New technologies could be a 
resource for such aims.
3  eHealth
In 2001, eHealth has been defined by Eysenbach (2001), who explained that the 
delivery of information to patients and stakeholders could be enriched by the inter-
section of medical informatics and public health business. On the other hand, he 
pointed out that not only a technical development is involved in the emergence of 
eHealth but also a new state of mind marked by a global-thinking attitude and by the 
intention to improve healthcare locally, regionally, and worldwide. In general, 
eHealth should be distinguished by medical informatics or the inclusion of com-
puter and software in medical treatments and management, in order to improve care 
effectiveness: this discipline is way more “ancient” than eHealth; according to 
Mihalas and colleagues (2014), the history of medical informatics can be traced 
back before the 1970s, with pioneer work on signal analysis, modeling and simula-
tion of biological processes, and the first attempts to develop decision support sys-
tems. It is around the 1980s that medical informatics acquired international 
recognition by means of funding, the development and sharing of methodologies, 
and the foundation of specialization schools. However, at the same time of the next 
generation in technology development, a first distinction is made between the use of 
computers for healthcare (to elaborate and process health-related information) to 
the communication features of technologies: this is the rise of “telehealth” and tele-
medicine” as concepts more focused on technological properties able to overcome 
boundaries and distances, this way promoting and strengthening communication 
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between health providers and patients (Krol 1997; Palazzini 2007; Rubel et  al. 
2004; Wade et al. 2010).
In this context, eHealth should be considered another third evolution of the con-
cept; according to Della Mea’s editorial (Della Mea 2001), it could be considered 
the “death” of both medical informatics and telemedicine, in the sense that it encom-
passes them but also goes further and is more inclusive. Specifically, according to 
other opinions (Allen 2000; Rosen 2000), the focus of telemedicine was on hard-
ware properties, while eHealth has a broader interest in how services are delivered; 
similarly, the “actors” of eHealth are the patients or better the health consumers, and 
not only the physicians or health providers. Reviews on eHealth definitions (Oh 
et al. 2005; Pagliari et al. 2005) highlighted that common aspects of different con-
ceptions of eHealth still emphasize the usage of technologies for promoting health-
care, not only in terms of strictly clinical outcomes but also well-being and quality 
of life.
But what technologies should be considered typical of eHealth interventions? 
Actually, this question is not so easy to respond to; as what previously happened to 
other fields (such as “commerce”), the addition of “e” (electronic) referred to the 
use of the Internet and highlighted the new ways of performing activities, thanks to 
connection features represented by the web. This is certainly true for eHealth too, 
but some authors (Gorini et al. 2008; Riva 2000) also include in eHealth experiential 
technologies which are not connected to the Internet, such as Virtual Reality for the 
simulation and training of healthy behaviors and lifestyles. Conversely, others con-
sider advanced “technical” technologies (i.e., for the analysis of clinical data and for 
supporting diagnosis, such as big data applications) examples of innovative eHealth 
applications (Luo et al. 2016).
According to a number of systematic reviews in the field (Barello et al. 2016; 
Black et al. 2011; Elbert et al. 2014), these appear to be the most frequent technolo-
gies used in eHealth interventions:
• Informational websites, that is, patients are given access to web resources that 
are either created or monitored by health providers, to guarantee reliable health 
information and promote health literacy.
• Telecommunication technologies, ranging from telephone to social media fea-
tures, in order to improve communication between patients and the health 
providers.
• Web platforms and “ePrescribing,” bespoke web resources that include ser-
vices for monitoring, signaling, and supporting treatment administration and 
adherence on patients’ side.
• Wearable technologies and mobile technology (mHealth), any use of portable 
technologies to monitor patients’ health status over time and/or sending daily 
reminders to take medications or to perform health-related activities.
• Online support groups, social media for peer support and peer education 
(Gorini et al. 2018).
G. Pravettoni and S. Triberti
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• Decision support systems, algorithm-based dedicated software that helps the 
physician and/or the patient to make decisions about the care path, by making 
explicit the possible choices and their consequences.
Other technologies appear considerably less often in eHealth literature but could 
be considered evolved tools, especially because they are based on more complex 
conceptions of technology’s potential influence on users’ everyday life and personal 
abilities. The design, development, and implementation of these technologies are 
often more expensive and require specific competences (Gorini et al. 2008; Riva 
2000; Riva et al. 2006; Rizzo and Kim 2005; Triberti and Barello 2016; Triberti and 
Chirico 2016; Triberti et al. 2019):
• Ambient Intelligence (AmI), which is an umbrella term identifying computers 
embedded in users’ environment (e.g., the home) supporting everyday activities 
and health monitoring.
• Video Games and Serious Games, which proved to be effective both as training 
of abilities and health education and coping or stress/emotion management.
• (Immersive) Virtual Reality, usually for rehabilitation or relaxation purposes
• Virtual Worlds, internet-based two-dimensional or tridimensional virtual envi-
ronments (that can be accessed by personal computer or mobile devices), 
explored by multiple users at a time, thanks to the use of digital avatars, includ-
ing opportunities both for communication/peer support and for training/health 
education.
• Robotics, the employment of more-or-less humanlike robots to help patients, for 
example, assists them in life tasks when at home.
Consistently, Moen and colleagues (2013), who conducted surveys among 
national member associations of the European Federation of Medical Informatics 
(EFMI), classify eHealth services in three main categories:
• Technical and social eHealth infrastructures, namely, services for secure, 
seamless transmission of health information between home care/primary care, 
hospitals, and GPs and between public and private health.
• eHealth repositories, services that allow patients and health providers to 
securely access information and resources for coordination and 
self-management,
• eHealth applications (cfr. Chap. 4), specific services permitting communication 
between patients and health professionals.
A critical approach to the eHealth phenomenon requires recognizing its poten-
tials but also its shortcomings; the next sections will explore the eHealth scenario in 
detail, in order to explain which aspects of healthcare technologies should be 
exploited or avoided in future implementations.
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3.1  Strengths of eHealth
A number of studies explored positive aspects of eHealth, especially its effective-
ness in improving physical (Norman et  al. 2007; van den Berg et  al. 2007) and 
psychological (Eland-de Kok et al. 2011) health outcomes.
Another fundamental aspect is related to cost-effectiveness or, better, the ability 
of eHealth interventions to reduce overall costs of managing disease and treatment 
in specific cases. Although methodological problems exist and there is always a 
quote of uncertainty in such evaluations (Bergmo 2015), data coming from simula-
tions suggest that eHealth is able to sensibly reduce costs on healthcare systems (cfr. 
Chap. 4) (Smit et al. 2011; Stroetmann et al. 2006).
Additionally, it is well known that one of the main strengths of eHealth (and of 
telemedicine already) is its ability to overcome distances and periods of time (Drury 
2005; Ray et al. 2015); for example, communication technologies for healthcare may 
be useful to reach patients living in rural areas and/or patients who, due to symptoms 
of their conditions or limited availability of caregivers, experience significant diffi-
culties to move around places and so to reach medical facilities or other locations that 
are important for treatment adherence (e.g., rehabilitation, pharmacy, etc.).
For the same reason, eHealth and telemedicine permit “democratization” of 
patient-doctor communication and healthcare in general (Brandt et al. 2018; Brown 
et al. 2015), in that some health services could be made more accessible for every-
one, more or less independently of the availability for the patient of economic 
resources.
eHealth is demonstrated to have a strong relation with engagement, on the one 
hand with user engagement, that is, patients are more likely to use technologies 
when these are designed to be pleasant, involving, or even funny (Craig Lefebvre 
et al. 2010; Graffigna et al. 2014); an example of this is the utilization of gamifica-
tion or the inclusion of features typical of games and video games in health-related 
technological interfaces (McCallum 2012; Sardi et al. 2017); for instance, patients 
are invited to report their adherence behaviors such as their game achievements and 
the positive feedback and prizes they received.
On the other hand, eHealth has proven to promote patient engagement (Ahern 
et al. 2008; Barello et al. 2016), which is, as written above, patients’ commitment to 
their own healthcare journey and ability to manage life commitments (e.g., work) 
despite illness (Riva et al. 2015). This is also related to the possibility for technol-
ogy to promote knowledge/literacy and empower decision-making (Kondylakis 
et al. 2012, 2013; Norman and Skinner 2006; Wozney et al. 2017); indeed, informa-
tion on health, therapy, and disease are made more accessible and easy to under-
stand, and decisions to be taken may be represented and explained in the context of 
technology-enhanced decision support systems.
Finally, eHealth could provide opportunities to structure the participation to 
healthcare of multiple actors, not only patients and physicians but also caregivers, 
stakeholders, and multiple types of health providers; indeed, in the context of social 
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media platforms, any figure important for patient’s health and wellness could be his/
her own profile and online presence, in order to actively and positively participate in 
the care process.
3.2  Criticalities of eHealth and Emerging Challenges
When considering eHealth, it is important to recognize also the shortcomings 
appearing in a number of technology implementation in healthcare and its possible 
risks and limitations.
One recent review (Granja et al. 2018) explored the factors determining success 
or failure of eHealth interventions: their results focused on category costs, specifi-
cally the authors highlighted that, from an organizational point of view, eHealth 
could enhance workload for healthcare professionals and cause workflow disrup-
tion, as well as complexify role definition and undermine face-to-face 
communication.
As abovementioned, eHealth is expected to reduce costs, but additional costs 
may develop regarding the technology design, maintenance, or possible redesign 
after negative results emerging from evaluation (Chaudhry et al. 2006). Consistently, 
the implementation of eHealth may require health providers to include additional, 
specific competences to make it work in the long run (e.g., technical assistance).
Moreover, although generally eHealth has potentialities in terms of user engage-
ment, it should be recognized that patients and users in general may not have a posi-
tive attitude towards it (Currie et al. 2015; Légaré et al. 2010); technology acceptance 
is an important issue in this field, in that people may not be prone to actually use it, 
or sometimes they could even refuse to. Such behavior can be related to various 
forms of digital divide (Voelker 2001), for example, patients do not have (or think 
they have not) basic knowledge and competences in technology usage. It can also 
happen that users have an initial positive attitude towards technology, but they cease 
to use it after a given period of time; that is the reason why technology acceptance 
and technology adoption should be considered two separate issues, the last one per-
taining to long-term usage and adherence to the system (Triberti et al. 2018). For this 
reason, the design of eHealth, and especially of its interfaces (i.e., the part of the 
technology which is in direct contact with the user), should be conducted giving high 
importance to usability and user experience, to the point that the gold standard for 
eHealth design is found by many authors in user-centered design (UCD) techniques 
cf. chapter 9 (Holzinger et al. 2009; Triberti and Barello 2016; Vorderstrasse et al. 
2016). UCD refers to any design process where final users have an important influ-
ence on how the design itself takes place (Garrett 2010; Lowdermilk 2013); usually, 
this means employing qualitative research methods to analyze users’ behavior, 
needs, and context to inform design and not only as a guide for evaluation, as it is 
done in the traditional usable approach. UCD may be costly as a first phase of an 
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intervention, and also designers/engineers should be inclined to base their own work 
on the research data; however, when correctly applied, this approach could effec-
tively eliminate usage issues that typically intervene at later stages of the interven-
tion process.
Other important criticalities to consider in eHealth are related to privacy, in that 
various kinds of patients’ data should be adequately preserved and protected, and 
ethics, because eHealth implementation should not become an excuse for physi-
cians to “transfer” clinical care from themselves to software and machines; such an 
automatization of the healthcare process could be partly achieved, thanks to eHealth 
technologies, but could not be an objective for a patient-centered, P5-informed 
approach to patients and their illnesses.
4  Conclusion
This contribution briefly presented the P5 approach to medicine as an innovative 
perspective on how future medicine should evolve; numerous factors in patients’ 
healthcare journey still have to mature in order to reach their full potentialities in 
terms of preventive, personalized, predictive, participatory, and psychocognitive 
properties. Taking this aim into consideration, we then proceeded to explore the 
concept of eHealth and its various incarnations in contemporary scientific literature; 
it has been shown how technologies for healthcare still hold tremendous potentiali-
ties to renovate the healthcare scenario globally, but also challenges and criticalities 
get in the way of progress.
For this reason, the subsequent contributions in the present book will explore a 
range of solutions to eHealth implementations issues, in order to give hints about 
the evolution of healthcare in general.
Five chapters will explore the 5 Ps one by one, focusing on guidelines for their 
implementations within technologies devoted to enhance the healthcare process; 
secondarily, other chapters will address specific issues such as the use for innovative 
technological resources for diagnosis, or common ethical dilemmas related to 
eHealth implementations.
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According to Fleming and colleagues (Fleming et  al. 2016), the traditional ran-
domised clinical trial approach may be problematic for the testing of eHealth inter-
ventions due to the speed of technology change. They state that alternative models of 
rapid development and iterative testing should be considered (cfr. Chap. 9), for exam-
ple, using AGILE software design principles, such as the lean start-up method (Nobel 
2011) or scrum (Schwaber and Beedle 2002). In AGILE development processes, the 
product is tested with users from the outset using rapid development and testing feed-
back loops. An important component involves the development of a minimal viable 
product (MVP). A MVP is a barely finished product that contains an essential ele-
ment, with missing details, and is provided to end-users to gage their reactions and 
inform the next steps in development. Reponses to the product are measured and used 
to inform next steps that are rapidly developed and tested in the same way. This itera-
tive process involves close collaboration between designers, software developers, 
and end-users. Larger-scale testing gradually replaces small opportunistic samples as 
progressively more complex features are tested. When a near-finished version is 
ready, more traditional testing can be carried out, for example, via a randomised 
controlled trial. As described by Mohr et al. (1994), Internet interventions can utilise 
approaches that focus on evaluating the working mechanisms, rather than a locked-
down version of the intervention. Such a framework allows for improvements in 
functionality to be made during a trial, subsequently resulting in a more generalisable 
and durable intervention (Favrod and Khazaal 2018).
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In accordance with this approach, the iManageCancer platform has been tested 
already by 19 of end-users as a result of the previous works of the project. Following 
the feedbacks received, the platform went through major updates and improve-
ments, to get the platform ready for clinical context and to better assess its efficacy 
(Kondylakis et al. 2017).
2  The IManageCancer Platform
The iManageCancer platform is a set of interconnected health apps and games 
intended to empower patients with cancer and to support them in the management 
of their disease. Figure 2.1 illustrates the overall structure of the iManageCancer 
platform to be tested in the pilot. The platform comprises three apps and a serious 
game for adult cancer patients (see Fig. 2.1). Basic characteristics of these apps are 
shown in Fig. 2.2 followed by an explanation of the intended purpose of these apps. 
All apps operate on a common backbone of the platform that contains the data store 
with the patients’ personal health records, the security and access control services, 
Fig. 2.1 High-level architecture of initial iManageCancer platform prototype. The applications 
shown with a blue background will be provided to the subjects of this pilot
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and also a central decision support framework. The latter provides for this pilot 
information services for patients for the management of side effects of cancer thera-
pies such as pain and fatigue.
The following sections briefly present each of the applications and the game with 
their intended purpose and their main characteristics.
2.1  My HealthAvatar for iManageCancer
MyHealthAvatar for iManageCancer is a solution to support patients with prostate 
cancer and breast cancer to optimise their lifestyle and to recover from cancer treat-
ment. The app offers access, collection, and sharing of long-term and consistent 
Fig. 2.2 Overview about the different end-user applications of the iManageCancer platform that 
will be used in this clinical investigation
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personal health status data through an integrated digital representation, which helps 
deliver prostate cancer patient empowerment, risk prediction, prevention, clinical 
analysis, and treatment tailored to individual citizens.
A comprehensive set of suite functions let the user manage his/her weight, diet, 
activity, sleep, and emotions. A specific exercise suite offers four different exercises 
for the patient to support recovery from prostatectomy or breast surgery (mastec-
tomy or quadrantectomy). And in the man’s version, a Questionnaire Suite collects 
the patient’s PSA information after surgery in order to let the doctor monitor the 
PSA changes for the patient. The patient can create alarms in the Medication Suite 
to remind him/her the appointments with the physician or to take a drug. A calendar 
feature allows him/her to easily schedule such events. A journal provides cancer-
related health tips and selected health information. A pain and emotion monitor is 
used to collect the patient’s mood and emotion information. The questionnaire of 
mood and emotion appears three times a day in the journal page. The patient can 
also set lifestyle-related goals, including weight monitoring, diet, or physical activ-
ity. A daily summary displays the daily/weekly/monthly results of the measured 
values comparing to the goals and reminders that help the patient to achieve his/her 
goals. The patient can also enable location tracking and check the daily location and 
tracking path in the app. Patient can annotate the places he/she visited which will be 
synchronized to the server. Furthermore, the patient can edit his/her health profile 
and share this information with other users of the app if he/she wants. And in the 
man's version, A Questionnaire Suite collects the patient’s PSA information after 
surgery in order to let the doctor monitor the PSA changes for the patient.
2.2  iManageMyHealth
iManageMyHealth is a multipurpose informative app intended for citizens and 
patients for general health management. It supports users (1) in managing their 
drugs and drug intakes, also by providing a reminder system to facilitate adherence 
to treatment; (2) in providing information on drugs and their interactions; (3) in 
managing and understanding their paper-based health documents; and (4) in record-
ing and overviewing specific vital signs and laboratory parameters.
Further, the app also provides specific management services in the context of 
cancer, as for the record of felt level of pain and the link to public information 
resources. The app as a whole is not intended for diagnosis and therapy but just as a 
supportive electronic solution for information provision and management of medi-
cal information.The following functionality is offered for the management of drugs:
• Add a new drug to the medication plan. When patients start to enter the medica-
tion name, an autocomplete feature proposes drugs with the help of one of the 
two external drug information services. The user is encouraged to take pictures 
of the drug package and the drug itself. Furthermore, he can specify drug intake 
times. The system reminds him with a message to take the drug. There is also 
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space for personal comments to the drugs. Information on a new drug in the 
medication plan is also sent to the iPHR (see description below).
• The new drug is checked for potential interactions with other drugs in the medi-
cation plan (if the drugs are known to the external drug information service). 
Warning symbols are shown in the medication plan, and drug-drug interaction 
information is presented when the user touches the warning symbol. This feature 
is only offered in the German and English version of the app, as it relies on exter-
nal national drug information services and their capabilities.
• Delete a drug from the medication plan. All information related to the drug is 
deleted from the system, and the patient is asked about its effectiveness. This 
information is also sent to iPHR.
• More information about a drug is shown by forwarding the user to the webpage 
https://www.drugs.com/ containing structured information about the drug (in 
English language only).
• This component leverages the Canadian Internet-based drug information service 
DrugBank of OMx Personal Health Analytics Inc. to select drugs from a list, to 
present information on drugs, and to check contraindications. The Canadian 
DrugBank does not only contain approved drugs for the US and Canadian mar-
ket but also includes drugs registered at EMA for the European market. However, 
as brand names of the different drugs may differ in Italy, the Italian drug infor-
mation tables “Lista farmaci di classe A e H per consentire a tutti gli Operatori la 
prescrizione per principio attivo” published on http://www.aifa.gov.it/content/
dati-sulle-liste-dei-farmaci-open-data is used in the Italian version of the app 
instead. In order to counterbalance the risk of patients self-adjusting drug intakes, 
the app contains a disclaimer which specifies that the app does not constitute or 
substitute a medical consultation and that changes to the medication plan should 
always be discussed with the treating physician(s).
The following functionality is offered for managing health documents:
The app offers the user to scan paper-based health documents and to store them 
in the Android device and to annotate them. Scanning is done with the camera, and 
a document is assembled as a set of images. The user can go through a document 
page by page and can zoom in and out in a page. He can mark a section with a key-
word and search with this marked text in Wikipedia or in the Personal Health 
Information Recommender. Results are presented to the user.
The following functionality is offered for monitoring vital signs and lab 
parameters:
• The patient can enter results of blood pressure readings, his weight, and his body 
temperatures. The values are presented in charts.
• The patient can enter lab results of the blood parameters PSA, leucocytes, and 
neutrophils.
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2.3  iManageCancer Portal iPHR
The iPHR enables an individual to own and manage a complete, secure, digital copy 
of his/her health and wellness information. It integrates health information across 
sites of care and over time. The system is essentially an inversion of the current 
approach to medical records, in that the record resides with the patients and the 
patients grant permissions to institutions, clinicians, researchers, and other users of 
medical information. iPHR is a distributed, web-based, personally controlled elec-
tronic medical record system that is ubiquitously accessible to the nomadic user, 
built to public standards.
The iPHR is composed of many applications including:
• eDiary – Calendar: A timeline view of all available information showing medica-
tions, problems, appointments, and procedures.
• Demographics: View and update patient information such as gender, date of 
birth, contact information, name, and surname.
• Labs: View and update laboratory result values.
• Problems: View and update diseases, illnesses, injuries, and physiologic, mental, 
or psychological condition or disorders.
• Procedures: View and update medical treatments or operations of the patient.
• Allergies: View and update abnormal reactions to encountered allergens.
• Medications: View and update drugs or other substances received.
• Measurements: View and update vital signs that indicate the status of the body’s 
vital functions.
• Contact: A form to communicate with other users of the system.
• Appointments: View and update appointments between the patient and doctors.
• Upload Documents: Upload your health data documents.
• Psychoemotional and health assessment tools.
• Personal Health Information Recommender: Allow patients to search in a high- 
quality document repository for useful information.
2.4  Game for Adults
The aim of the serious game is to promote self-efficacy, i.e. the belief of the patients 
to be able to manage and face their disease, also to help the patient deal with the 
psychological dimension of their disease, and to promote a healthier lifestyle and 
disease management. The serious game for adults puts the user in the role of an 
authority figure who manages a small town where they help residents with their 
cancer-related lifestyle problems. The user is invited to think critically and strategi-
cally in order to balance their resources and time, while also viewing the issues 
surrounding their cancer from a different perspective. The game is intended to pro-
mote the concept that a good management of a person’s cancer disease is possible, 
together with the achievement of a sense of wellbeing.
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The serious game’s implementation is a full 3D simulation utilising the unity 3D 
platform and running on Android mobile devices. The game world itself is a colour-
ful and stylised representation of a town, providing an environment for the user’s 
avatar to exist and interact with town services and other characters. The game pro-
vides an easy-to-use social interface to allow users to make and manage friends. The 
serious game also links into the iMC back end services in order to leverage a user’s 
personal activity as an in-game resource. Users can also customise their avatar’s 
appearance and clothing using the simple character builder and in-game item store. 
The game avoids making recommendations about the user’s real cancer disease; 
instead, the game attempts to provide generalised knowledge related to health and 
lifestyle through the trivia mini-game and the instructions given to the simulated 
cancer patient (not the user) by the in-game doctor.
3  iManageCancer Within the p5 Approach
The iManageCancer project is a good example of how an eHealth intervention can 
be integrated with the properties of the P5 medicine towards the improvement of 
patient empowerment and quality of life: the following paragraphs will give an 
overview on how eHealth-based projects can lead medical practice towards a pre-
ventive, personalised, predictive, participatory, and psychocognitive approach 
(Pravettoni and Gorini 2011).
The multiple monitoring functions of the iManageCancer platform act as a pre-
ventive, according to its definition as the ability to proactively address diseases. 
Some of the apps are meant to give patients and clinicians the possibility to achieve 
a complete medical profile of patients and easily monitor their quality of life, by 
assessing both psychological and physical condition. In the iPHR, patients are pro-
vided with a set of three questionnaires to assess psychological wellbeing by mea-
suring factors that play an important role in the care path. The questionnaires are 
ALGA, developed to assess physical and mental characteristics of cancer patients 
(Gorini et al. 2015); a psychoemotional monitoring tool; and FaRe, a questionnaire 
to assess the family resilience (Faccio et al. 2018). Moreover, the MyHealthAvatar 
(Zhang et al. 2018) is an activity tracker and a lifestyle monitoring app: it keeps 
track of sleep, weight, diet, sedentary lifestyle, and motor activities. The app pro-
motes a good lifestyle and encourages healthy habits by helping patients manage 
their activities; it also monitors psychological status by proving a journal and a 
mood state to be updated every day from patients. In addition, the three question-
naires give an insight about the psychological status of patients and monitor poten-
tial changes in their mental wellbeing. Thanks to all these features, the platform that 
provides health professionals – both physicians and psychologists – with real-time 
data allows capturing any situation at risk and intervening in advance in order to 
address potential pathologies and provide patients with the necessary medical or 
psychological support.
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As we have seen in the detailed description of the apps, many of their internal 
functions have been conceived as containers in which patients can insert all the 
specific information of their personal state: from the average information, such as 
values and findings, to the details of their lifestyle and habits and from the emo-
tional and psychological status to their decision preferences. All the contents in this 
virtual database create a personalised profile of the patient, which can be used as a 
basis for a tailored intervention. For instance, the iPHR provides the psychological 
questionnaires to assess not only physical but also mental health degeneration and 
social alienation and to provide personalised information for coping strategies. 
Even the iManageMyHealth app is totally customisable, helping patients manage 
the variety of their drugs, prescribed by different factors for different clinical condi-
tions and comorbidities. It acts as a container for all medical reports and prescrip-
tions, and patients can insert the drugs they are taking, including time and mode of 
intake. This app is programmed to give back personalised information as output, 
including potential integrations among drugs and predictable side effects related to 
their clinical condition. A comprehensive consideration of all this aspects, which go 
beyond the mere biological information, points towards a more personalised medi-
cine (Cutica et al. 2014; Renzi et al. 2016), as described in the P5 model. Also, the 
application contains specific features, such as the digital avatar to represent the user 
and his/her own health state, which could be important for personalisation in terms 
of self-expression (cfr. Chap. 4).
Putting together the advances of systems biology in the diagnostic field with the 
potential of the technological tools available today opens up new scenarios and 
increasingly important challenges for eHealth to predict the onset of pathological 
events. Considering that the exploitation of ICT in all its forms is, in this field, a 
recent development, one of the objectives of iManageCancer has been (Kim et al. 
2018) to develop and incorporate in the platform predictive models for the early 
detection of severe adverse reaction to chemotherapy, in order to increase patients 
safety and wellbeing.
The general aim of the iManageCancer project is to empower patients by giving 
them tools to gain a more active role in their therapeutic path. Not only patients and 
clinicians are called to participate in the process of healthcare, but also patients’ 
family and caregivers play an important role. This is even more true in the case of 
oncological diseases, which have repercussions and consequences not only on the 
patient but also on people close to him or her (Mohr et  al. 1994; Pitceathly and 
Maguire 2003; Woźniak and Iżycki 2014). Within the iManageCancer platform, the 
serious game is the app that more effectively promote social wellbeing. Serious 
games are meant to support the patient in reducing stress, anxiety, and related nega-
tive impact of the disease on their lives and social relations and thus to contribute to 
keep a positive attitude towards the disease and life (Kelley et al. 2017; Sardi et al. 
2017). In addition, family resilience is an important factor in the oncological thera-
peutic path, which is why family members are encouraged to answer the FaRe ques-
tionnaire (available on the iPHR), allowing the healthcare professionals to capture 
any uneasy situations and intervene. The iManageCancer platform mostly encour-
ages a more direct involvement from the patient but also involves families and 
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 caregivers, thus promoting an effective alliance among all the actors of the thera-
peutic path, according to the P5 participatory property (Gorini and Pravettoni 2011; 
Kabat-Zinn 2000).
The iManageCancer project perfectly matches the psychocognitive approach 
suggested by Pravettoni and Gorini (Gorini and Pravettoni 2011; Pravettoni and 
Gorini 2011); its objective is the patient’s empowerment, starting from the belief 
that patient empowerment in medical care is only possible if based on a multi-level 
consideration of patients. As a matter of fact, the platform itself promotes a broad 
consideration of patient health: every feature of the platform has been designed to 
meet all the need of patients in managing their health as persons and therefore as a 
set of complex biological systems but also as a subject of emotions, fears, hopes, 
and needs, who has relationships and lives in a social context. In some cases, the 
idea behind an application has been to support an all-inclusive wellbeing of patients, 
with a specific focus on the psychological aspects.
Above all the apps, the serious game aims at helping patients to manage the psy-
chological impact of the diagnosis and consequent treatment. Serious games have 
been proposed as a strategy to encourage healthy habits and the participation in 
social life, face disease in a different perspective, and promote illness management 
(Hoffmann and Wilson 2018; Kelley et al. 2017; Sardi et al. 2017). Serious games 
can also enhance patient’s knowledge through education, reduce feelings of uncer-
tainty, and simultaneously increase confidence in decision-making. From this per-
spective, serious games will provide also the opportunity to experience skills and 
coping strategies in facing cancer (Reichlin et al. 2011).
The iPHR also promotes a personalised approach, as it gives patients the chance 
to fill the previously mentioned questionnaire; this provides clinicians an interactive 
psychoemotional health assessment tool for the monitoring of psychological and 
physiological health status of patients.
4  Conclusion
The advances of technology allow today an ever better degree of participation, 
thanks to the tools of virtual and augmented reality that offer a much more direct 
interaction between the user and the external environment and a much more all- 
encompassing experience. Also in terms of prevention, research combined with 
eHealth can go a long way, exploiting the potential for data collection and interac-
tion with the user of today’s tools in conjunction with recent knowledge in systems 
biology.
Certainly, we can say that iManageCancer is an attempt to put technology at the 
service of medicine, with the aim of giving patients a device that can increase the 
involvement in their own care path, and clinicians a set of tools to personalise care 
processes by the consideration of patient as a whole, from biological factors to qual-
ity of life. As we have extensively debated, every constituent aspect of patients as 
human beings has been taken into account in the design and development of the 
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platform. Thanks to the first tests of usability, the platform has been renewed for the 
first time, and the pilot study on efficacy will allow us to rethink and implement 
some of the functions of the platform, in order to always meet the requests of 
patients and respond more effectively to their concrete needs during the course of 
care. P5 considers the impact on quality of life as an additional fundamental marker 
of effectiveness.
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Chapter 3
The Prevention of Chronic Diseases 
Through eHealth: A Practical Overview
Dario Monzani and Silvia Francesca Maria Pizzoli
1  Introduction
The implementation of effective prevention programs delivered through eHealth 
technologies is a promising approach to prevent the onset and progression of chronic 
conditions as P5 underlines. Specifically, eHealth prevention interventions combine 
the effectiveness of the traditional preventive programs with substantial advantages 
and functionalities of the new technologies.
Indeed, eHealth prevention interventions allow to target larger segments of popu-
lation, by giving each individual tailored and real-time feedback (cfr. Chap. 4) about 
personal risk and behaviors (Baker 2001; Evers 2005; Fotheringham et al. 2000).
Nowadays, chronic diseases are the leading cause of disability and mortality all 
over the world (World Health Organization 2009, 2017). According to the World 
Health Organization, chronic diseases are illnesses with a slow progression and 
prolonged duration; they generally do not resolve spontaneously and could be 
treated but rarely cured completely (World Health Organization 2017). They could 
be defined as health conditions lasting 3 months or more that could not be prevented 
by vaccines or cured by medications (MedicineNet 2016). Time duration and the 
fact that symptom control is the primary scope of the cure render chronic conditions 
a relevant issue for patients and for the healthcare system.
All chronic conditions are characterized by four main common qualities 
(Australian Institute of Health and Welfare 2016). First, they are typified by com-
plex and multiple causalities because their onset and progression are influenced by 
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several interacting factors, such as genetic, environmental, and behavioral factors. 
Second, chronic conditions generally start with early developmental phases that are 
often asymptomatic and then develop slowly. Third, they display a prolonged course 
of illness that generally flows into other related health complications. Finally, 
chronic diseases lead to several and serious impairment or disability. Heart disease, 
cancer, type 2 diabetes, arthritis, Alzheimer’ disease, depression, HIV, hyperten-
sion, chronic respiratory diseases, and asthma are among the most prototypical 
example of this kind of health conditions. Chronic respiratory diseases, cardiovas-
cular diseases, cancer, and diabetes are the most widespread chronic conditions 
worldwide (World Health Organization 2015). Their burden is a common challenge 
for developing and developed countries; because of their huge health and economic 
costs, they constitute one of the main challenges for healthcare systems around the 
world. Together, they account for more than 30 million of deaths of people between 
the ages 30 and 70 years (World Health Organization 2017). Hundreds of millions 
of people suffer from chronic respiratory diseases worldwide (World Health 
Organization 2008a) and diabetes (International Diabetes Federation 2018), while 
in middle- and low-income countries, the percentage of deaths ascribed to cardio-
vascular diseases is nearly 30% of the all-cause mortality (World Health Organization 
2008b). New cases of worldwide cancer are estimated around 14.1 million of people 
each year (Cancer Research UK 2018). Globally, most deaths for chronic diseases 
might be avoided or at least delayed by implementing and delivering effective inter-
ventions aimed at preventing or controlling these conditions.
2  Risk Factors for Chronic Diseases
The first necessary step in the effective prevention of each chronic condition is the 
identification of substantial risk factors for its onset, development, and progression 
(World Health Organization 2009). Several risk factors for chronic diseases have 
been described, and they can be classified as non-modifiable and modifiable risk 
factors. The first ones refer to causes and conditions out of people’s control and that 
could not be changed or treated. Age, gender, ethnicity, genetic, and family history 
(cfr. Chap. 4) are among the most important and common non-modifiable risk fac-
tors for several chronic diseases, such as cardiovascular diseases (Sharkey and 
Modarai 2018), cancer (Nindrea et  al. 2018; World Health Organization 2015), 
chronic obtrusive respiratory disease (Singanayagam et al. 2013), and type 2 diabe-
tes (Seuring et al. 2015). On the other hand, modifiable risk factors are aspects that 
could be treated, controlled, and changed and that are, at least at some degree, under 
subjects’ will. They include overweight or obesity, cigarette smoking, physical 
inactivity, high-cholesterol or lipid levels, and high blood pressure. These modifi-
able risk factors can be targeted efficiently by implementing effective interventions 
to promote health, salutogenic lifestyles, and behavioral change. It is also relevant 
to stress that a bunch of modifiable risk factors are responsible for the onset and 
progression of several health chronic conditions. For example, cardiovascular 
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diseases, obtrusive respiratory conditions, diabetes, and cancer share the same mod-
ifiable risk factors. Specifically, the most deadly modifiable risk factors for these 
chronic conditions are hypertension (responsible for more than 10% of global 
deaths each year), tobacco (9%), hypercholesterolemia (6%), sedentariness, and 
obesity (5%) (World Health Organization 2009).
3  Primary, Secondary, and Tertiary eHealth Prevention
Each eHealth prevention intervention could be adequately described by considering 
a bunch of conceptual and practical aspects that were commonly used to elucidate 
differences among traditional preventive efforts. The first distinction refers to pri-
mary, secondary, and tertiary prevention (Institute for Work and Health 2018). 
Specifically, primary prevention is aimed at preventing diseases and medical condi-
tions before they occur. Primary preventive efforts try to avoid the exposures to 
environmental risk, inform and educate people about unsafe and healthy habits, and 
target modifiable risk factors, such as unsafe behaviors or unhealthy habits, through 
lifestyle modification. For example, several mHealth interventions have been imple-
mented to promote healthy sun-related behaviors and attitudes to prevent skin can-
cer (for a review, see Finch et  al. 2016). These interventions were primarily 
informative and educational about the risk of unprotected exposure to the UV radia-
tion and were delivered through daily text messages, e-mails, and written reminders 
asking people to apply sunscreen protection. Secondary preventive efforts are aimed 
at reducing the impact of disease or medical conditions through their early detection 
and treatment in order to mitigate their impact and slowdown progression. eHealth 
secondary prevention interventions especially focus on monitoring symptomatol-
ogy and promoting screening behavior. Prototypical examples of eHealth secondary 
prevention are mobile applications aimed at facilitating early detection of mela-
noma in people at high risk for developing melanoma by promoting annual total 
body skin exams and instructing about the skin self-examination (for a review, see 
Wu et al. (2016)). Specifically, the SkinVision mHealth, an integrated risk assess-
ment algorithm for melanocytic lesions and melanoma detection, evaluates picture 
taken with the smartphone camera and then gives user useful information about 
each lesion and its associated risk for developing skin cancer (Thissen et al. 2017; 
Udrea and Lupu 2014). From this point of view, this mobile app could be a useful 
eHealth secondary prevention effort to detect melanoma in early stages, mitigate its 
possible progression, and then potentially reduce rates of mortality for skin cancer. 
Finally, tertiary prevention interventions focus especially on patients’ self- 
management abilities, efficient proactive strategies, and lifestyle modification to 
prevent recurrence, progression, and long-term severe outcomes of the disease. The 
specific aim of this kind of eHealth intervention is to soften the impact of an ongo-
ing chronic disease or medical conditions. Tertiary prevention intervention through 
mobile technologies was recently implemented to promote self-management abili-
ties, self-care, and glycemic control in patients with type 2 diabetes (for a review, 
3 The Prevention of Chronic Diseases Through eHealth: A Practical Overview
36
see Wu et al. (2018)). These mobile apps permit patients to monitor automatically 
and real-time the glucose level through a wireless glucometer, store this information 
in the smartphone, and receive personalized information with remainders, motiva-
tional message, and indication about lifestyle modifications.
4  Population-Based vs. Individual-Based eHealth Prevention
Alongside classification among primary, secondary, and tertiary prevention, eHealth 
prevention intervention could be categorized by referring to the specific target pop-
ulation of their preventive effort. Specifically, the epidemiologist Geoffrey Rose 
proposed a relevant distinction among different strategies for the prevention of 
chronic conditions and health problems. He stated that preventive efforts could be 
efficiently implemented by adopting one of the two main approaches or strategies 
to prevention: the population-based and the individual high-risk approaches (Rose 
1995). The first one targets the entire population with health promotion actions and 
activities that prevent disease and negative outcomes through the implementation of 
policies and interventions aimed at promoting population-based behavioral change 
and healthy lifestyle and influencing the physical, social, and economic environ-
ment. Through the adoption of new technologies, innovative eHealth prevention 
interventions could be potentiality delivered to a wider audience than the one 
reached with traditional approaches for the prevention of chronic diseases. One 
example of a population-based mHealth preventive strategy is the Stroke Riskometer 
app for the primary prevention (Feigin et al. 2015, 2017; Parmar et al. 2015). This 
mobile application informs the general population about individual and overall risk 
for stroke, educates people about warning signs of stroke, and empowers them with 
effective strategies to reduce their cardiovascular risk by providing evidence-based 
and internationally recognized guidelines about pharmacological treatment and 
behavioral change.
Conversely, in accordance with the P5 approach, the individual high-risk 
approach aimed at firstly identifying individuals with high risk for developing dis-
eases or negative outcomes and then targeting this specific population with ad hoc 
preventive interventions. This kind of prevention strategies focuses especially on 
individuals with high level of known risk factor for chronic diseases or people that 
show premorbid signs prior to the onset of illness. Subsequently, personalized 
health education, health promotion, and behavioral change interventions are deliv-
ered to promote healthy lifestyles and reduce risk factors and premorbidity. The 
adoption of new technologies has the potentiality of boosting the implementation of 
personalized interventions in medicine (Cutica et  al. 2014; Renzi et  al. 2016), 
because they offer unique opportunities to personalize contents and stimuli (Pizzoli 
et al. 2019). For example, innovative technologies obtain a clear and real-time pic-
ture of each individual by taking into account individual risk factor, behaviors, abili-
ties, and needs and then tailor preventive efforts to this specific individual and 
disease profile (Vergani et al. 2019). One example of an innovative eHealth preven-
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tion intervention is the Consumer Navigation of Electronic Cardiovascular Tool 
(CONNECT; Coorey et al. 2017; Redfern et al. 2014). It is a web application, acces-
sible via a mobile device or computer, delivering a multicomponent and personal-
ized eHealth prevention effort to empower people with moderate-to-high 
cardiovascular risk in opting for or increasing treatment adherence and healthy life-
style modifications. CONNECT enables the real-time calculation of individual risk 
score for cardiovascular diseases. Other core features of this eHealth individual 
high-risk intervention are tracking of actual behaviors, interactive educational 
resources about risks and benefits of lifestyle, and delivering of tailored healthy 
habit recommendations and motivational messages for effective behavioral changes.
5  eHealth Behavioral Change Interventions
Behavioral change techniques and personalized motivational factors for lifestyle 
modification are among the most common core features of several eHealth interven-
tions to prevent the onset and progression of illnesses. Specifically, the most innova-
tive and promising approaches deliver traditional, theoretical, and evidence-based 
behavioral change interventions by means of new and digital technologies, such as 
mobile applications, websites, text messages, and serious games. For what concern 
behavioral change intervention, starting from the 1950s, several theories and mod-
els of behavioral change have been proposed to effectively target health- 
compromising habits responsible for the onset and progression of acute and chronic 
diseases. The Health Belief Model (Rosenstock 1974), the Social Cognitive Theory 
(Bandura 1977), the Transtheoretical Model (Prochaska and Diclemente 1983; 
Prochaska and Velicer 1997), and the Health Action Process Approach (Schwarzer 
1992, 2008; Schwarzer et al. 2011) are the most known clinically and empirically 
grounded theories of behavioral change. Meta-analytical results demonstrated the 
superiority, in comparison with usual primary health care, of theoretically based 
health behavioral change interventions in promoting healthier lifestyle in terms of 
reduced intake of calories and saturated fats, improvement in intensity and fre-
quency of physical activity, and smoking cessation (Bully et al. 2015). Each model 
has its specificity in promoting lifestyle modifications (for a brief overview, see 
Stroebe (2011)). Even if there are radical theoretical and conceptual differences 
among these models, all of them stress the role of personal control and self-efficacy 
belief in promoting lifestyle modifications. Specifically, as the P5 approach high-
lights, they suggest that individuals are more likely to change unhealthy behaviors 
and to maintain lifestyle modification over time when they perceive themselves as 
able to effectively succeed in these tasks (Bandura 1977, 1982). For example, peo-
ple are more likely to quit smoking when they have strong beliefs about their ability 
to abstain from smoking and maintain abstinence (Gwaltney et  al. 2013). 
Furthermore, self-efficacy beliefs seem to shape the relationship between perceived 
health satisfaction and illness severity in cardiovascular diseases (Greco et al. 2015; 
Steca et  al. 2013, 2015). As we will deepen in the next section, eHealth 
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interventions have been developed by taking advantage of the technical capabilities 
of web-based and mobile technologies to track real-time behavioral and health 
information, involve the healthcare providers, leverage peer and social influence, 
and increase the accessibility of health information to deliver more effective preven-
tive interventions (Klasnja and Pratt 2012). These technical features are especially 
useful for the promotion of people’s self-efficacy, one of the main core features of 
both traditional and eHealth preventive interventions, because they permit the real-
time monitoring of actual behaviors and then deliver personalized vicarious experi-
ence, modeling, and tailored feedbacks. Other determinants of intention to change 
and actual lifestyle modification have been proposed in the main behavioral change 
theories. Among these determinants, the most relevant are perceived risk or vulner-
ability, attitude toward unhealthy and healthy behaviors, and outcome expectancy 
(Stroebe 2011). Starting from this theoretical knowledge and empirical evidence, 
several eHealth interventions have approached the prevention of chronic diseases by 
taking advantage of technical solutions introduced by new media. These eHealth 
interventions have the qualities of engaging users deeply, permitting an easy inte-
gration between usual care and self-management practices, obtaining real-time and 
online monitoring of clinical outcomes and behaviors, and personalizing feedback 
and motivational messages to users (Kebede et al. 2017).
Even if some preventive interventions apply theoretical knowledge on behavioral 
change, two recent meta-analyses on the use of lifestyle modification in web-based 
and mobile interventions for self-management respectively of asthma (Al-Durra 
et al. 2015) and type 2 diabetes (Van Vugt et al. 2013) highlighted that a consider-
able proportion of eHealth preventive efforts does not adopt any documented and 
empirical-based behavioral change theories. The remaining eHealth interventions 
adopt the Health Belief Model (Rosenstock 1974), the Transtheoretical Model 
(Prochaska and Diclemente 1983; Prochaska and Velicer 1997), and the Self-
Efficacy and Social-Cognitive Model (Bandura 1977, 1982), alongside with gamifi-
cation and tailored communication, to promote self-management, self-care, and 
healthy habits in this kind of patients.
Upon reviewing the literature on mHealth behavioral interventions to counteract 
physical inactivity and sedentary habits, Direito et al. (2017) highlighted that there 
is a strong heterogeneity in the terminology used to describe behavioral change 
interventions. Specifically, in detailing their interventions, developers are more 
likely to refer to specific core features and strategies rather than reporting actual 
behavioral change theories and models. Specifically, the vast majority of interven-
tions adopted goal setting, alongside with self-monitoring, social support, feed-
backs, and educational components, to foster moderate-to-vigorous physical 
activity. This kind of techniques implicates the development of a detailed action 
plan to motivate and orient people toward a meaningful goal (Bryan and Locke 
1967; Latham and Locke 2009; Locke and Latham 2006). Goal setting involves the 
development of an action plan designed to motivate and guide people in goal pur-
suit. Thus, individuals are educated to establish clear objective about behavioral 
change, instructed on how to efficiently pursue them, and constantly motivated to 
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reach these specific health-related goals. The importance of establishing clear and 
detailed objectives for effective behavioral change has been acknowledged by a few 
eHealth preventive programs that have implemented the SMART criteria. 
Specifically, SMART goals – which stands for “Specific, Measurable, Achievable, 
Relevant, and Time Bound” – are the best type of goals to be set (Macleod 2013; 
Moskowitz and Halvorson 2009). This technique has been implemented in the 
strengthening and stretching (mySARAH; Srikesavan et al. 2018), an online tertiary 
preventive effort for people suffering from rheumatoid arthritis of the hand. This 
web-based program includes educational videos about upper limb mobility exercise 
and strength exercise for hands. Adherence to the exercise plan is fostered with 
behavioral support strategies of self-monitoring, goal setting, SMART goals, and 
action planning. Specifically, patients are asked to set SMART goals about exercise, 
plan their workout schedule, and constantly review their SMART goals on the basis 
of actual behaviors and performance.
Overall, in most cases, there is still a lack of evidence-based and solid theoretical 
foundations of eHealth prevention interventions. However, regardless of the specific 
behavioral change model being adopted, web-based behavioral change interven-
tions have been demonstrated to be more effective than traditional ones in increas-
ing knowledge about nutrition and physical exercise and people’s awareness about 
health risk factors and individual risk and in promoting subsequent lifestyle modifi-
cation in terms of being more active and having an healthy diet (Wantland et al. 
2004). For example, wearable devices, such activity and sleep trackers and blood 
pressure and heart monitors, bring new possibilities in delivering effective and tai-
lored behavioral change interventions to increase the frequency and intensity of 
physical exercise. Results of a recent meta-analysis showed that behavioral change 
interventions comprising both wearable devices and mobile applications are effec-
tive in promoting physical activity, measured through objective measure and daily 
step count, in the general population (Gal et al. 2018).
To sum up, while several eHealth preventive programs have been developed 
without referring to a specific theory of behavioral change, the adoption of a solid 
theoretical foundation is a necessary and preliminary step in the development of this 
kind of interventions. The selection of the specific behavioral change theory or tech-
nique to be implemented in eHealth preventive program aimed at promoting life-
style modification should be facilitated by considering the classification proposed 
by Michie and colleagues (Michie et al. 2011, 2013). Specifically, upon reviewing 
the literature on traditional health behavioral change, they developed an extensive 
and useful taxonomy of 93 hierarchically clustered techniques that could be used to 
implement lifestyle modification interventions through eHealth modalities. As 
stated by Van Vugt et  al. (2013), the selection of the specific technology of an 
eHealth intervention is secondary and should follow the decision about the specific 
behavioral change theory or strategy to be implemented. All these steps must be 
guided by a critical evaluation of theories, empirical evidence, contextual back-
ground, and specific nature of the behavior to be targeted.
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6  Strategies of eHealth Prevention
The classification proposed by Michie and colleagues highlighted a huge heteroge-
neity in strategies being implemented in traditional intervention programs aimed at 
promoting preventive habits and lifestyle modifications. Specifically, through a con-
sensus exercise involving more than 50 experts in implementing and delivering life-
style modification interventions, they developed a list of 93 strategies to promote 
behavioral change. These methods have been subsequently clustered into high-order 
classes of (1) reinforcement (e.g., punishment, response cost, chaining), (2) reward 
and threat (e.g., social and self-reward), (3) repetition and substitution (e.g., 
Behavioral substitution, habit formation, and reversal), (4) antecedents (e.g., 
restructuring the social and physical environment), (5) associative learning (e.g., 
exposure, classical conditioning, and prompt cues), (6) covert learning (e.g., vicari-
ous reinforcement and convert conditioning), (7) consequences (e.g., salience of 
consequences, health and emotional consequences), (8) feedback and monitoring 
(e.g., feedback on behavior, biofeedback, and self-monitoring of behavior), (9) 
goals and planning (e.g., action planning including implementation intention and 
goal setting), (10) social support (e.g., practical and emotional support), (11) com-
parison of behavior (e.g., modeling of behavior and social comparison, (12) self- 
belief (e.g., self-task, focus on past success, and verbal persuasion to boost 
self-efficacy), (13) comparison of outcomes (e.g., persuasive argument, pros, and 
cons), (14) identity (e.g., self-affirmation and cognitive dissonance), (15) shaping 
knowledge (e.g., reattribution and instructions on how to perform a behavior), and 
(16) regulation (e.g., regulate negative emotions, pharmacological support, and con-
serving mental resources) (for a review, see Michie et al. (2011, 2013)).
The vast majority of these overarching strategies have been transferred and 
adapted to deliver eHealth prevention and behavioral change intervention while tak-
ing advantage of the technical capabilities of the World Wide Web, personal com-
puters, smartphones and mobile apps, and wearable devices. In 2012, Klasnja and 
Pratt (2012) developed a concise taxonomy of strategies that have been generally 
used in mobile-based healthcare interventions. Specifically, four of these core strat-
egies might be used to describe each eHealth prevention effort: (1) promoting health 
information and awareness, (2) tracking behavioral and health information, (3) 
leveraging social influence, and (4) utilizing entertainment and gamification. 
Generally, effective eHealth preventive efforts rely on a peculiar combination of two 
or more of these strategies.
One of the core components of most eHealth interventions (and also of the P5 
approach) is educational and information feature aimed at promoting awareness and 
knowledge about health and risk factor for the onset and progression of chronic 
diseases and reminding and motivating users or patients to promote their self- 
management abilities, treatment adherence, and behavioral change. New media 
technologies permit to deliver health information to a wider audience than the one 
possible reached by traditional prevention program. Web-based and interactive 
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 educational efforts that allow users to navigate through online information on their 
own are effective in increasing self-management abilities and self-care habits for the 
secondary and tertiary prevention of illnesses and medical conditions (Fredericks 
et al. 2015; Webb et al. 2010). This kind of interventions is especially useful for the 
prevention of chronic diseases because it allows people to access autonomously 
relevant health information and decide the type and amount of data they are willing 
to consult. For example, HeartCare is an intervention dealing with the secondary 
and tertiary prevention of chronic cardiac diseases. It is a web-based tool aimed at 
improving self-care and adherence to treatment by allowing patients to access use-
ful information on their disease, medication, and behavioral recommendations, in 
terms of diet and physical activity (Brennan et al. 2001, 2010). This kind of web- 
based educational intervention is more cost-effective than the traditional ones in 
delivering evidence-based and specialized health information to acute and chronic 
patients (Brennan et al. 2010; Côté et al. 2011; Martorella et al. 2012; Runge et al. 
2006). Indeed, educational eHealth interventions strongly rely on the involvement 
and engagement of people that are requested to actively search and autonomously 
consult information about their health and behaviors.
On the contrary, other technologies, such as text messages and notifications from 
mobile apps, permit to deliver health information, prompts, and reminders to people 
that receive them without any active searching or commitment and permit to pro-
vide information at the right time (e.g., at dinner time when patients should take 
medications). Text messages and notifications could be used as (1) educational con-
tent, (2) prompts to remind patients to take their medications, and (3) tips to moti-
vate them to behavioral change. For example, daily phone text messages have been 
used to promote self-care and adherence to treatment in people suffering from 
chronic respiratory diseases (Strandbygaard et al. 2010). General educational mes-
sages are used to inform users or patients about their health condition, symptom-
atology, possible preventive efforts, and lifestyle modification that could counteract 
the onset or progression of medical conditions (Beratarrechea et al. 2017; Orr and 
King 2015). The adoption of eHealth modalities allows the easy implementation of 
tailored or personalized communication that, compared to generic information, is 
more effective in promoting lifestyle modification and screening behaviors 
(Ovbiagele et al. 2015). Moreover, text messages and notifications might be used as 
prompts to remind users and patients to take medications or to engage in a specific 
behavior. This is particularly useful in behavioral change interventions to increase 
users’ perseverance and consistency in performing preventive and health-promoting 
actions that they are very likely to forget to do. Finally, personalized education and 
informative contents could be also used as tips or advices to motivate users to 
change their unhealthy behaviors or be adherent to treatment by teaching them 
effective strategies on how to counteract to obstacles and difficulties interfering 
with adherence and behavioral change (Gerber et al. 2009).
Nowadays, mobile applications and new wearable devices allow the constant and 
automated monitoring of users’ behaviors and clinical conditions, in accordance 
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with the P5 approach. The key core of many eHealth prevention interventions takes 
advantage from the possibility to easily track physiological parameters, health- 
related behaviors, and psychological states. Patients could track and record all these 
data by (1) using automated sensors and (2) actively logging behaviors, health infor-
mation, and medication. Self-monitoring is a viable strategy to prevent illness and 
foster healthy behavioral change by promoting patients’ awareness about their own 
health and health-related behaviors, motivating users in treatment adherence and 
behavioral change recommendations, and promoting frequency of healthy habits 
(Consolvo et  al. 2008; Gasser et  al. 2006; Nelson 1977; Ness et  al. 2007). 
Furthermore, constant and recorded information on physiological parameters allow 
and facilitate the participation and inclusion of informal caregivers and healthcare 
providers in patients’ self-management process. This feature is especially relevant 
for the secondary and tertiary prevention because people suffering from chronic 
diseases are generally required to monitor their symptomatology, adhere to complex 
treatment, and maintain healthy habits. A bunch of eHealth intervention monitor 
patients’ conditions and alert healthcare providers or informal caregivers where 
severe clinical outcome has been detected. For example, a complex system of wear-
able devices consisting of a high blood pressure bracelet, ECG sensor, and acceler-
ometers permits patients with chronic heart failure or heart diseases to automatically 
record their health status (Rubel et al. 2004, 2005; Villalba Mora et al. 2006, 2009). 
Informal caregivers and the healthcare team are automatically contacted if neces-
sary. As mentioned above, accelerometer, activity and sleep trackers, blood and 
heart rate sensors, and step counter integrated in many smartphones are useful wear-
able devices that foster the possibilities of new eHealth preventive efforts to increase 
behavioral change, especially in terms of increasing physical exercise (Gal et al. 
2018). Self-monitoring is also an effective way to promote weight management for 
the prevention of obesity and overweight problems in adult populations (Burke 
et al. 2011; Madigan et al. 2015; Zheng et al. 2015). As highlighted by a recent 
meta-analysis by Ho et  al. (2018), many eHealth programs delivered web-based 
self-monitoring to prevent obesity during adolescence as well. All these assessed 
studies employed logging of behaviors and health information that, differently from 
automated tracking of personal information through wearable devices, requires 
users to provide and record all the relevant health-related data. Specifically, adoles-
cents are asked to daily log information about their diet, physical activity, and 
weight. Results suggested that daily self-monitoring, supported by goal setting and 
face-to-face counseling, is effective in reducing adolescents’ body mass index.
Besides being positive influenced by individual engagement and active effort, the 
effective health promotion, lifestyle modifications, and preventive interventions are 
leveraged by a supportive social environment for patients and users. Specifically, 
emotional and instrumental social support from partners, relatives, and friends may 
facilitate self-care, behavioral change, and adherence to treatment in healthy people 
and patients with chronic diseases (Finlay et al. 2018; Holt-Lunstad 2018; Lange 
et al. 2018; Tregarthen et al. 2015; Uchino et al. 2018). By recognizing the pivotal 
role of social influence and support for the effectiveness of each preventive effort, 
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several traditional and eHealth interventions have included specific features aimed 
at leveraging social influence to promote self-management skills, screening behav-
iors, lifestyle modifications, and treatment adherence. There are three main strate-
gies that have been implemented within eHealth preventive programs to take 
advantage of social influence for health promotion by leveraging (1) social support 
from family and friends (cfr. Chap. 4), (2) peer-to-peer influence, and (3) vicarious 
experience and peer modeling.
The first strategy might be especially useful for people facing strong difficulties 
in changing their unhealthy habits or maintaining an adequate self-care. In this case, 
close relatives and friends may support and motivate those people in accomplishing 
their health-related goals and improving their self-management skills. An eHealth 
preventive program aimed at helping people quit smoking by leveraging social sup-
port from a support person nominated by the quitter is an example of this category 
(Obermayer et al. 2004). Specifically, this web-based intervention allows the sup-
port person to constantly monitor the progress of the quitter and then send the absti-
nence smoker motivational and supporting text messages. The second strategy aims 
at leveraging social influence by allowing interaction among people working on the 
same health-related task. This might be especially useful either for sharing how-to 
practices, reassurance, encouragement, and information or motivating people 
through competition. Peer-to-peer social support allows sharing instrumental infor-
mation on strategies and practical instructions on how to effectively deal with self- 
care practices, behavioral change, and adherence to treatment and also foster 
discussions about feelings and emotions or share encouragement, reflection, and 
reassurance among users. For example, a bunch of eHealth intervention for the pro-
motion of physical activity have implemented peer-to-peer discussion boards, 
buddy systems (i.e., two or more people are able to monitor and help each other), 
live chats, and forums to allow people to motivate each other and share their feelings 
and thoughts about physical exercise (Webb et  al. 2010). On the contrary, other 
eHealth interventions have adopted peer-to-peer competition to foster motivation in 
changing unhealthy lifestyles. For example, Mobile Lifestyle Coach app used com-
petition among users to boost their levels of physical activity and their healthy nutri-
tional habits (Gasser et al. 2006). As this mobile app employed also gamification, 
users were assigned into teams that compete one against the other. The winning 
team is the one that obtains the higher individual and cumulative scores of healthy 
habits measured as progress toward daily goals of balanced diet and physical activ-
ity. Peer-to-peer influence and social support from family might be powerful strate-
gies to enhance people’s self-efficacy in following preventive programs and 
recommendations for behavioral change. In fact, as clearly stated by Bandura (1977, 
1982), people’s belief about their ability to succeed in a specific task can be devel-
oped by four main sources of influence: (1) mastery or enactive experience (success 
increases perceived self-efficacy and failure reduces it); (2) vicarious experience or 
modeling (when people observe someone succeeding in a task, their self-efficacy 
generally increases); (3) verbal and social persuasion (motivational feedback and 
direct encouragement from other people might foster individual self-efficacy); and 
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(4) physiological factors (perception and belief about sign of distress, such as nega-
tive emotion, fatigue, and pain, may alter self-efficacy). eHealth providing peer-to- 
peer influence and social support from family and friends might be especially 
helpful for people dealing with complex health-related task such as lifestyle modi-
fication because these strategies allow people to receive verbal persuasion about 
their ability to alter given tasks and thus catalyze greater effort. Also the third and 
last strategy of leveraging social influence through vicarious experience and model-
ing may be relevant to foster people self-efficacy. Specifically, this approach relies 
on the power of peer-to-peer exchange of useful information about tips and effective 
strategies to effectively deal with behavioral change and overcome health-related 
difficulties. Successful peers are thus competent and proficient models that dissemi-
nate effective skills and schemes for managing task demands that consequently 
raise perceived efficacy. For example, Schweier et al. (2014) have developed a web- 
based peer-modeling intervention to promote healthy lifestyle changes and self- 
management ability in German patients with cardiovascular diseases and chronic 
back pain. Their open access and no-cost website provides more than 1000 texts, 
audios, and videos of people with coronary heart disease and chronic back pain 
reporting how they had efficiently modified their unhealthy behaviors focusing on 
obstacles and their successful strategies in maintaining healthy habits.
Overall, eHealth behavioral change and preventive interventions must face the 
main challenge of motivating people to act appropriately and to maintain lifestyle 
modifications over time. It is often hard to motivate healthy but physical inactive 
people in changing their unhealthy habits. Furthermore, most people are very likely 
to adhere to an eHealth preventive program only for a short time. However, it is pos-
sible to take advantage of the motivational capacity of entertainment content, gami-
fication, and games to keep users engaged (Craig Lefebvre et al. 2010; Gal et al. 
2018; Graffigna et al. 2014; McCallum 2012; Sardi et al. 2017). As the P5 approach 
suggests, the use of entertainment content and gamification has been adopted as one 
of the four core strategies of many eHealth prevention interventions.
One prototypical example of the power of gamification to motivate people to be 
more physically active is Pokémon GO, a commercial mobile-augmented reality 
game that has been proved effective in fostering physical activity in young and inac-
tive people (Althoff et al. 2016; Gabbiadini et al. 2018; Howe et al. 2016). Similarly, 
gamification has been implemented in REACH for Success, an innovative mHealth 
prevention and early intervention program targeting anxious symptomatology in 
youth (Stoll et  al. 2017). Specifically, this mobile app relies on gamification to 
increase people’s engagement and adoption of effective self-management strategies 
for managing stress and anxiety-provoking situations. An animated avatar, shaped 
like a blob, delivers personalized motivational messages and interacts with the user. 
This avatar is designed following the Proteus effect positing that animated represen-
tation that rewards people for being successful in a task increased motivation to 
perform such activity (Yee and Bailenson 2007). When users complete daily home-
work delivered by REACH, they can tap on the blob and see it performing some 
leveled tricks.
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7  Conclusion
This chapter briefly introduced the eHealth approach to the primary, secondary, and 
tertiary prevention of chronic diseases. Compared to traditional interventions, 
eHealth prevention programs can offer several additional benefits. Specifically, this 
kind of interventions takes advantage from the huge functionalities of new tech-
nologies that allow people to access easily and briefly health information and edu-
cational content, to constantly monitor their health status and behavior, and also to 
receive real-time and personalized feedbacks about the appropriateness of their 
actions and about their physiological parameters. Moreover, new media allow an 
easy and online communication of patients with their caregivers and their peers as 
well. All these features might be especially relevant in facilitating and motivating 
people to adopt and maintain healthy lifestyles and subsequently prevent the onset 
or progression of several chronic conditions. Finally, thanks to the possibility of 
employing gamification, eHealth interventions might better motivate people to fol-
low preventive and lifestyle modification programs over a long time. For all these 
reasons, eHealth preventive interventions are promising ways to approach effi-
ciently the primary, secondary, and tertiary prevention of chronic diseases.
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Chapter 4
An Introduction to Personalized eHealth
Valeria Sebri and Lucrezia Savioni
1  Introduction
In recent years, the field of personalized medicine has greatly expanded and has 
attracted great interest not only among professionals but also from the general pub-
lic. The concept of “therapy for a disease” is no longer satisfactory, and the need for 
a drug that takes into account the individual becomes more and more a necessity 
(Ginsburg and Willard 2009; Plebani 2016).
However, the paradigm of personalized medicine is not new in the field of care; 
medicine has always taken into consideration the variability of individuals by treat-
ing the patient in relation to his/her differences both in terms of diagnosis and 
response to treatment; for example, blood typing has long been used to conduct 
blood transfusions and organ transplants (Collins and Varmus 2015).
Advancements in science and technology have allowed a more in-depth study of 
human genetic individuality. In particular, the enormous development of genetics, 
through DNA sequencing, has enabled scientists to manage a large amount of data.
Some examples are the powerful methods to characterize patients (such as differ-
ent cell dosages, geomorphology, proteomics, metabolomics, and even mobile 
health technology), the development of large-scale biological databases (such as the 
human genome sequence), and computational tools for the analysis of large data 
sets.
All these advances, inseparable from the sociological aspects, have allowed the 
development of a more objective approach to diagnosis and targeted therapies and 
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the ability to predict the response to therapy, avoiding undesirable effects (Collins 
and Varmus 2015; Offit 2011). The field of oncology has derived the largest benefits 
from the use of personalized medicine. The application of molecular biology tech-
nology has allowed a precise distinction between the different types of cancer, an 
early diagnosis for some forms of cancer, and a definition of ad hoc therapeutic 
strategies for the cancer patient.
1.1  What Are the News of Personalized Medicine?
Compared to “traditional” medicine, personalized medicine allows greater preci-
sion in predicting risk and responding to therapies (Ginsburg and Willard 2009; 
Swan 2009; Zhang et al. 2012).
The result is P5 approach, a model of healthcare based on proactive (preventive) 
planning (cfr. Chap. 3), unlike the traditional model of reactive health (episodic). 
Indeed, traditional medicine interventions were implemented in acute crisis, i.e., 
when the disease was already established and sometimes irreversible. Furthermore, 
disease treatment and prevention strategies are developed for the general popula-
tion, without distinction. We then move from a one-dimensional clinical approach 
to one focused on the patient, in order to optimize medical decisions and to apply 
specific treatments.
1.2  A Brief History
As previously mentioned, personalized medicine is a known field. Since ancient 
times, doctors were convinced that the onset of diseases had different causes. They 
believed that subjects with the same disease should be treated differently from one 
another because of the physical and psychic differences.
Previously, the Egyptians distinguished the endogenous causes (corruption of the 
intestinal contents due to a “matter pecans”), the exogenous causes (natural calami-
ties, parasites, bites of animals), the hidden causes (revenge of a dead person, wrath 
of God, hatred of enemies), and finally the psychogenic causes (mood disorders or 
psychosomatic pathologies).
Subsequently, Hippocrates (480–390 b.c.) began to take care of the ill person and 
not of the disease (Grmek 1993), considering alimentation, physical activity, life-
style, and climate. Hippocrates unifies “in a critical analysis the patient, the sick-
ness, the physician and above all proposes the integration of the physical and 
psychological uniqueness of the subject with the socio-cultural and physical- 
geographical complexity of his environment” (Zitelli and Palmer 1979). Claudio 
Galeno introduced the concept of predisposition (129–200  a.c.). Taking up the 
humoral theory of Hippocrates, he introduced two internal causes beside the body’s 
external causes:
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• Causes that predispose a certain individual to certain diseases
• Immediate causes that the doctor can only see when the disease has started
Galeno also expanded this theory to the healing of the patient; he argues that 
healing from an illness also depends heavily on the patient’s life habits (alimenta-
tion, rest, sexual activity, emotional state). According to this theory “the patient 
needs individualized attention, since the preservation of health changes according to 
the complexions and bodily habitus” (Sotres 1993).
More recently, Sacks dealt with this theme. He showed that patients with the 
same disease are fundamentally different from each other and that the technical- 
scientific evaluations were insufficient because they “revealed only the deficits and 
not the abilities; they provide us only fragmentary data and patterns, while we need 
to see a music, a story, a series of actions lived” (Sacks 1986). For example, he men-
tions that patients with Tourette syndrome were never the same.
The development of technologies and the progress of science have today led to 
the study of interindividual variability through genotypic characteristics. The dis-
covery and study of the human genome has allowed an incredible advancement of 
personalized medicine. Although personalized medicine is an area that has always 
been known and it is an intuitive concept, there are different opinions about its defi-
nition. In fact, today there is not yet a precise and universally accepted definition of 
personalized medicine (Table 4.1).
In Table 4.2 instead, we compare the five main definitions of personalized medi-
cine. The first one by Carlson (2008) considers the prevention and treatment of 
disease based on the patient’s genetic profile. Differently, Personalized Medicine 
Coalition’s definition considers prevention as predisposition of patients to particular 
disease and the management of illness.
The definition from the America Medical Association is only about pharmaco-
logical treatment. Finally, the third definition gives information about prevention, 
treatment, and individuality.
As we can see, psychological aspects are considered by only one definition 
(Personalized Medicine Coalition’s definition). As we saw before, personalized 
medicine uses the information about patient’s life, to create an individualized care 
and cure (cfr. Chap. 1). It is fundamental to consider that the patient’s life is 
Table 4.1 Personalized medicine definitions
Definition Reference
Prevention, diagnosis, and therapy of a specific disease based on the 
individual genetic profile
Carlson (2008)
Use of new methods of molecular analysis to better manage an illness 
or the predisposition to pathologies
Personalized Medicine 
Coalition
Provide the right treatment to the right patient at the right dose European Union




Medicine that uses information about genes, proteins, and the person’s 
environment to prevent, diagnose, and treat diseases
National Cancer 
Institute
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 constituted not only by genomic aspects but also by his social condition, work 
(activity), family history, etc. (cfr. Chap. 3).
This underlines the confusion surrounding the definition of personalized 
medicine.
In general, personalized medicine can be defined as the medical approach that 
uses the specific biological characteristics, environment, needs, and lifestyle of an 
individual to create ad hoc therapy, including drugs, dosages, and other possible 
remedies (Swan 2009; Capurso 2018; Jameson and Longo 2015).
2  The Development of Personalized Medicine
The development of personalized medicine and the increased knowledge between 
genes and external factors have brought some changes in different fields of 
healthcare:
• Treatments
• Diagnosis and risk prediction
• Doctor-patient communication
• Disease/illness management
Further, we will analyze them one by one to better understand how and what are 
the changes that personalized medicine has brought in each of these areas.
2.1  Treatments
From the earliest times, it was known that the response to drugs is genetically deter-
mined. Over the years, we have seen how, together with its genetic heritage, other 
factors play a fundamental role, including health status, environmental exposure, 
nutrition, and age (cfr. Chap. 3).
The introduction of personalized medicine has allowed the extension of the 
approaches traditionally used for the understanding and treatment of diseases 
(Vogenberg et al. 2010; Ginsburg and Willard 2009).
Table 4.2 The definition of personalized medicine on comparison
Definition Prevention Treatment Individuality Psychological aspects
Carlson (2008) x x x –
Personalized Medicine Coalition x – – x
European Union – x – –
American Medical Association – – x –
National Cancer Institute x x x –
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Thus, pharmacogenomics was born, a discipline that consists in the study of 
genomic characteristics that determine individual differences in the response to 
drugs; it has allowed doctors to select drugs and to create customized intervention 
protocols on the nature of diseases, diagnosis, responses to treatments, and its indi-
vidual characteristics (Panahiazar et  al. 2014). Pharmacogenomics allows the 
following:
• The prediction of possible side effects of drugs on specific patients
• The identification of the susceptibility of an individual to certain diseases, allow-
ing doctors to draw up a monitoring and prevention plan
• To define a priori the best treatment and the best drugs for specific patients
Doctors will be able to make more effective clinical decisions for each patient, 
going beyond the classic “one-size-fits-all” concept.
The personalization of treatments also allows identifying the subpopulations that 
behave differently toward a given drug, compared to the typical patient. This creates 
more stringent inclusion/exclusion criteria that make treatment positive in terms of 
safety and efficacy (Richmond 2008).
2.2  Diagnosis and Risk Prediction
The progress of genomics has allowed, through the execution of genetic tests, the 
identification of genomic alterations that underlies many genetic diseases. This 
allows to obtain information on the probability that an individual can develop a 
disease, especially the most difficult to treat, such as cancer, diabetes, or cardiovas-
cular disorders. In this way, doctors will be able to develop individual interventions 
to avoid or control the development of the pathology, by implementing, for exam-
ple, changes in the patient’s lifestyle (cfr. Chap. 3) (Steffen and Lenz 2013; Gaitskell 
2017).
In this way, we can focus more on prevention rather than on the management of 
the disease (cfr. Chap. 3). With this aim, we can, in the future, use the collection of 
genetic information from prenatal tests, to outline possible diseases that can be 
avoided or adequately controlled.
The use of personalized medicine in the field of prevention, and also in P5 
approach, can therefore significantly reduce the incidence of diseases, especially 
chronic ones. However, the development of biological markers based on primary 
prevention is still distant, despite the enormous development of research (Panahiazar 
et al. 2014; Katsios and Roukos 2010).
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2.3  Doctor-Patient Communication
With the introduction of personalized medicine, there will be more and more infor-
mation about the available treatment options, to be understood and discussed by the 
patient and the doctor. This implies a change in the relationship and, in particular, in 
the patient-doctor communication. The doctor-patient communication concerns two 
subjects who are in an unfair and often in a not voluntary position. Both patient and 
the physician find themselves in difficulty: the patient, following a diagnosis, finds 
himself in a state of shock and refusal that makes it difficult to process the informa-
tion that is provided or does not have the necessary knowledge to understand them; 
on the other hand, the doctor often lacks the confidence and training necessary to 
provide patients with clear, understandable, and empathetic information and finds 
himself having to conduct the interview quickly and in an unsuitable place. In this 
situation very often the patient’s expectations or understandings are left in the back-
ground, focusing only on the biomedical aspects (Kerr et al. 2003; Ong et al. 1995). 
The introduction of personalized medicine implies a change in the relationship and, 
in particular, in the patient-doctor communication. Communication must be charac-




In accordance with P5 approach, this means that the professional will aim to cre-
ate a more personalized environment that promotes the flow of information; com-
munication will be more informative: the specialist will tend to be more clear, using 
a colloquial language that is understandable for the patient and will provide such 
information with empathy, dignity, and respect. In this way, the whole process of 
diagnosis and treatment is clear and understandable. At the same time, the patient 
will feel more involved and no longer a passive subject (cfr. Chap. 1); he will be able 
to express his preferences on treatments, for example, he will be able to have a say 
in the choice of treatment planning or in the choice of the various exercises pro-
posed, etc.. In this way, the doctor will no longer feel the only responsible for the 
outcome of the intervention, but a sharing of responsibility is established (Lemay 
et al. 2017; Cutica et al. 2014).
2.4  Disease/Illness Management
The change in communication between doctor and patient has made healthcare 
more collaborative, allowing patients to be participants and guides of their path to 
recovery (Gorini et al. 2018). The involvement of the patient in the decision-making 
process recognizes the autonomy of the latter, who will be more inclined to accept 
and follow the treatment leading to the possibility of a better prognosis (Cutica et al. 
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2014). The patient’s knowledge of his condition will lead to more and more experi-
enced and more active patients managing their pathology in the future, which is the 
purpose of P5 approach.
In the future, the patient-driven medicine could expedite dramatically the clinical 
trial process. Health social networks can bring standardized digital data and pre- 
aggregated patient registries to clinical trial conductors. Moreover, a collaboration 
between health social networks and clinical trial representatives can be created, on 
their needs for electronic data collection, ensuring that the quantitative information 
necessary for clinical trials is already available to all participating patients. Clinical 
trial prescreening survey can be administered easily through health social network 
websites (Swan 2009).
3  The Role of eHealth (and mHealth Specifically)
Considering the complexity of eHealth resources (cfr. Chap. 1), we will focus on 
mHealth, which is characterized by technologies particularly useful for the aim of 
personalization.
When we speak about mHealth, we refer to mobile telecommunication technolo-
gies supporting wellness through the delivery of healthcare (Steinhubl et al. 2013; 
Gorini et al. 2018; Triberti et al. 2019).
The smartphone could become the hub of future medicine, also regarding mental 
health services (Ben-Zeev et  al. 2013). Personalized medicine in P5 approach 
includes for example the possibility to access real-time patient self-report data (cfr. 
Chap. 3) during the time interval between visits. In other words, eHealth could be a 
support for patients and caregivers in terms of self-monitoring. Mobile phones and 
other personal devices indeed can improve the accessibility to these data sets. 
Indeed, these can be utilized in order to help patients in gathering information about 
their own diseases so to make them able to manage their own situation more 
effectively.
Iterative development processes could create applications that will be available 
on multiple platforms (cfr. Chap 9), used also to improve patients’ acceptance of 
disease in often complicated day-to-day routines (Diamantidis and Becker 2014). 
Patients could have access to data collection, becoming active managers of their 
symptoms, potentially leading to more accurate assessment. Berrouiguet et  al. 
(2018) describe an example in which eHealth tools allow an endocrinologist to chart 
blood glucose levels. In this way, before and after a doctor’s appointment, health 
professionals could observe and control these values with a portable blood glucose 
meter. At the same time, changes in sleep, appetite, mood, and other behavioral and 
psychological data could be recorded, which is important both for physical and 
mental health management. In general, smartphones and portable computers have a 
pluripotent impact in terms of collection of data about blood pressure, glucose, 
brain waves, and heart rhythm.
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Therefore, we can observe an interesting aspect in P5 approach: patients could 
update their data in order to be carried on by medical staff in each moment of the day; 
at the same time, the combination of real-time self-monitoring and contextual infor-
mation could enhance medical decision-making, according to data analysis tools. 
Data can be collected by patients or caregivers themselves, and they could be reported 
in a portable device or could be captured through sensors in the patient’s living envi-
ronment. The choice and challenge of using artificial intelligence data- mining tech-
niques give the possibility for improving clinical decision-making and a more 
personalized treatment (Van der Krieke et al. 2013; Durand et al. 2014; Gorini et al. 
2018). In addition, it is possible to reduce the number of visits to the doctor. Many 
measurements will be acquired by oneself; people will collect data also respecting 
their own convenience, and it is possible to assume that much more information will 
be acquired than ever before (Van Dyck et al. 2016; Steinberg et al. 2013).
eHealth could become an instrument of cost reduction and prevention (cfr. Chap. 
1); the idea is that this technology will be developed with the aim of leading a reduc-
tion in resource consumption, emergency room use, and number of patients recover-
ing in hospitals. Indeed, the delocalization of therapeutic procedures permitted by 
the use of mobile-based resources will make possible to reduce the necessity for the 
patients to reach the hospital for any healthcare need. This would be desirable also 
in terms of keeping away infections and other problems related to recovery in hos-
pitals (Hayes et al. 2014). For example, the high risk of social isolation caused by 
recovery could increase delays in patients’ discharges from care hospitals (Landeiro 
et al. 2016). Possibly, hospital recovery will be necessary only in specific condi-
tions; it will be part of an important change; for all other cases, patients will be taken 
care of at their homes, with the help of mobile healthcare technologies. These 
instruments can also answer to the emergence of new treatment paradigms able to 
determine when a disease is a current or a future burden for someone, with the 
desire to anticipate illness and its consequences (preventive medicine) (Rotily and 
Roze 2013) (see Fig. 4.1).
It is clear that the importance of safety and regulation of smartphone apps in this 
advancing field is in continuous growth, aiming to an accurate and meticulous shar-
ing of a person’s care (Hayes et al. 2014), which also raises ethical issues such as 
privacy concerns (cfr. Chap. 10). A future perspective of eHealth-related personal-
ized medicine could include the role of caregivers. Family members and friends are 
an important form of support for patients (cfr. Chap. 3); in this sense, eHealth could 
become a key facilitator of medical adherence helping unprepared people for the 
demand of caring. Technologies indeed could require support and training in the 
process of caring (Car et al. 2017). In addition, in the future we could assume the 
ongoing growth of new services based on a user-centered approach and iterative 
development processes, even evaluating the context of use (Scandurra and Sjölinder 
2013) (cfr. Chap. 9).
Another interesting resource for personalization among digital technologies (relat-
ing both mobile and non-mobile devices) regards avatars. Avatars are digital repre-
sentations of users within digital environments, ranging from static images (e.g., in 
social networks) to dynamic figures able to act and move (e.g., in video games). 
Avatars are often customized by users, and according to literature, such customization 
V. Sebri and L. Savioni
61
process is not random, rather users tend to use avatars to represent aspects of their 
physical appearance, personality, and even beliefs in a symbolic manner.
In that some eHealth technologies entail social network features or video games/
serious games, avatars can appear in this field. An interesting development is to exploit 
this specific feature beyond its basic representational features; creating dynamical 
avatars whose appearance changes over time depending on users’ behavior (e.g., 
adherence to therapy and to healthy activities) would create a digital feedback of 
patients’ progress through their own healthcare journey (Triberti and Chirico 2017).
Moreover, recent studies are exploring the idea that digital avatars created by 
patients could be analyzed such as drawings and personal artifacts, in that they may 
be characterized by relevant features to be considered for psychological assessment 
(e.g., patients with low self-esteem and depression symptoms may create less 
detailed avatars) (Triberti et al. 2017; Villani et al. 2016).
Indeed, giving patients the opportunity to represent themselves is another 
resource both in terms of engagement and self-expression and also an innovative 
source of health-related information for health providers and researchers.
4  Liability: The Road Toward Becoming Active Patients
During the specification of technologies referring to P5 approach, we cannot forget 
an important included aspect: the sense of liability. Technologies in general, and 
also eHealth, should include a reflection on this ethic element because the usage of 
these instruments has both benefits and limits.
Fig. 4.1 The impact of personalized medicine on hospitalization
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Firstly, a great advantage of eHealth in terms of liability underlines that people 
can become healthier in their lifestyle. Patients indeed can be incentivized to be 
healthier in all sorts of ways, and the possibility of having one’s own data could be 
a stimulus. This concept is also linked to an idea of prevention; in this case, people 
ideally prevent the development of a chronic disease, involving an own sense of 
liability (Hayes et al. 2014). Therefrom, liability is a positive reaction that an indi-
vidual could improve in front of a possible disease, helped by eHealth. In order to 
explain how eHealth can help the development of liability, we can consider the use 
of genomic markers for personalized medicine. Genomic markers should be a great 
way in order to underline people at high risk of the more common side effects or 
with a high probability of nonresponse. In this case, eHealth could be an accurate 
and current helper in order to find alternative strategies: either with other drugs or 
through preventive means, including diet and physical exercise (Norman et al. 2007).
The overall goal is based on the possibility to have patients even more character-
ized by an increase in level of information flow, transparency, and collaboration 
with personal care as well as quantitative, predictive, and preventive aspects that 
are basic conditions for taking responsibility as P5 approach underlines. This idea 
is sustained by the current and continuous expansion of the healthcare through new 
services. About this, Swan (2009) underlines that social networks are a potential 
instrument in the field of health. Through social networks, everyone can share infor-
mation and knowledge about conditions, symptoms, and treatments, creating a plat-
form for discussion about different issues; if I would have the possibility to know 
my symptoms, I can prevent chronic disease or monitor a future state of illness (cfr. 
Chap. 3). In addition, I can read and understand similar experiences of others; 
patients have to accept a radical change: the repositioning from being a minimally 
informed advice recipient to become an active manager of their own health.
Everyone has the liability of their health, and evaluating this fundamental role, 
individuals must become instigating collaborators, peer leaders, and information 
sharers in participative medicine. In other words, liability through eHealth can bring 
to a transition from paternalistic healthcare to partnership models (Townsend et al. 
2015). In this way, individuals become more and more engaged in the course of 
their care, for example, by participating in a variety of self-testing and self- 
management activities and becoming more and more aware of the personal and 
environmental factors that impact their health (Swan 2009).
Liability should not only increase in patients but also in physicians, which are 
active protagonists of a care co-building. If patients will be more careful about the 
management of their symptoms, physicians should adapt their behavior and work-
out strategies to this new shift, starting to become a care consultant and collaborator 
for patients. This possibility prefigures a collaboration between patients and medi-
cal staff (Appelboom et al. 2014).
In summary, eHealth could be a basic condition to supply people with personal-
ized data for better quantification of their wellness by involving a sense of liabil-
ity; individuals are more likely to have positive behavioral changes, becoming 
active protagonists of their life and not passive recipients of others’ decisions 
(Flores et al. 2013).
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5  Communication Through eHealth
Genetic and genomic technologies were the start for the development of many med-
ical specialties involved in personalized medicine. This is indeed the strategy to 
reduce disjointed or uncoordinated clinical care, in order to optimize effective com-
munication. The overall goal aims at the promotion of patients’ understanding and 
engagement regarding the need, and the consequent use, for these services. An 
interpersonal approach can also optimize the quality of care starting from the mini-
mization of duplicate testing, providing accurate information to patients and their 
families and reducing gaps in healthcares. This can be the optimal result to achieve 
when different medical care roles will collaborate and communicate correctly with 
each other. This way, healthcare services can work together with patients to address 
all issues in a cohesive manner (Haga et al. 2015), moving to a co-diagnosis and a 
co-care model between physicians, patients, and other parties.
We could assist to a change of mental representation within the P5 approach; a 
collaborative communication could start to make physician a colleague and advisor, 
as one of many sources during a care plan. At the same time, patients could become 
more and more of an informed participant, an active responsibility taker, and a coor-
dinator of his/her health program and health data (Hood and Friend 2011). Future 
interactions will be focused on this new way of communication: in this case, patients 
will call physicians in order to have a consultative co-interpretation of the results, 
bringing quantitative reports from their self-testing and self-tracking activities hold 
through eHealth services. Speaking about a change of communication, another 
option is to assume that could be the emergence of on-demand web-based physician 
consultation services with video and chat (Swan 2009).
The usage of eHealth has benefits and limitations at the same time. Several 
advantages of eHealth are evident starting from the high flexibility in its usage 
regarding time and place. Patients could formulate questions and understand 
responses in each moment through communication with healthcare professionals. 
We assume that eHealth could potentially contribute to an increased quality of care 
in front of the new awareness of patients themselves.
At the same time, if many studies underline the positive attitude of patients 
toward self-management, others report to patients’ feeling of inability to judge the 
seriousness of their side effects and symptoms. A research of Schulman-Green et al. 
(2011) establishes the necessity of the assessment related to patients’ preferences 
and ability to self-manage over time, putting attention during transitions and its pos-
sible changes.
Other limits in the use of eHealth could be patient’s age and different cancer 
diagnosis. Regarding the first point, Schulman-Green et al. (2011) underline that 
higher age is associated with lower eHealth usage. It is also possible that the number 
of comorbidity conditions in older persons influences self-management ability neg-
atively. Variations toward eHealth among different cancer diagnosis groups are 
instead examined in depth by Boyes et al. (2012); they report that prostate and tes-
ticular cancer survivors had a more positive attitude toward online contact with 
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healthcare professionals. It’s clear the preference to communicate online intimate 
symptoms encountered, such as incontinence, infertility, and reduced sexual func-
tioning. Børøsund et al. (2013) describe different attitudes toward eHealth between 
breast and prostate cancer patients; sex is in fact another important element of dis-
cussion. Among women with breast cancer, high use of eHealth is typical of those 
with depression and low levels of perceived social support; for men with prostate 
cancer, eHealth’s usage is instead linked to symptom distress. In another study 
(Triberti et al. 2018), males were more likely to use mobile app’s notes function to 
communicate with the health providers, both in terms of medical information and 
personal confidences, comments, and emotional states.
As a solution, future eHealth and mHealth resources should be designed basing 
on users’ personal characteristics, desires, and contexts, in order to tailor such 
devices and services on their own predispositions; according to literature, this would 
augment the probability that such solutions will be accepted and productively used 
(cfr. Chap 9).
6  Health Social Networks
In this chapter, we have had the occasion to discover how eHealth (mobile technolo-
gies and social networks specifically) can support the introduction of personalized 
medicine in the P5 approach. It is important to focus on social networks in order to 
provide more details on how this important resource of web-based technologies can 
be used within a P5 approach to healthcare:
 1. Health social networks are primarily directed to patients, but, at the same time, 
we know that caretakers, families, and other interested parties may be involved 
(Gage-Bouchard et  al. 2017). Sharing information and emotional support is 
important in order to build networks of relationships, reducing the idea to be 
lonely during the healthcare process.
 2. Several health social networks (e.g., eHealth forum) give the possibility to pose 
some questions to physicians (Hawn 2009). This transparency changes the image 
of doctors: it is not a 10-min accessible collaborator in care, but it could become 
a professional role based on the willingness to interact with patients. Even this 
basic mechanism of lightweight doctor-patient interaction could change burdens 
on the healthcare system.
 3. eHealth forum could also be used in order to create a community with other 
patients in which feeling of commonality and mutual comprehension are pre-
sented. This eHealth forum offers the sharing of feelings and personal opinions 
that could be useful for patients lacking social relationships or having the need 
to speak with other people with their same medical condition (Nabi et al. 2013).
 4. Another type of service offered by health social networks is based on quantified 
self-tracking, that is, an easy-to-use data entry screening for symptoms, treat-
ments, and other biological information (Aral and Nicolaides 2017; Morris and 
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Aguilera 2012). The use of graphical displays or other strategies could improve 
patient’s ability of understanding treatments, in order to become active protago-
nists of their cares and, eventually, to be able to call physicians if there is a nega-
tive symptom of disease. This object aims at a personalized medicine based on 
prevention.
 5. In addition, regarding the importance of scientific publications, we could assume 
the possibility to use information for clinical trials. The availability of large 
searchable online databases in which health history and condition information of 
patients are included could improve traditional clinical trials, making them more 
efficient (Groves et al. 2013).
7  Challenges to eHealth Usages and Possible Solutions
New health technologies (eHealth) are recognized as having a major impact on 
health promotion and management. These tools allow to develop the implementa-
tion of integrated, sustainable, and patient-centered services and to promote an 
effective exchange between patient and doctor, with the patient acquiring an active 
role in the health process (Barello et al. 2016; Gorini et al. 2018). However, in some 
cases, eHealth is often unacceptable and/or long term adopted by its users.
There are many factors that can influence the use of eHealth to monitor patient 
health. Firstly, in some patients the idea of being constantly monitored can create 
excessive anxiety; in fact, patients with low self-control, through the use of self- 
monitored technologies, may be afraid of having more problems or treatments for 
the well-being of patients (Kessel et al. 2017). If the patient is not convinced of the 
usefulness of these tools for his health management, or if he/she is excessively 
afraid of the disease, such new commitments could be a source of further stress and 
negative attitude treatment comparisons. In such situations, patients can not only 
abandon the eHealth tools but also their trust in healthcare professionals can be 
reduced with detrimental effects on the effectiveness of the health management pro-
cess as a whole.
In most cases, considering eHealth not useful for oneself, it is related to the lack 
of customization of the tools. The functions and contents of eHealth (including 
required information, patient feedback, etc.) should be adapted to the patient’s 
 individual biopsychosocial characteristics to provide more useful, more accepted, 
and nonredundant information (Gorini et  al. 2015; Pravettoni et  al. 2016). 
Furthermore, the personalization factors also refer to the possibility of the patient to 
express himself within the use of the technology. For example, eHealth functions, as 
well as automatic communications, will not be generalized to patient populations, 
but will be based on individual characteristics.
Secondly, some patients were concerned about the implementation of eHealth as 
a result of the budget cuts being treated. The need for face-to-face contact with pro-
fessional figures is always a very requested and reassuring aspect for patients 
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(Mattsson et al. 2017). It is important to explain the reason for using eHealth, which 
is intended to accompany the work of physician and not to replace it.
In conclusion, the goal of personalized medicine, and the specific approach of 
P5, is to highlight the importance of a personalized technology for each type of 
patient.
8  Conclusion
In recent years, personalized medicine has attracted great interest and has expanded 
more and more, involving different areas of healthcare. In particular, it allowed 
changes in the choice of treatment through pharmacogenomics. Through this disci-
pline, it has indeed been possible to predict the possible side effects of drugs on 
individual patients, define a priori the best treatment and the best drugs that fit the 
specific patient, and identify the susceptibility of an individual to certain diseases, 
favoring the identification of a preventive treatment plan.
All these aspects have favored the shift of attention more on prevention than the 
treatment of diseases. The use of personalized medicine in the field of prevention 
can significantly reduce the incidence of diseases, especially chronic ones.
Another aspect that has been involved since the advent of personalized medicine 
is the communication between doctor and patient. The doctor is more attentive to 
the needs of the patient, providing clear information about diagnosis and treatment. 
At the same time, the patient has a voice in relation to the decisions that determine 
their state of health and their care.
The patient is no longer a passive subject, but becomes an active one, both in 
decision-making and in the management of his illness. This aspect is favored by 
technology that through different devices has made it easier to monitor your health 
and communication.
eHealth, for example, could be a useful instrument for helping monitoring and 
managing diseases. eHealth, indeed, makes it possible for patients to be carried by 
medical staff in each moment of day through the combination of real-time self- 
monitoring with many contextual information. The result of this health strategy can 
enhance medical decision-making, in combination to data analysis tools. This not 
only brings to a reduction of the number of times patients have to visit the doctor but 
also is a means of reducing costs and healthcare service prevention. At the same 
time, as well as known, putting patients at the center of their medical care is essential 
for their sense of participation. It could be interesting also for increasing the sense of 
liability of patients through a new awareness. A collaborative communication could 
start to make the physician a colleague and advisor, one of many sources during a 
care plan. In conclusion, personalized medicine as aspect of the P5 approach is a 
great strategy of intervention for increasing personal skills of illness management.
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Chapter 5
Predictive Precision Medicine: Towards 
the Computational Challenge
Cosimo Tuena, Michelle Semonella, Javier Fernández-Álvarez, 
Desirée Colombo, and Pietro Cipresso
1  Introduction
Medicine is an evolving field that updates its applications thanks to recent advances 
from a broad spectrum of sciences such as biology, chemistry, statistics, mathemat-
ics, engineering and life and social sciences. Generally, discoveries in such sciences 
are applied to medicine with three main aims of preventing, diagnosing and treating 
a wide range of medical conditions.
The current approach to diseases can be summarized with the “one-size-fits all” 
statement; although this view of medicine has been used for the past 30 years, appli-
cations of effective treatment, for example, can lack efficacy and have adverse or 
unpredictable reactions in individual patients (Roden 2016).
Precision medicine is the extension and the evolution of the current approach to 
patient’s management (Ramaswami et al. 2018). Unlike “one-size-fits all” approach, 
precision medicine is mainly preventive and proactive rather than reactive (Mathur 
and Sutton 2017) (cfr. Chap. 3). Barak Obama, who claimed the importance of 
“delivering the right treatments, at the right time, every time to the right person”, 
has highlighted the critical impact of this emerging initiative in healthcare practice. 
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The personalized approach has been therefore emerged as a critique to an oversim-
plified and reductive medicine to disease categorization and treatment. Precision 
medicine uses a broad spectrum of data, ranging from biological to social informa-
tion, tailoring diagnosis, prognosis and therapy on patient’s needs and characteris-
tics, in accordance to the P5 approach.
Another crucial element of this initiative is the use of informatics: incorporating 
technology would allow to create a data ecosystem that merges biological informa-
tion and clinical phenotypes, thanks to imaging, laboratory test and health records, 
in order to better identify and treat the disease affecting the individual, reducing 
financial and time efforts and improving the quality of life of the patients.
The present chapter will focus on the potential of predictive precision medicine 
as new approach to health sciences and clinical practice, giving an overview on the 
tools, the methodology and a concrete application of the P5 approach.
2  Predictive Medicine and Precision Medicine
Among healthcare applications, predictive medicine is a relatively new area, and it 
can be defined as the use of laboratory and genetic tests to predict either the onset of 
a disease in an individual or deterioration or amelioration of current disease, to esti-
mate the risk for a certain outcome and predict which treatment will be the most 
effective on the individual (Jen and Teoli 2019; Jen and Varacallo 2019; Valet and 
Tárnok 2003). In this sense, biomarkers could be used to forecast disease onset, 
prognosis and therapy outcome. Biomarker or biological marker indicates a medical 
sign that can be measured in an objective way, accurately and reproducibly; the 
World Health Organization defined biomarker as “almost any measurement reflect-
ing an interaction between a biological system and a potential hazard, which may be 
chemical, physical, or biological. The measured response may be functional and 
physiological, biochemical at the cellular level, or a molecular interaction” (Strimbu 
and Tavel 2010). Biomarkers are used for drug development and clinical outcome; if 
the current approach to clinical trials is “one-size-fits-all” (i.e. the effect of a treat-
ment is similar for the whole sample), the future of medicine is to provide the “the 
right treatment for the right patient at the right time”, identifying different subgroups 
depending on certain biomarkers that respond to an optimal therapy (Chen et  al. 
2015).
As we have seen in the previous chapters, precision medicine is one of the P5 
approach’s features that tailor healthcare applications on the basis of individual 
genes, environment and lifestyle (Hodson 2016). If personalized medicine takes 
into account patient’s genes but also beliefs, preferences and social context, preci-
sion medicine is a model heavily based on data, analytics and information; thus, the 
latter approach has a wide “ecosystem” that includes patients, clinicians, research-
ers, technologies, genomics and data sharing (Ginsburg and Phillips 2018). In order 
to realize precision medicine, it is crucial to determine biomarkers using either omic 
(i.e. genomic, proteomic, epigenetic and so on) data alone or in combination with 
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environmental and lifestyle information (Wang et al. 2017) with the objective of 
creating prognostic, diagnostic and therapeutic interventions based on patient’s 
needs (Mirnezami et al. 2012).
This new concept of medicine involves the medical institutions that collect every 
day healthcare information, such as biomedical images or signals. New analytical 
methods computed by computer, such as machine learning, prompted the “Big Data 
Revolution”; thus Big Data analysis in predictive medicine (Jen and Teoli 2019; Jen 
and Varacallo 2019), computational psychometrics (Cipresso 2015; Cipresso et al. 
2015; von Davier 2017) and precision medicine (Richard Leff and Yang 2015) may 
soon benefit from huge amount of medical information and computational tech-
niques (Cipresso and Immekus 2017). New technologies such as virtual reality 
enable to extract online quantitative and computational data for each individual to 
deepen the study of cognitive processes (Cipresso 2015; Muratore et al. 2019; Tuena 
et al. 2019). eHealth generally is an accurate instrument in collecting data; further-
more, Big Data differ from conventional analyses in three ways according to Mayer- 
Schönberger and Ingelsson (Mayer-Schönberger and Ingelsson 2018): data of the 
phenomenon under question are extracted in a comprehensive manner; machine 
learning such as neural networks are preferred for statistical analyses compared to 
conventional methods; and finally, Big Data do not only answer to questions but 
generate new hypotheses.
Consequently, technologies and informatics will gradually become the future of 
medicine (Regierer et al. 2013). eHealth aims at using biomedical data for scientific 
questions, decision-making (cfr. Chap. 4) and problem-solving (Jen and Teoli 2019; 
Jen and Varacallo 2019) in accordance with the P5 approach. On the one hand, 
informatics is crucial for precision medicine since it manages Big Data, creates 
learning systems, gives access for individual involvement and supports precision 
intervention from translational research (Frey et al. 2016); on the other hand, clini-
cal informatics is crucial for predictive medicine providing clinicians tools that able 
to give information about individual at risk, disease onset and how to intervene (Jen 
and Teoli 2019; Jen and Varacallo 2019). The importance of informatics in the field 
of medicine is confirmed by the fact that in the United States the use of electronic 
health records grew from 11.8% to 39.6% among physicians from 2007 to 2012 
(Hsiao et al. 2014).
Besides the medical and scientific elements of precision medicine, this field has 
an impact also on patient and global population (Ginsburg and Phillips 2018; 
Pritchard et al. 2017). In particular, the precision medicine coalition’s healthcare 
working group defined novel challenges within this field:
• Education and awareness: Precision medicine is complex and sometimes con-
fusing; awareness should be improved in potential consumers and healthcare 
providers, and education within the scientific and clinic areas should integrate 
the precision medicine approach.
• Patient empowerment: Precision medicine is a way to engage and empower the 
patient. However, consent form needs to clarify the use of molecular informa-
tion, and providers do not properly involve patient in healthcare decision- making, 
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and preferences are not always taken into account; lastly, privacy and security of 
the digital data must be improved and assured.
• Value recognition: There are ambivalent sentiments concerning precision medi-
cine, where stakeholders think that precision medicine can be beneficial for 
patients and healthcare system, whereas payers and providers are not sure to 
modify policies and practices without clear positive evidence of clinical and eco-
nomic value.
• Infrastructure and information management: In order to pursue, the precision 
medicine approach is needed to effectively manage the massive amount of data 
and the connections among the infrastructures; for instance, processes and poli-
cies should assure clear communications across healthcare providers, genetic 
patients’ data could be gathered with clinical information within electronic 
health records, and medical data need to be standardized across platforms.
• Ensuring access to care: This point needs a shift in the perspective of stakehold-
ers that is achieved by covering the aforementioned key points; at the moment, 
insurance companies do not cover high-quality diagnostic procedures, electronic 
health records should be upgraded to integrate complex biological data, some 
physicians avoid to embrace the precision medicine approach due to misleading 
perception (e.g. cost/benefit distortions), there is no guideline that coordinates 
the partners and products, and services cannot be used by population especially 
in rural environments.
Predictive precision medicine in the P5 approach can be defined as the merging 
of these two new fields of medical sciences by means of biomarkers to forecast 
disease onset, progression and its treatment tailored on individual features like 
omic, environmental and lifestyle elements that could lead to significant improve-
ment from patients’ life to global population and healthcare systems.
3  Imaging Techniques, Artificial Intelligence and Machine 
Learning
3.1  Imaging Techniques
In the context of predictive medicine and precision medicine, biomedical imaging 
instruments used in radiology are the most promising techniques and methods 
(Herold et al. 2016; Jen and Teoli 2019; Jen and Varacallo 2019). In particular, with 
radiology techniques, it is possible to extract structural, functional and metabolic 
information that can be used for diagnostic, prognostic and therapeutic purposes 
(Herold et al. 2016). Imaging techniques (Jen and Varacallo 2019) acquire a vital 
role not only in applied medicine but also in system biology that attempts to model 
the structure and the dynamics of complex biological systems (Kherlopian et  al. 
C. Tuena et al.
75
2008). Model imaging techniques enable to visualize multidimensional and multi-
parametrical data, such as concentration, tissue characteristics, surfaces and also 
temporal information (Eils and Athale 2003). According to Kherlopian and col-
leagues (Kherlopian et al. 2008), the most promising imaging instruments will be 
microscopy methods, ultrasound, computed tomography (CT), magnetic resonance 
imaging (MRI) and positron emission tomography (PET); advances in biomedical 
engineering will improve spatial and temporal resolution of such images, but with 
the introduction of contrast agents and molecular probes, biomedical images will 
allow for the visualization of anatomical structures, cells and molecular dynamics, 
and consequently, microCT, microMRI and microPET are going to be at the centre 
of basic and applied research.
Multiphoton microscopy, atomic force microscopy and electron microscopy are 
capable of giving, respectively, cell structure, cell surface and protein structure with 
a spatial resolution of nanometres; enabling ultrasound had a great impact in cardi-
ology, where, for instance, computer is used to interpret echo waveforms bouncing 
back from tissue and create images of the vascular system with a resolution of 
micrometres. CT by means of intrinsic differences in X-ray absorption provided 
imaging with a high spatial resolution (12–50 μm), that is, lung or bone imaging. 
Interestingly, microCT in combination with volumetric decomposition allows to 
represent bone microarchitecture. MRI, thanks to the use of strong magnetic field, 
creates anatomical images with a good spatial resolution; if MRI is combined with 
magnetic resonance spectroscopy, it can provide anatomical and biochemical infor-
mation of a particular region of the organ; if one’s interest is functional activation of 
the brain, then functional MRI detects differences in oxygenated and deoxygenated 
haemoglobin that lead to a change in contrast of the image. MicroMRI is used in 
animal studies at the moment and uses higher magnetic field compared to MRI; with 
such technique, it is possible to track stem cells, monitor the proliferation of immune 
cells and follow embryological development. In PET radioactive tracers, the most 
used is fluorodeoxyglucose (FDG), which is incorporated in molecules to provide 
metabolic information and therapeutic effects on the disease as well. Even if it is 
possible to study a specific metabolic activity of interest, the spatial resolution 
(1–2 mm) is lower compared to the aforementioned techniques; however, microPET 
has a spatial volumetric of 8 mm3, with incoming scanners having higher resolution 
and bigger field of view.
The use of imaging tools such as CT, MRI and PET is growing increasingly, for 
instance, in the United States from 1996 to 2010 in six healthcare systems, the usage 
increased by, respectively, 7.8%, 10% and 57% (Smith-Bindman et  al. 2012). 
However, imaging techniques are several in the present chapter; we only focused on 
the main technologies used in medical field and in particular radiology. This under-
lines the importance of technology and eHealth as opportunity for improving preci-
sion medicine at large.
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3.2  Artificial Intelligence and Machine Learning
Artificial intelligence (AI) aims at simulating human cognition (Hassabis et  al. 
2017). One of the recent technologies used within the context of AI is machine 
learning (ML); ML enables machine to have a human-like intelligence without prior 
programming (Das et al. 2015). Moreover, ML is the most used method to analyse 
data and make prediction using models and algorithms (Angra and Ahuja 2017). 
Within the context of ML, deep learning (DL) and neural network (NN) assume 
great relevance (Ker et al. 2018; Schmidhuber 2015). The concept of NN was first 
introduced in 1943 by McCulloch and Pitts and found its application in the 
Rosenblat’s Perceptron; an artificial NN consists of a layer of neurons that links 
inputs that perceive a certain stimuli, hidden neurons that get activated via weighted 
connections of active neurons and output that gives the computation made by the 
NN. DL is multiple layers of artificial neural networks, wherein the machine can 
learn details and merge them in high-level features in brain-like manner. DL and NN 
enabled complex computations using supervised, unsupervised and reinforcement 
learning. The algorithms used in ML can be classified as follows (Das et al. 2015; 
Hassabis et al. 2017; Jiang et al. 2017):
• Supervised learning: When a comparison between output and expected output 
is made, then error is computed and adjusted to give the wanted output; within 
the context of supervised learning, the most used DL algorithm is convolutional 
neural network (CNN), especially used in image recognition and visual learning 
in 2D and 3D images, enabling the analyses of X-ray and CT or MRI images; 
recurrent neural network (RNN) is used for text analysis task (e.g. machine 
translation, text prediction, image caption) similar to a working memory func-
tion and evolved into the long- and short -term memory networks to avoid van-
ishing gradient problem; indeed, an application of AI in this field is a natural 
language processing that can be used for extracting medical notes and connect-
ing these to medical data. Other supervised learning methods are linear regres-
sion, logistic regression, naïve Bayes, decision tree, nearest neighbour, random 
forest, discriminant analysis, support vector machine (SVM) and NN.
• Unsupervised learning: In this case, the machine discovers and adjusts itself 
based on input. For example, an autoencoder input codes the stimuli-gathered 
codings and reconstructs from these the output; in this case, the output must be 
as close as possible to the input information; restricted Boltzmann machines are 
composed of visible and hidden layers that reconstruct the input estimating the 
probability distribution of the original input; in deep belief network, the output 
of a restricted Boltzmann machine is the input of another Boltzmann machine; 
finally, generative adversarial networks are generative models that are composed 
of two competing CNNs: the first CNN generates artificial training images, and 
the second CNN discriminates real training images from artificial ones; the 
desired expectation is that the discriminator cannot tell the difference between 
the two images; this algorithm is very promising for medical image analyses; 
other unsupervised methods are clustering, which can be used to divide data in 
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groups, and principal component analysis that reduces data dimension without 
losing critical information and then creating groups.
• Reinforcement learning: In this case, learning is enhanced with a reward when 
the machine executes a “winning” choice; similarly, Q-learning algorithm 
(Rodrigues et al. 2008) allows to compute the future rewards when the machine 
is performing a certain action in a particular state in order to keep on acting in an 
optimal manner.
• Recommender system: In this case, the online user customizes a site as what 
happens in e-commerce.
ML problems include pattern classification, regression, control, system identifi-
cation and prediction that can be summarized into two main elements: developing 
algorithms that quantify relations among data and using these to make prediction on 
new data (Wernick et al. 2014).
3.3  Medical Imaging and Machine Learning
ML and AI find in medical imaging field a concrete application in order to analyse 
images and help physician with particular regard in the field of radiology in decision- 
making processes improving patient’s management (Jiang et  al. 2017; Ker et  al. 
2018; Kim et  al. 2018). Indeed, the P5 approach underlines the importance of 
decision- making process and the usage of eHealth in order to improve it. ML tech-
nology is used in the sector of medical imaging for computer-aided diagnosis 
(CADx) and computer-aided detection (CADe); the former can also help to identify 
region properties useful for surgery. In radiology, CADx and CADe usages are, 
respectively, classification and detection although ML techniques can be used for 
anatomy educational purposes (i.e. localization) and to facilitate surgery (i.e. seg-
mentation, registration) (Kim et al. 2018).
According to the review conducted on PubMed from 2013 to 2016 by Jiang and 
co-authors (Jiang et al. 2017), AI applications critical in medical field are cardiol-
ogy, cancer and neurology. In their report, Jiang and colleagues evidenced that the 
fields of medical application of AI are diagnostic imaging, genetic and electrodiag-
nosis, with diagnostic imaging showing the greater impact on research. As concerns 
the disease conditions, the order of impact on research activity are neoplasms, ner-
vous system, cardiovascular, urogenital, pregnancy, digestive, respiratory, skin, 
endocrine and nutritional; finally, the most used algorithms in this field are NN and 
SVM, and in particular, DL technology is applied mostly in diagnostic imaging and 
electrodiagnosis; interestingly, from 2013 to 2016 CNN increased the application in 
literature, whereas RNN diminished, and deep belief network and deep neural net-
work remained stable across the periods.
In particular, CNN, autoencoders and RNN are excellent algorithms for medical 
imaging analysis (Kim et  al. 2018). Convolution that is based on addition and 
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 multiplication is suitable for image recognition; the procedure takes into account 
connected information (i.e. voxel or pixel); within convolution layers, there are 
pooling layers that increase the field of view, and then fully connected layers acti-
vate previous layers; autoencoders are composed of multiple perceptrons; encoders 
can be stacked and can be used to de-noise image of input data; and finally RNN 
uses feedback and current data enabling to model sequential data with spatial and 
temporal information. CNN architectures can be used to detect different organ (e.g. 
brain, liver, heart, prostate or retina) lesions or diseases; to predict disease course, 
treatment response and survival; and to classify disease, lesion and cell using CT, 
MRI, PET and other imaging techniques (e.g. retina image, mammography or fluo-
rescent image). Autoencoders have been used in research to detect lesion with 
breast histology images, predict risk for cognitive deficits and classify lung and 
breast lesions, whereas stacked autoencoders have been applied for segmentation 
and image enhancement/generation. Also other algorithms are applied in radiology, 
for instance, reinforcement learning in combination with data mining helps in 
decision- making for physicians in cancer diagnosis, for segmentation tasks and for 
classification of lung nodules (Rodrigues et al. 2008). A critical element of these 
technologies is that before applying AI to medical imaging and more broadly to 
healthcare system, algorithms need to be trained with data derived from clinical 
activities and in different forms; for example, 1.2 million of training data are being 
used to teach DL algorithms on MRI brain imaging; by the way, the quality of DL 
techniques depends on the quality of training data; this issue can be improved by 
adopting multisite, standardized and methodologically adequate acquisition proto-
cols (Jiang et al. 2017).
4  Predictive Precision Medicine in Neurodegenerative 
Diseases
An increasing lifespan and expectancy with a reduction of mortality result in an 
increment in aged population in our society; consequently, these factors have 
brought the attention of scientific and clinical community to chronic age-related or 
degenerative diseases. Due to the complexity of the aetiology and pathogenesis, 
resulting in interplay among genetic, epigenetic and environment, prevention (pri-
mary, secondary and tertiary) (cfr. Chap. 3) and, in particular, predictive and preci-
sion medicine assume a crucial role as features of the P5 approach, with omic 
approach to biology and computational methods acquiring a relevant position 
(Licastro and Caruso 2010; Reitz 2016). In particular, predictive genetic testing and 
molecular genetic diagnosis have well-established position in clinical practice and 
translational research in the field of neurodegenerative disorders (Paulsen et  al. 
2013). Indeed, neurodegenerative diseases have specific gene profiles (Bertram and 
Tanzi 2005). For instance, symptomatic testing in Alzheimer’s disease (AD) requires 
neurological and neuropsychological examination; then genetic counselling and 
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risk administration are determined: either an autosomal dominant history is present 
or the onset is early or sporadic, or there is a nonautosomal dominant family cluster-
ing; in the first case, genetic testing is offered; if not or in the second case, it is pos-
sible to discuss availability of genetic research and/or DNA banking; always in the 
first case, post-test results are emitted and follow-up/predictive testing for relative is 
provided; conversely for predictive testing, family mutation in relevant genes 
(PSEN1, PSEN2 or APP) is known; genetic and risk counselling is provided; neu-
rological, neuropsychological and psychiatric evaluations are offered; and then 
genetic test and follow-up follow the latter step (Goldman et al. 2011).
Neurological disorders account for 17% of global deaths, and precision medi-
cine gathering genomics, electronic medical records and stem cell models might 
be vital for therapeutic interventions in neurology; in this sense, drugs tap common 
symptoms, but adopting a precision medicine approach, it is useful to create drugs 
that target group of people with similar genetic variation (Gibbs et  al. 2018). 
Besides drug administration, precision medicine can be applied in the context of 
neurodegenerative diseases to evaluate preclinical stages, facilitate differential 
diagnosis and define the better treatment at the right moment taking into account 
genes, epigenetic modifiers and nongenetic factors on neurodegeneration; the 
combination of these elements should be used to create a patient’s omic profile 
(Strafella et al. 2018).
4.1  Current Application: From Dementias to Parkinson’s 
Disease
As already mentioned, ML approaches could be very useful in the field of brain 
imaging for classification and preventive aims. We will provide some interesting 
studies of ML within the context of preventive precision medicine for neurodegen-
erative disorders in order to highlight the importance of technology, and eHealth 
specifically, into precision medicine.
Katako and colleagues (Katako et al. 2018) used well-known FDG-PET meta-
bolic biomarker (Dubois et  al. 2007) from images from four datasets of the 
Alzheimer’s disease neuroimaging initiative. The researchers compared five 
machine-based classification (i.e. voxel-wise general linear model, subprofile mod-
elling and SVM). Subprofile modelling is a type of PCA used for differential diag-
nosis and prognosis in neurodegeneration, whereas SVM is a form of supervised 
learning used to solve binary classification. Subprofile modelling was utilized with 
two PCA approaches (single principal component and linear combination of princi-
pal components); for SVM iterative single-data algorithm or sequential minimal 
optimization was applied. All five methods discriminated patients and controls, 
when compared with tenfold cross-validation SVA with iterative single-data algo-
rithm gave the best results in terms of sensitivity (0.84) and specificity (0.95). In 
terms of prediction of AD from mild cognitive impairment (MCI), this SVA 
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 algorithm had the best performance; interestingly, when comparing PET and single- 
photon emission computed tomography (SPECT), the iterative single-data algo-
rithm showed higher sensitivity compared to sequential minimal optimization SVM, 
whereas the latter has higher specificity compared to the former. To test clinical 
application of the method, a retrospective imaging study was conducted with MCI 
and subjective cognitive complaints individuals referred from the local memory 
clinic. All five methods classified as AD the majority of patients later diagnosed 
with this disease; however, patients who later developed dementia with Lewy body 
(DLB) and Parkinson’s disease dementia (PDD) were diagnosed as having AD, 
showing nonspecificity for different types of dementias. Despite that, FDG-PET 
images showed that DLB and PDD brain pathology suggest AD-like biomarker that 
is not present in non-demented Parkinson’s diseases (PDND) individuals when 
using SVM algorithms. Lama and co-authors (Lama et al. 2017) classified structural 
images from the Alzheimer’s disease neuroimaging initiative. Using structural MRI 
(i.e. grey matter tissue volume), the researchers compared brain images from 
patients with AD, MCI and healthy controls using SVM, import vector machine 
(IVM) based on kernel logistic regression and regularized extreme machine learn-
ing (RELM); moreover, to reduce the dimensionality of data, PCA was performed, 
and permutation testing such as 70/30 cross-validation, tenfold cross-validation and 
leave-one-out cross-validation was applied. The best classifiers appeared to be the 
RELM with PCA for feature selection approach; this machine improved classifica-
tion of AD from MCI and controls. In particular, binary classification (AD vs. con-
trols) with PCA revealed that in terms of accuracy, there was no significant 
difference, but RELM is better than others with tenfold cross-validation, whereas 
SVM is better than the latter with leave-one-out cross-validation. Sensitivity was 
77.51% for SVM, and specificity was 90.63% for RELM with tenfold cross- 
validation, whereas with leave-one-out cross-validation, IVM has a sensitivity of 
87.10% and RELM a specificity of 83.54%. Multiclass classification (AD vs. MCI 
vs. controls) with PCA showed that RELM with tenfold and leave-one-out cross- 
validation has an accuracy of 59.81% and 61.58% and a specificity of 62.25%. 
Another study that used MRI is the one of Donnelly-Kehoe et al. (Donnelly-Kehoe 
et al. 2018). In their research, neuromorphometric features from MRI classify con-
trols, MCI, MCI converted to AD and AD. Participants were divided in three groups 
according to Mini-Mental State Examination (MMSE) scores with the aim of 
searching the main morphologic features; these were used to design a multiclassifier 
system (MCS) composed of three subclassifiers trained on data selected depending 
on MMSE; MCS was compared with three classification algorithms: random forest, 
SVM and Ada-Boost. MCS with three architectures each outperformed single clas-
sifiers in terms of accuracy, and for area under the receiver operating curve (AUC), 
multiclass AUC was 0.83 for controls, 0.76 for MCI converted to AD, 0.65 for MCI 
and 0.95 for AD. Accuracy for neurodegenerative detection (AD + MCI converted 
to AD) was 81%. Random forest and SVM had similar performances, but the former 
was chosen as the best algorithm since it has few parameters. In particular, accuracy 
on neurodegenerative detection for the three random forests was 0.71, 0.63 and 
0.81. The authors claim that MCS based on cognitive scoring can help MRI AD 
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diagnosis compared to well-established algorithms. Interestingly, Guo and col-
leagues (Guo et al. 2017) developed an ML technology that exploits hypernetwork 
able to overcome conventional network methods and fMRI data of AD individuals. 
After data acquisition, they built the hypernetwork’s connectivity and extracted 
brain regions with a nonparametric test method and subgraph features with fre-
quently scoring feature selection algorithm; then, kernel (vector and graph, respec-
tively) matrix classification with multikernel SVM was computed. Findings from 
brain regions and graph features are in line with previous network disruption in AD 
(Buckner et al. 2008). SVM classification was used for classification of the sample 
(AD, early MCI and late MCI), and the hypernetwork enabled to extract interactions 
and topological information. The results of the ML were compared with conven-
tional methods based on partial and Pearson correlations. Findings reveal that the 
method identifies both interactive and representative high-order information; more-
over, AUC for brain region features was 0.831 and 0.762 for graph features but for 
multifeature classification was 0.919. Multifeature classification can therefore ame-
liorate AD diagnosis based on biomarker.
Interestingly, ML can be used also to compute electroencephalography (EEG) 
biomarker in order to identify AD pathology and drug intervention (Simpraga et al. 
2017). Data were used to calculate muscarinic acetylcholine receptor antagonist 
(mAChR) index in healthy participants who received scopolamine to simulate cog-
nitive deficits from 14 EEG biomarkers (spatial and temporal biomarker algorithm); 
the index had cross-validated accuracy, sensitivity, specificity and precision ranging 
from 88% to 92% in classifying performances compared to single biomarkers. The 
mAChR index successfully classified AD patients with accuracy of 62%, 35% sen-
sitivity, 91% specificity and 81% precision; also an AD index was computed from 
12 EEG biomarker with accuracy, sensitivity, specificity and precision ranging from 
87% to 97%. The findings are useful not only for diagnosis between healthy partici-
pants and patients with AD but also for experimental pharmacology because the 
index assesses the well-known AD cholinergic electrophysiology and drug penetra-
tion in this disease.
Frontotemporal dementia (FTD) is one of the most common causes of early 
onset dementia; among FTD profiles, behavioural FTD is the most frequent and is 
characterized by specific biomarker (Piguet et al. 2011). Meyer and co-authors used 
MRI from multicentre cohort to predict diagnosis in each single patient showing the 
potential of precision medicine (Meyer et al. 2017). They calculated brain atrophy 
differences between controls and patients and used SVM to differentiate these 
groups on an individual level. Grey matter density from the conjunction analyses of 
the cohorts evidenced an overlap in the frontal poles bilaterally. When using the 
algorithm to predict diagnosis individually, accuracy ranged from 71.1% to 78.9% 
in the same centre sample (19 behavioural FTD patients vs. 19 controls) and from 
78.8% to 84.6% in the whole sample analyses (52 behavioural FTD patients vs. 52 
controls). The better predictive region was the frontal lobe compared to the tempo-
ral area (80.7% vs. 78.8%); the accuracy increased when accuracy was computed 
for frontal and temporal regions together and furthermore ameliorated when adding 
other relevant brain regions such as insula and basal ganglia. Despite researchers 
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found an intercentre variability, they encourage the use of ML and imaging tech-
niques for predictive purposes based on biomarker for personalized early detection 
of brain degeneration.
Another neurodegenerative disease that represents a social burden is Parkinson’s 
disease (PD). Biomarkers and imaging can improve the diagnosis of neurodegen-
erative diseases such as PD (Pievani et al. 2011). Abós and co-authors used ML to 
define biomarker associated with cognitive status in PD individuals (Abós et  al. 
2017). Functional connectivity was used to assess PD depending on cognitive pro-
file (with MCI or without MCI) with ML methods and resting-state fMRI. In their 
study, supervised SVM algorithm, functional connectomics data, neuropsychologi-
cal profile, leave-one-out cross-validation and independent sample (training group 
vs. validation group) validation for the model were applied. Leave-one-out cross- 
validation for subject classification prediction for PD-MCI and PD-nonMCI was for 
both 82.6%; the independent sample validation correctly classified with the trained 
SVM machine the participants with AUC of 0.81. Leave-one-out cross-validation 
and randomized logistic regression were used to select the most relevant edges (21) 
and nodes (34) of the network. There was an alteration of the edges for the PD-MCI 
compared to PD-nonMCI group. For 16 edges, connectivity was reduced in the 
former group, for 13 of these edges, connectivity was impaired also compared to 
controls, but for the remaining 5, the network was stronger in PD-MCI compared to 
PD-nonMCI. For the 16 weakened edges, correlations were found with executive 
functions, visuospatial deficits, levadopa daily dosage and disease duration. This 
methodology proposed by the authors shows that ML and fMRI could be useful for 
PD cognitive diagnosis and assessment.
ML can successfully be applied also to nonimaging data to predict the risk for 
dementia from population-based surveys (de Langavant et al. 2018). Langavant and 
colleagues developed unsupervised ML classification with PCA and hierarchical 
clustering on the Health and Retirement Study (HRS; 2002–2003, N = 18,165 indi-
viduals) and validated the algorithm in the Survey of Health, Ageing and Retirement 
in Europe (SHARE; 2010–2012, N  =  58,202 individuals). The accuracy of this 
method was assessed with a subgroup of the HRS with dementia diagnosis from 
previous study. The machine identified three clusters from HRS: individuals with no 
functional and motor (e.g. walking) impairment, with motor impairment only and 
with both functional and motor deficits. The latter group showed a high likelihood 
for dementia (probability of dementia >0.95; area under the curve [AUC] = 0.91) 
also when removing cognitive/behavioural measures. Similar clusters were found in 
SHARE. After 3.9 years follow-up, survival rate for HRS and SHARE in cluster 3 
were 39.2% and 62.2%; surviving participants in this cluster showed functional and 
motor impairments over the same period. The authors claim that the algorithm is 
able to classify people at risk for dementia and survival and therefore use this clas-
sification for prevention and trial assignment.
In their review, Dallora and colleagues (Dallora et al. 2017) found that for the 
prognosis of dementia, the most applied ML technique is SVM; among ML, neuro-
imaging studies (i.e. MRI and PET) were most frequent compared to  cognitive/
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behavioural, genetic, lab tests and demographic data with the main of predicating 
the proportion of MCI individuals that will develop AD. The researchers in terms of 
validation procedure, datasets used, number or records within the same dataset and 
follow-up period found limitations. However, defining biomarkers in the field of 
neurodegenerative diseases could improve diagnosis and treatment and consolidate 
the role of precision medicine and prediction of disease progress (Dallora et  al. 
2017; Reitz 2016; Rosenberg 2017). As we have seen, technologies (and eHealth 
especially) could be a good instrument, also in the context of the P5 approach and 
future medicine.
5  Conclusion
In this chapter, we elucidated the potential role of predictive precision medicine as 
a feature of the P5 approach with a particular focus on radiological imaging and ML 
algorithms applied in neurology. Despite the benefits of precision medicine, the 
complexity of this approach could be simplified with artificial intelligence methods 
that can reduce the amount of information and target specific biomarker useful for 
diagnosis, prognosis and treatment. We reported excellent evidences that this 
approach could improve the management of neurodegenerative disorders (i.e. AD, 
PD, FTD, MCI, DLB, PDD) from different perspectives: individual and whole sam-
ple and metabolic, structural, functional, electrophysiological and cognitive/behav-
ioural methods. For this reason, we encourage the healthcare system that in this 
sense comprises of researchers, clinicians, institutions, providers and stakeholders 
to embrace this vision of medicine.
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Chapter 6
Participatory Aspects of ICT 
Infrastructures for Cancer Management
Haridimos Kondylakis, Lefteris Koumakis, Ketti Mazzocco, 
Manolis Tsiknakis, and Kostas Marias
1  Introduction
As cancer research has come up with new, more effective treatments more and more 
cancer patients are being cured, and very many more enabled to live with their can-
cer. The disease is now frequently managed as a chronic illness requiring long-term 
surveillance and, in some cases, maintenance treatment. Cancer care occurs on a 
continuum that stretches from prevention to the end of life, with early detection, 
diagnosis, treatment, and survivorship in between. This implies a transformation in 
the nature of the existing healthcare model from reactive to preventive, and to per-
sonalized medicine. As a chronic illness, however, there is an urgent economic and 
pragmatic need for patients and families to manage their own care, and for the 
healthcare system to develop efficient strategies in supporting the achievement of 
this objective. Self-management support is defined as ‘what health services do in 
order to aid and encourage people living with a long term condition to make daily 
decisions that improve health related behaviours and clinical and other outcomes’. 
Educating patients to self-management of disease strengthens health behaviours by 
promoting health literacy and collaborative decision-making skills, problem solving 
and action planning related to their condition. Such an approach is being embraced 
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by government policies and in clinical practice, as demonstrated by the increasing 
number of initiatives and trials for patients’ self-management.
Advances in information and communication technology (ICT), together with 
the recent spread of portable devices such as smartphones and tablets, offer the 
opportunity to re-design self-management. ICT can provide the means to transform 
the role of the patient from a passive recipient of healthcare services to an active, 
informed participant of medical decision-making processes in charge of his or her 
own well-being.
In this chapter, we review how this vision of building ICT platforms that promote 
and enhance the participation of all stakeholders involved in cancer management 
has been implemented in the context of five European research projects. Primarily 
they focus on the individual patient, empowering them and enabling better self- 
management, but also on the various care providers and health experts involved in 
the patient journey. Those projects focus on the transformation of the paternalistic 
model of patient–doctor to a new model that promotes the participatory aspects of 
all involved participants. We present achievements in the area of those five EU pro-
posals, we identify the solutions provided and we discuss lessons learnt. Then we 
summarize and provide guidelines on the development of future ICT platforms.
The rest of this chapter is structured as follows: In Sect. 2, we elaborate on par-
ticipatory aspects for cancer management and we highlight the need to transform 
the existing model, discussing also recent evidences on the area. Then in Sect. 3 we 
present experiences from five relevant EU projects (iManageCancer, 
MyHealthAvatar, p-Medicine, EURECA and INTEGRATE) and we elaborate on 
their approach to enable patients to participate in the management of their disease. 
Then in Sect. 4 we summarize the findings and we present directions for the devel-
opment of future ICT platforms with a strong focus on further enhancing the patient 
participation on the management of their disease.
2  Participatory Aspects for Cancer Management
2.1  From Personalized to Participatory Medicine
Since the early 2000s, we are observing a profound revolution in the healthcare, with 
a shift in the medicine approach toward a predictive, preventive and personalized one, 
slowly moving towards the so-called 3P model (Hood et al. 2004; Weston and Hood 
2004). Personalized medicine refers primarily to the genomic and molecular biology. 
Thanks to a unique combination of biological information, it is possible to design new 
pharmacological therapies tailored to the specific molecular picture of the patient.
Despite the important changes of this new approach, the underlying paradigm 
considered the patient still as a passive recipient of care, with the healthcare profes-
sionals as main actors. Three main aspects make this perspective suboptimal:
 1) Medicine normally acts under uncertainty conditions, and some relevant infor-
mation lies locked within the patient’s body (Sox et al. 2013). To reduce uncer-
tainty, besides the clinical examinations, some data can be obtained only from 
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the patient: doctors must rely on what the patient reports during the visits or 
using the patient reported outcomes measures (PROMs). In line with this per-
spective, the need to consider patients’ knowledge, experiences and needs is not 
a mere ethical position, but it has also clinical consequences. As shown by 
Stacchiotti and Sommer, patients are not only passive care receivers but special 
collaborators that proactively can help clinicians and researchers reduce the 
aforementioned uncertainty (Stacchiotti and Sommer 2015) and find new thera-
peutic solutions.
 2) The last 40 years has seen another initially slow but important shift in medicine: 
from a biomedical to a bio-psycho-social paradigm (Engel 1977; Inerney 2018). 
The World Health Organization has indeed defined health as a state of complete 
physical, mental, and social well-being, emphasizing the shift from the domi-
nant paradigm with a focus on the disease to the new paradigm of wellness as a 
whole (WHO). The disease cannot be considered in isolation from its host: there 
is the need to understand and treat the disease considering the patient as a sys-
tem, where the single parts strictly interact and produce an outcome that is some-
thing more than the sum of the single parts. In this perspective, personal 
psychological characteristics and social contexts interact with the biological fac-
tors in affecting the clinical outcomes. Consequently, the health professionals’ 
aim within this paradigm is not anymore just to cure and increase life expecta-
tion, but to guarantee a good quality of life. Beside objective outcomes, the 
attention is paid also to subjective outcomes. The participation of the patient 
becomes therefore necessary, since the evaluation of what a life of quality means 
depends on the person’s subjective values, priorities and preferences.
 3) The spread of technology has made it easier for patients to access health infor-
mation through the Internet. The constant growth of Internet as a source of health 
information (Morahan-Martin 2004; Internet World Stats 2016) (independently 
on the quality of the information) has contributed to make the patient a ‘clinical 
expert’, changing his/her role from passive recipient to active agent that wants to 
know and wants to participate in the decisions relevant for his/her health.
All these factors pushed for integrating the P3 medicine approach with other Ps, 
in particular a fourth P, standing for participatory (Hood and Friend 2011), and a 
fifth P that stands for psycho-cognitive (Gorini and Pravettoni 2011). In other words, 
the need for actively involving the patient in the care pathway has become a moral 
imperative (Pravettoni et al. 2016).
2.2  Critical Factors of Participatory Medicine
The Society for Participatory Medicine defined participatory medicine as ‘a move-
ment in which networked patients shift from being mere passengers to responsible 
drivers of their health, and in which providers encourage and value them as full 
partners’ (Frydman 2010). Individual’s genetic, molecular, cellular, organ and social 
networks will be combined into an overall ‘network of networks’, to give a detailed 
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picture of the normal and disease-perturbed states. Following this approach, health-
care and wellness is not restricted anymore within the hospitals but moves into 
foundations and the patients’ home. Chordoma Foundation (http://www.chordoma-
foundation.org) is a strong example of the power that the patient can have to make 
the difference in research for the cure of cancer or other fatal diseases, transforming, 
for example as in the case of Chordoma, a rare cancer to a not-so-rare cancer. 
Thanks to technology, indeed, Sommer, the executive director of Chordoma 
Foundation and personally diagnosed with Chordoma cancer, rounded up patients 
and researchers working on that specific cancer, optimizing the resources earlier 
scattered around the world, increasing awareness of the problem and breaking down 
barriers to progress.
Patients’ participation in healthcare is relevant not only for improving research 
on new cancer treatments, but has positive effects on the patient’s health condition. 
Barnato et al. (2007) noted that ‘in an ideal world […] patients would come to a 
cancer consultation armed with sufficient knowledge, clarity about their personal 
value, and the ability to engage in a thoughtful discussion about the pros and cons 
of treatment options. Providers, in turn, would be prepared to support their patients, 
armed with an understanding of the patient’s knowledge gaps, personal values about 
possible outcomes and treatment preferences’ (p. 627). The nature of malignant dis-
eases such as cancer requires patients to learn about and comprehend the illness, 
make difficult decisions regarding ensuing treatment, and cope with the conse-
quences of the illness. It has been found that having relevant information not only 
helps cancer patients to understand the disease, but it also facilitates their decision 
making and coping with the disease. Especially with cancer becoming a chronic 
disease, treatment places new demands on patients and families to manage their 
own care. A collaborative and interactive relationship between patients and health 
professionals can empower patients to take on responsibility for their condition with 
the appropriate clinical support. In this new concept of healthcare, clinician and 
patient are part of the same team: patients are empowered by more available infor-
mation, and take a more active and responsible role, while clinicians welcome them 
as knowledgeable partners in clinical practice. The value of co-participation is par-
ticularly evident in the short- and long-term outcomes of shared decision making 
(Kane et al. 2014). Among the short-term outcomes are: satisfaction with and con-
fidence in the made decision, satisfaction with physician–patient relationship, trust 
in the physician, increase in patient’s self-efficacy and improvement in physical and 
emotional well-being. Long-term patient’s outcomes are increases in treatment 
adherence, remission and quality of life. Despite the added value of the participation 
of patient in the information exchange and on decision-making process, its imple-
mentation in clinical practice is however still low. A systematic review (Kane et al. 
2014) found that decision aids (DAs) improve patients’ knowledge, reduce deci-
sional conflict and motivate people to take a more active role in decision making. 
Informed decision making should combine the patients’ personal values and the 
best available data. However, many patients have difficulties in associating these 
two components. Support tool such as a prompt list or decision aids can help them 
better manage the situation (Brown et  al. 2013). However, DAs are usually 
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 standardized and are not necessarily adapted to the psycho-emotional state of the 
patient (Bekker et al. 2003; Davis et al. 2014).
2.3  Psychological Factors as Moderators of Participatory 
Medicine
In order to make the participatory approach efficient, we should open up space to 
explore patients’ personal psychological, cognitive and social (familial) state 
(Gorini and Pravettoni 2011; Pravettoni and Gorini 2011). All these factors act as 
barriers or facilitators in patient’s self-management.
Dealing with health information and decisions is not a straightforward process, 
especially if we consider that health literacy is generally poor among the popula-
tion. Several studies have demonstrated that terminology is a barrier that decreases 
the level of engagement in the healthcare pathway (Keselman and Smith 2012) 
because of a poor understanding of medical documents, a high difficulty in adding 
non-understandable terms (their personal medical information) in Personal Health 
Records (PHR) (Genitsaridi et al. 2013, 2015), the discomfort in communicating 
with the physician about something they do not completely understand.
A first step in this direction is to understand how patients process information 
and what factors affect their capability to adapt and manage their illness and the 
decisions related to treatment, adherence, and lifestyles. The information selection 
and interpretation strongly depend on the patient’s status quo, including knowledge, 
values, needs, believes and emotions, where emotions have a fundamental role in 
guiding the search for information and therefore the construction of preferences 
(Pravettoni et al. 2016b; Gorini et al. 2014).
In line with the aforementioned bio-psycho-social approach, besides a focus on the 
biological and psychological individual characteristics, it is important to consider 
social dynamics that can affect patient’s self-management. The impact of a cancer 
diagnosis is indeed not limited to the individual; rather it influences their family and 
social network, which in turn can affect the patient’s psychological state and therefore 
their empowerment. According to the family systems theory, a change in one member 
of the system affects the whole system (Von Bertalanffy 2003). In presence of an 
inadequate readjustment to the trauma, the system can develop clinically significant 
levels of distress, higher risk of developing psycho-social problems, high levels of 
conflict and low family cohesion (Van Schoors et al. 2015). The level and type of 
family adaptation eventually affects the patient’s ability to cope with the illness.
The challenge of research in the last years, in line with the P5 approach, has been 
to build supportive environments that could be personalized for the specific patient. 
The multidisciplinary collaboration between oncologists, psychologists, engineers, 
IT professionals allowed the progress in the development of e-tools which can 
enhance patient empowerment and self-management, being also time-efficient and 
thus more easily integrated with the current clinical routine. What seemed an ideal 
in the traditional clinical practice becomes possible in the ‘virtual’ eHealth environ-
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ment: to integrate all patient’s data to provide a real personalized medical service. 
Coherently, information provided by physicians are tailored on the patient’s psycho- 
cognitive profile; decision aids can support patient’s choice according to his/her 
preferences and values, and that facilitate physician–patient shared decision mak-
ing; specific smart applications support the patient to cope with cancer, manage 
their condition and adhere to healthy lifestyle; alerts from eHealth platforms inform 
physicians about clinical and psycho-emotional states of the patients.
3  ICT Solutions from Relevant EU Projects
3.1  iManageCancer
The iManageCancer project with the subtitle ‘Empowering patients and strengthen-
ing self-management in cancer diseases’, aims to provide a cancer disease self- 
management platform designed according to the specific needs of patient groups 
and focusing on the well-being of the cancer patient with special emphasis on 
psycho- emotional evaluation and self-motivated goals, as P5 approach shows. The 
platform is centred on a Personal Health Record that exploits recent advances on 
Health Avatars for the individual cancer patient surrounded by mHealth applications 
designed to encourage the patient, enhance clinician–patient communication, maxi-
mize compliance to therapy, inform about drug interactions, and contribute to the 
management of pain and other side effects of cancer treatment.
3.1.1  Technological Contribution
The iManageCancer platform was designed on clinical evidence and in close col-
laboration with clinical experts, IT specialists and patients and was assessed in 
clinical pilots with adult and paediatric cancer patients. The architecture of the tech-
nological contribution of the iManageCancer project is shown in Fig. 6.1.
Apart from the Personal Health Record that is the core component of the iMan-
ageCancer (Kondylakis et al. 2017a), the platform provides tools to assess adher-
ence to therapy, physiological and psychological status and recommendations to the 
patient (Iatraki et al. 2018) according to his or her disease type and psycho- emotional 
status in order to promote a positive and healthier psycho-emotional state (Faccio 
et al. 2018) (Kazantzaki et al. 2016). The platform is further complemented by an 
expert system with formal self-management models oriented to decision support 
(Schera et al. 2018), serious games for children (Hoffmann and Wilson 2018) and 
adults (Zhang et  al. 2018), e-Consent tool (Kondylakis et  al. 2015c, 2017b) and 
anonymized data analysis (Koumakis et al. 2016b).
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3.1.2  Participatory Aspect of the Developed Solution
iManageCancer aimed to arrange planned eHealth decision-making aids in cancer, 
promoting a self-aware and informed decision-making approach, compensating dif-
ficulties in shared decision-making approach with clinicians. In clinical practice, 
barriers in shared decision making are multiple. The most common ones are health-
care professionals’ concerns about not having enough time, the perception that 
patient characteristics or the specific clinical situation were not conducive to shared 
decision making, the belief that some patients prefer a paternalistic approach without 
asking patients about their preferred role in decision making, and limited familiarity 
with shared decision making (Gravel et al. 2006).The proposed solution includes a 
novel approach for the collaborative management of cancer diseases with the 
informed and encouraged patient in a central role in the decision-making process.
Furthermore, the iManageCancer integrated mobile services act as the entry 
point for interactive disease self-management in close collaboration with the health-
care team. It advances disease management through reinforcement of the role of the 
patient in the management process, enabling better collaboration and interaction of 
Fig. 6.1 The main components of the iManageCancer platform and their interactions
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informed patients with doctors, better planning of management processes and better 
compliance of patients to therapy through the mobile services of the platform.
Disruptive technologies for healthcare were also included such as serious games 
for monitoring the psychological dimensions of the disease. To this direction, games 
for children and adolescents but also for their relatives were developed and piloted 
for mobile platforms.
3.1.3  Lessons Learnt
While for several of the iManageCancer technological components there is already 
evidence that they can work for the benefit of the patient (e.g. psycho-emotional 
evaluation for improving therapy services etc.), the clinical pilots deployed in this 
project had to eventually face and overcome scepticism regarding the acceptance of 
such mHealth empowering technologies designed for the cancer patient. iManage-
Cancer overcomes this obstacle by its serious commitment in the clinical pilots for 
paediatric oncology and adult oncology (prostate, breast and lung cancer) as well as 
the continuous focus on the cancer patient, offering technology for the best possible 
care, targeting on making cancer therapy a more personalized, continuous and par-
ticipatory experience.
Another barrier to innovation in research projects relates to the unavailability of 
clinical data. There are usually significant complexities with respect to involving 
both clinicians and patients in real-life pilots. The large datasets available in the 
iManageCancer project and the real-life evaluations with patients and clinicians can 
eventually speed up innovation in areas such as data mining (Koumakis et al. 2018) 
and clinical decision support.
Results showed mixed evidences of improvements in patient empowerment due 
to lack of time and treatment-induced stress and psychological problems. 
Nevertheless, coping with cancer, mood and cancer resilience were improved for 
the trial arm using the platform. In addition, users recognized the usability and the 
usefulness of the developed platform. The different tools and services of the iMan-
ageCancer platform were developed and further optimized in several cycles imple-
menting feedback of end-users and experiences from the pilots.
3.2  MyHealthAvatar
MyHealthAvatar project (http://www.myhealthavatar.eu/) (Kondylakis et al. 2015b; 
Maniadi et al. 2013) was an attempt to record digitally the health status of individual 
citizens. The goal was to create a digital representation of the user, a health avatar, 
acting as a mediator between the end-users and health-related data collections. It was 
designed as a lifetime companion for individual citizens that facilitates the collec-
tion, the access and the sustainability of health status information over the long term.
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3.2.1  Technological Contribution
The architecture of the technological contribution of the MyHealthAvatar project is 
shown in Fig. 6.2. It consists of the following layers: (a) the data repository, (b) the 
semantic integration layer, (c) the auditing service, (d) the layer for linking with 
external sources, (e) the MyHealthAvatar toolbox and (f) the GUI (graphic user 
interface) layer. The data repository includes a data lake with various data sources 
that are available to the project, a tool/model repository and an imaging repository. 
Selected data out of this data lake are extracted, transformed and loaded onto a 
Virtuoso triple store where they are integrated. Data can also be extracted from 
Fig. 6.2 The main components of the MyHealthAvatar platform and their interactions
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external data sources using the various linking services. In addition to these data, 
the MyHealthAvatar toolbox includes all necessary services and implements the 
business logic to be presented through the GUI layer either using the MyHealthAvatar 
portal or the MyHealthAvatar Mobile app. The GUI layer facilitates and encourages 
self-monitoring and self-management via a number of different approaches (semi/
automatic monitoring of individuals’ steps count, calories consumption, active min-
utes, locations, movements, mood) through a ‘virtual avatar’, assists self-knowledge 
discovery through analysis and mining of personal health and activity data. Finally, 
it supports self-management of general health and well-being, and a range of chronic 
diseases via tailored intelligent tools (hypertension management, cardiovascular 
risk, diabetes, etc.). A specific branch of the platform (Zhang et al. 2018) is targeting 
lifestyle management support for cancer patients with all available tools.
3.2.2  Participatory Aspect of the Developed Solution
The MyHealthAvatar project focused on providing an ICT infrastructure for enhanc-
ing citizen’s participation in self-management, disease prevention and patient 
empowerment as P5 suggests. It tried to lift the barriers primarily from the perspec-
tive of raising awareness, knowledge and motivation via risk appraisal and informa-
tion provision. In addition, it provided tools to facilitate patients with chronic 
conditions to build and improve their health literacy and to provide a repository for 
recording medical, health, activity and diet information in the long term. Analyzing 
and mining those data, important events in personal life can be highlighted, personal 
life patterns can be identified and outliers can be detected such as sudden changes 
of lifestyles; allowing for self-assessment of health status; summarizing and report-
ing the performance of individual users over a certain period.
3.2.3  Lessons Learnt
In the process of building and piloting such a diverse platform, multiple lessons 
were learnt. For example, any platform trying to empower patients with chronic 
diseases should be validated in a real setting, involving multiple clinical partners 
and patients as well. Solutions ‘one size fits all’ are not appropriate in such a context 
and specific reconfiguration is needed for different types of diseases, as the informa-
tion needs are different in each case.
In addition, the incorporation of health psychology models, is a key as they pro-
vide a foundation for health behaviour intervention. This enables the identification 
of key roles in patients’ self-management, with a focus on their influence, and even-
tually on the compliance with medication plans, yielding individually tailored 
behaviour interventions to improve their compliance.
Finally, further investigation on usage of decision support tools is required. As 
gradually those tools mature, and their recommendations (Kondylakis et al. 2015a) 
are based on solid evidences, the confidence of the citizens will also increase 




p-Medicine (From data sharing and integration via VPH models to personalized medi-
cine) tried to formulate an open, modular framework of tools and services for efficient, 
secure sharing and handling of large personalized datasets (Marés et al. 2014). The 
platform enables demanding Virtual Physiological Human (VPH) multi- scale simula-
tions (in silico oncology), builds standards-compliant tools and models for VPH 
research and provides tools for large-scale, privacy-preserving data and literature min-
ing, a key component of VPH research. The project ensures that privacy, non-discrim-
ination and access policies are aligned to maximize protection of and benefit to patients. 
The p-Medicine tools and technologies were validated within the concrete setting of 
advanced clinical research. Pilot cancer trials were conducted, based on clear research 
objectives, emphasizing the need to integrate multi- level datasets, in the domains of 
Wilms tumour, breast cancer and leukaemia. To sustain a self-supporting infrastruc-
ture, realistic use cases were built, demonstrating tangible results for clinicians.
3.3.1  Technological Contribution
Figure 6.3 shows the main components and their interdependency of the pmedicine 
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Fig. 6.3 The main components of the p-medicine platform and their interactions
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A user is able to get access to p-medicine via a secure portal to use tools and 
workflows from the p-medicine workbench to execute his or her models by mining 
data from the data warehouse. The data warehouse is fed by data from Hospital 
Information Systems (HIS) or the integrated Clinical Trial Management Systems 
(CTMS) via a push service. The CTMS can synchronize with the HIS using a sync 
service. Data entering the p-medicine environment are pseudonymized/anonymized 
and semantically annotated (Sfakianaki et al. 2015). Access to external biobanks 
can be established and freely available data from the web can be stored in the data 
warehouse with the aid of literature mining (Potamias et al. 2005). Depending on 
the scenario, users are able to execute models (Sfakianakis et  al. 2009), use the 
p-medicine Oncosimulator (Stamatakos et  al. 2014), systems biology models 
(Koumakis et al. 2016a; Koumakis et al. 2017; Mehta et al. 2016) or they can use 
the Decision Support System (Bucur et al. 2016). In all cases results lead to person-
alized medicine via decision support. Patients as users of p-medicine can interact 
with the p-medicine environment via IEmS (Kondylakis et al. 2012), a collaborative 
environment for patient empowerment.
3.3.2  Participatory Aspect of the Developed Solution
The project aimed at providing clinical researchers with an infrastructure to support 
the requirements of modern clinical trials. From data collection and integration, to 
workflow design and result analysis, initial studies in the project detected some 
major points of interest for the area. There were specific needs to cover to alleviate 
end-users from the most resource-consuming tasks in their daily work. The combi-
nation of thorough analysis of scenarios, research on previously proposed solutions 
and an extensive tool and service development led, after four years of work, to the 
completion of the p-Medicine Platform. Intensive testing within real-world scenar-
ios provided highly promising results.
A novel personal health record (PHR) system was developed within the project, 
enabling patients to actively participate in the management of their disease, employ-
ing psycho-emotional questionnaires to monitor patients and to automatically give 
recommendations to their carers about their psycho-emotional status and optimal 
communication guidelines.
3.3.3  Lessons Learnt
The patient health records, and the diversity of data sources comprising these, make 
imperative the development of easy-to-use, standardized health informatics plat-
forms. p-Medicine was designed to link pseudonymized patient data from multiple 
clinical sources, on which analytics and modelling tools may be applied. The flexi-
ble, distributed nature of the system makes it highly robust and scalable. The imple-
mentation of an e-consent scenario through pseudonymization enables, unlike many 
similar platforms, results from the analytic processes that are found to have an 
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impact on an individual patient, to be directly communicated, via the trusted third 
party, to the clinicians treating the patient.
Central to the challenges addressed by the p-medicine was the issue of semantic 
interoperability between production systems in both the clinical word (Electronic 
Health Record (EHR) systems) and the research domain (Clinical Trial Management 
Systems, Clinical Report Forms (CRF) systems, etc.). As a result, the issue of stan-
dards became a central activity in the project. Standards relate to both technical 
aspects of the systems developed as well as terminology and semantic aspects of 
this work. It was the intention of the project to integrate concepts from existing 
standards, models and architectures, while extending and refining them where 
appropriate and required. In achieving this objective the project had a dedicated task 
focusing on standards. The activities involved monitoring of standards develop-
ment, critical review and assessment of their applicability in the p-medicine frame-
work, refining such standards based on domain specific requirements.
3.4  EURECA
The goal of the EURECA project was to enable seamless, secure, scalable and con-
sistent linkage of healthcare information residing in EHR systems with information 
in clinical research information systems, such as clinical trial systems, supporting 
the two currently separated worlds of clinical research and clinical practice to con-
nect and benefit from each other. EURECA objective was to build an advanced, 
standards-based and scalable semantic integration environment, enabling seamless, 
secure and consistent bi-directional linking of clinical research and clinical care.
3.4.1  Technological Contribution
The aim of EURECA was to provide a framework of tools which can be easily 
interconnected in different configurations, tailored to the needs of different environ-
ments and end-users. To obtain this high flexibility, loose coupling and a service- 
orientated approach was chosen. The focus was thus on interoperability and 
interfacing in the architectural description. Modules and components designed and 
built within the project operated seamlessly through well-specified interfaces on 
different levels (i.e., interoperability on the level of IT-protocol, data format, infor-
mation content, etc.). Figure 6.4 shows the architecture of the EURECA platform.
To obtain high flexibility, loose coupling and a service-orientated approach was 
chosen, emphasizing on interoperability and interfacing. Thus, EURECA architec-
ture was determined by its interfaces. Modules and components designed and built 
within the project could operate together thanks to these well-specified interfaces at 
different levels. On the implementation level, EURECA internal services relied on 
SOAP as communication protocol.
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The EURECA platform was designed as a multi-layered architecture, with 
responsibilities assigned to the various architectural layers. Every component 
designed within EURECA was mapped to one of these layers (or spanned over 
multiple layers). The architectural layers were:
• End-User Applications: The components situated in this layer could be seen as 
endpoints to the end-users of the system, presenting the underlying back-end 
functionality in an intuitive and user-friendly way. The components usually made 
use of a (advanced) graphical user interface (GUI) for displaying this (complex) 
back-end functionality.
• Application Services: This business layer provides the core functionality of the 
EURECA services as it houses a variety of application services. The components 
in this layer contained the functional algorithms that handled information 
exchange between the semantic integration layer and the presentation layer. 
Where possible, EURECA promoted the approach of providing re-usable ser-
vices in the application layer.
• Semantic Integration Services: This layer utilized the ontology-based informa-
tion model and translated or mapped the model to the underlying data and infor-
mation sources. The semantic integration layer was abstracting the underlying 
data sources for the upper application layers.
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Fig. 6.4 The main components of the EURECA platform
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• Data Access Services: This layer contained the various data and the metadata 
repositories. Services on this layer were responsible for the actual data access. 
The data warehouses exposed standardized query interfaces, and queries were 
expressed using the EURECA core dataset.
• Infrastructure Services: The components placed in this layer provided service 
communication and service management capabilities to other EURECA 
components.
• Platform Management Services: Included components that were enabling the 
management of the integration of the various components in the EURECA 
platform.
• Security Services: On an orthogonal axis, the security layer was connected to all 
other architectural layers. The EURECA security solution consisted of re-usable 
modular components that respectively dealt with authentication, authorization, 
audit and privacy enhancing (i.e. services oriented specifically at data privacy 
protection).
3.4.2  Participatory Aspects of the Developed Solution
EURECA supported more effective and efficient execution of clinical research by: (i) 
Allowing faster eligible patient identification and enrolment in clinical trials, (ii) pro-
viding access to the large amounts of patient data, (iii) enabling long-term follow- up 
of patients, (iv) avoiding the need for multiple data entry in the various clinical care. 
In order to achieve the aforementioned goals, EURECA platform provided the clinical 
research access—in a legally compliant and secure manner—to the large amounts of 
patient data collected in the EHR systems to be used for new hypotheses building and 
testing (e.g. to benefit rare diseases), cohort studies, as well as protocol feasibility.
At the core of the project was the semantic interoperability among EHR and clini-
cal trial systems, consistent with existing standards, while managing the various 
sources of heterogeneity: technology, medical vocabulary, language, etc. This required 
the definition of sound information models describing the EHR and the clinical trial 
systems, and capturing the semantics of the clinical terms by standard terminology 
systems. The scalability of the solution was achieved by modularization, identifying 
core data subsets covering the chosen clinical domains. The project demonstrated and 
validated concepts developed in EURECA by implementing a set of software services 
and tools that were deployed in the context of pilot demonstrators. EURECA devel-
oped solutions that fulfill the data protection and security needs and the legal, ethical 
and regulatory requirements related to linking research and EHR data.
3.4.3  Lessons Learnt
The main barriers of secondary use of EHR data for research and of enabling a con-
sistent feedback loop to care are the lack of common technology standards and 
concept terminologies. While solving the interoperability issue in healthcare at the 
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generic level is not a realistic approach (Boyle and Levin 2008), EURECA aimed at 
semantic interoperability on domains of concepts (i.e. describing specific clinical 
areas). It began from disease- and treatment-related sets of concepts in the oncology 
domain and demonstrated the proposed solution in concrete clinical scenarios. On 
top of the achieved semantic interoperability software services and tools to support 
more efficient research, better care and improved patient safety were developed.
The approach taken in EURECA was to rely when possible on existing initiatives 
and previous efforts in terminology development and standardization. The viability 
of the solutions was demonstrated and developed by implementing a set of loosely 
coupled interconnected services/modules that have been deployed in the context of 
several pilot demonstrators in the cancer area, at healthcare sites.
The EURECA environment aims to provide several software services that help to 
securely interconnect the clinical trial systems and the electronic health record sys-
tems. This will bring several benefits, among which are early detection of patient 
safety issues and more efficient recruitment of eligible patients. Consistent linkage 
between CTS and EHRs will also help to significantly reduce the need for double 
data entry, which is currently often common practice.
3.5  INTEGRATE
The FP7 INTEGRATE project (http://www.fp7-integrate.eu/) focused on the devel-
opment of innovative biomedical applications for streamlining the execution of 
clinical research on cancer (Kondylakis et al. 2016). This was achieved by enabling 
multi-disciplinary collaboration, contributing to the management and the large- 
scale sharing of multi-level heterogeneous datasets, and by developing new method-
ologies and predictive multi-scale models on cancer.
3.5.1  Technological Contribution
The technological infrastructure developed for the INTEGRATE project was com-
posed of five layers as shown in Fig. 6.5.
On top, the presentation layer includes the various components that the end-users 
are using to access the patient screening application, the central pathology review, 
the cohort selection client and the analytical tools. The patient screening facilitates 
efficient identification of eligible patients for clinical trials through automatic 
matching of their characteristics and trial inclusion and exclusion criteria. Usually, 
patient data are described in free-text and this applies for trial exclusion and 
 inclusion criteria. As such, automatic identification of eligible patients is a challeng-
ing task. On the other hand, enabling the collaboration and the participation of mul-
tiple clinical trial experts is an important challenge in modern multi-centric setting 
of clinical trials. The central pathology review tool enables high-quality, remote, 
decision making of multiple pathologists based on microscopy slides that are stored, 
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examined, annotated and commented online. Besides this, clinical researchers are 
able to formulate at run-time cohorts, based on multiple criteria available. In selected 
data can be visualized and analyzed in real time using the cohort selection and the 
analytical tools offered by the infrastructure.
Effective and efficient collaboration of clinical trial participants remains an 
important challenge in the modern multi-centric setting of such, post-genomic tri-
als. The primary use of this Central Review for Pathology tool was to enhance the 
collaboration among groups of expert pathologists and to enable efficient, high- 
quality decision making for patients participating in a clinical trial.
The business layer includes all necessary services for patient screening, cohort 
selection, analytical services, imaging services and central review services. The 
semantic interoperability layer provides access to the homogenized data through an 
ontology. As such, the data layer includes the various data sources along with their 
corresponding metadata. Finally, a security layer establishes all necessary services 
for authentication, authorization and identity management.
3.5.2  Participatory Aspect of the Developed Solution
Although the specific project did not focus on enhancing the participatory aspect of 
the patient, it is interesting to see that it was focusing on the participatory aspect of 
multiple experts involved in multi-centric clinical research and trials in cancer 
(oncologists, research and trial nurses, researchers, bioinformaticians, pathologists, 
trial coordinators). More specifically, the project developed ICT solution to improve 
Fig. 6.5 A high-level view of the INTEGRATE technical Architecture (Kondylakis et al. 2016)
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the efficiency of clinical research and the data and knowledge flow between clinical 
research and clinical care and to enable the effective collaboration of all persons 
involved in the process. Evaluation performed showed that providing efficient and 
effective tools can be of high benefit in daily practice.
3.5.3  Lessons Learnt
Several lessons were learnt from this project, in the process of streamlining the 
execution of clinical research and to speed up the transfer of results to the clinical 
practice. A key lesson for example was that compliance to trial-related legislation, 
especially to the data protection laws, is a critical success factor for any 
research-network.
Next, effective and efficient graphical user interfaces are of utmost importance 
when dealing with domain experts who have no time to waste and usually show 
inertia when new methods and approaches are proposed to them. In this regard, a 
really important lesson is that providing useful applications with nice GUI is not 
enough. Those applications should be properly integrated with the ICT tools they 
are already using and with their daily routine. In addition, service performance and 
stability are two keys in workflows with multiple participants with limited time.
4  Conclusions and Guidelines for Future Development
This chapter presented experiences from five European research projects, all focus-
ing on enabling patients and related stakeholders to actively participate effectively 
and efficiently in the journey of the patient. We described the technological solu-
tions that were built, we focused on the participatory aspect of each individual proj-
ect and we described relevant lessons learnt.
As described, transforming the recent model of paternalistic care to a participa-
tory one has many challenges, especially in a chronic illness domain like cancer, 
with multiple participants and stakeholders involved in a journey that might span 
multiple years. Although ICT and the proliferation of portable devices have the 
potential to lead to a leap forward, the steps needed come with many challenges. 
This is being reflected by the high number of research projects currently focusing 
on promoting specifically this participatory aspect. Capitalizing on the presented 
lessons learnt we can summarize the following guidelines:
User-centred design: Technological tools should always involve end-users in all 
phases of the development in an iterative process and that usability is equally 
important to the effectiveness of the tools in order to gain user acceptance. Patient 
should not only be employed to use the final product, but should actively co- 
design the developed solutions, as eventually they are the ones to use them.
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Integration to daily workflow: In addition, in order to gain user acceptance the 
integration of the tools in the daily workflow of both the patients and the care 
providers is really important as they have limited time and they would like to 
minimize their potential involvements. Challenges related to semantic interoper-
ability between production systems in both the clinical word (EHR systems) and 
the research domain (Clinical Trial Management Systems, CRF systems, etc.) 
should be resolved, whereas consistent linkage between clinical research and 
clinical practice will also help to significantly reduce the need for double data 
entry, which is currently often common practice. Specific attention should be 
paid to the fact that different professionals and organizations that participate in 
the patient’s journey have different priorities (Schaller et al. 2016).
Mass scale: For long-term data collection of health-related data, individual partici-
pation at a mass scale is important. Such a comprehensive data collection will 
have a very strong clinical significance for diagnosis, prediction and individual-
ized treatment, leading to significant evidence in health outcomes and quality of 
life.
Health psychology: Further involvement of the health psychology models will pro-
vide a foundation for health behaviour intervention, allowing the identification of 
key roles in patients’ self-management, with a focus on their influence, and even-
tually on the compliance with medication plans, yielding individually tailored 
behaviour interventions.
Security and legal aspect: Securely interconnecting the clinical trial systems and 
the electronic health record systems can bring several benefits, among which are 
early detection of patient safety issues and more efficient recruitment of eligible 
patients. In addition, key challenges to be resolved are: assessing the validity of 
electronically given consent, data protection implications of access and use by 
third parties, the need for certification of apps/tools under the medical devices 
regime, and potential ex post facto liability in case of harm to users.
All these guidelines are essential, when creating ICT systems that are intended to 
be used by all involved participants in the journey of cancer management, but also 
for other chronic diseases as well, achieving eventually the P5 vision.
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Chapter 7
Psycho-cognitive Factors Orienting 
eHealth Development and Evaluation
Alessandra Gorini, Enrico Gianluca Caiani, and Gabriella Pravettoni
1  The P5 and the Personomics Approach
“Individuality of human beings affects predisposition to disease and response to 
treatment” (Potter, 1988; Sykiotis, Kalliolias, & Papavassiliou, 2005), stated 
Hippocrates in the fifth century BC, becoming the first known physician mentioning 
the relevance of a personalized approach to diagnosis and treatment. Many centuries 
later, personalized medicine has gained increasing attention (Britten, Pope, Halford, 
& Richeldi, 2016; Brownell et al., 2016), applying the Hippocratian vision to the 
need of “delivering the right treatment to the right patient at the right time” (MRC, 
2017) (cf. Chap. 4).
Starting from the individuality of human beings—and to further enrich the per-
sonalized medicine approach—that is mainly based on the biological characteriza-
tion of each individual, some years ago we proposed the P5 approach (Gorini & 
Pravettoni, 2011; Pravettoni & Gorini, 2011). The fifth P (that followed the other 
four P’s: predictive, personalized, preventive, and participatory (Hood & Friend, 
2011)) indicated the psycho-cognitive aspects that characterize a patient not only as 
a biological and genetic entity, but also as a person with specific needs and values, 
habits and behaviors, hopes and fears, beliefs, personality, and cognitive disposi-
tions. Introducing the fifth P, we underlined the need of integrating all these aspects 
with biological and genetic information in order to empower the patient, increase 
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his/her quality of life (QOL) and transform him/her from a passive recipient of care 
into an active decision-maker during the entire treatment process (Joseph-Williams, 
Elwyn & Edwards, 2014) (cfr. Chap. 1).
In line with this patient-centered approach, a few years later, the term “per-
sonomics” was introduced (Ziegelstein, 2015). Inspired by the other “-omics,” 
including genomics, proteomics, metabolomics, epigenomics, and pharmacoge-
nomics, created to characterize patients by their biological uniqueness and to pro-
vide more precisely tailored diagnostics and therapeutics, personomics refers to the 
patient’s unique psychosocial situation and life circumstances that may alter disease 
behavior and response to treatment (Ziegelstein, 2015). In accordance with the pre-
vious P5 approach, personomics distinguishes individuals not only by their biologi-
cal variability, but also by their psychological characteristics, health beliefs, social 
support networks, education, socioeconomic status, health literacy, and all the other 
life conditions and events that may have important consequences on when and how 
a certain health condition will manifest in that individual and how it will respond to 
treatment (Ziegelstein, 2015). As the other -omics, these individual characteristics 
are critical to patient care, being useful for a better understanding of the pathogen-
esis and treatment of disease and allowing a more personalized care that takes into 
account the patient’s internal world and external life circumstances.
By embracing the P5 and the personomics approaches, non-pharmacological 
interventions, including, among others, psychological support, a greater involve-
ment of patients in shared decision making, and lifestyle coaching, appear to be 
relevant to reinforce the effects induced by traditional pharmacological treatments. 
Assessing the individual needs and perspectives, together with the patient’s psycho-
logical attitudes and preferences may be also relevant to improve his/her treatment 
adherence, satisfaction, and, overall, his or her short- and long-term quality of life. 
Moreover, since such personal characteristics can change over time, or because of 
the presence of an illness or, again, its progression or recovery, an iterative evalua-
tion of the individual patient may become a key feature for an effective personalized 
disease management (cfr. Chap. 3).
In traditional care paradigms, patients are physically evaluated when the diagno-
sis is established, and, only when necessary, at one or more follow-ups. Sometimes, 
psychological and/or quality of life evaluations are also performed depending on the 
patient’s illness and local guidelines. Nevertheless, such evaluations, when present, 
are not sufficient to guarantee the right attention to the above individual factors and 
do not allow a long-term monitoring of the patient’s characteristics and evolution. 
Moreover, time and cost constraints, other than patients’ limitations and difficulties, 
prevent the application of the P5 approach in the actual clinical practice.
According to the P5 and the personomics approaches, collecting organized 
patient’s input throughout the entire disease course is important for different 
reasons:
• To correlate psychological variables and quality of life with physical events, 
clinical state, and clinical recurrences
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• To better respect the patient’s needs and preferences to not lose treatment 
adherence
• To provide better tailored treatments
• To maintain a contact with patients during and after recovery
• To empower patients in improving their understanding of their health conditions 
and in making them actively involved in the management of their own disease
2  The Key Elements for the P5-Personomics Approach
What are the key elements of the P5-personomics approach and how can they be 
collected? Which instruments can be used by physicians to understand the patient as 
an individual?
The National Institute for Health and Clinical Excellence (NICE) has proposed a 
guideline document ((UK), 2012) that outlines 5 areas containing the elements of 
knowing the (adult) patient as an individual (p. 48). These areas include the consid-
eration of:
 1. How clinical conditions affect the person and how the person’s situations and 
experiences affect his/her condition and treatment.
 2. How the patient’s life circumstances affect his/her treatment involvement and 
experiences, and his/her lifestyle choices.
 3. How the patient’s concerns, values, and preferences affect the way he/she 
engages with the treatment experience.
 4. How the patient’s psychological, social, spiritual needs affect his/her condition 
and treatment.
 5. They also include an admonition to clinicians not to make assumptions about the 
patient based on appearance.
To answer the second question as to how such information can be collected, the 
most intuitive solution would be to interview each patient for as much time as pos-
sible. Unfortunately, this is not a feasible solution in the everyday clinical practice 
for the following reasons:
• Physicians have not enough time to investigate such aspects.
• Collecting this information requires different methods compared to those used to 
investigate medical symptoms.
• One single interview is not sufficient to implement a new model of cure based on 
the P5 approach.
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3  Solutions Come from the eHealth Apps
A very promising approach to solve the above limitations and to collect as much 
data as possible involving patients in managing their health comes from eHealth. 
eHealth solutions have been considered in the last two decades as the “holy grail,” 
able (if properly implemented and scaled up) to reduce healthcare costs (cfr. 
Chap. 1), and improve patient experience while maintaining adequate levels of care 
(Tang and Lansky 2005; Bradford & Palmer 2016) (cfr. Chap. 4). In particular, 
eHealth solutions provide the basis for “participatory health” (cfr. Chap. 6), in 
which active involvement of all the involved parties—the patient, caregivers, and 
healthcare professionals alike—is encouraged. This assumes particular importance 
in the context of searching for innovative ways of supporting chronic patients, 
where it is fundamental to keep under control the underlying pathology and detect 
as early as possible the signs of worsening in order to anticipate countermeasures 
and prevent possible hospitalization. Thanks to the developments in the field of 
information and communication technology (ICT) observed in the last years, in 
particular with the large penetration of mobile cellular phone technology in the 
global market and its ubiquitous access to the World Wide Web, a large proportion 
of the world population has now access to and uses the Internet in their daily lives 
(via, e.g., a PC, tablet, wearables, and/or smartphone), thus finally providing the 
tools for the “holy grail” to exploit its potentials within healthcare (Internet World 
Stats, 2018; Kay et al., 2011).
This technologically permeated background, if properly utilized in the context of 
clinical medicine, has the potential to switch the way healthcare is provided from a 
paternalistic model to a collaborative approach, by means of self-management, 
shared decision making, and a coaching relation between the physician and the 
patient (Mead and Bower, 2000; Bacigalupe & Askari, 2013) (cfr. Chap. 4). In this 
way, the focus of healthcare could be moved from management of acute episodes to 
secondary prevention, and also to primary prevention (cfr. Chap. 3), physical fit-
ness, nutrition, mental health, end-of-life care, home-care, and other fields related to 
an individual’s health.
4  Digital Health in the Patient’s Journey
Indeed, the use of technology for health is already permeating the patient journey, 
from prevention to treatment: while there are no diseases, access to specific tools 
such as mobile applications (or “apps”) could increase knowledge about possible 
risks associated to incorrect lifestyle behaviors and help in increasing levels of well-
ness through self-monitoring of exercise and fitness, diet and nutrition, alcohol 
moderation, and smoking cessation.
Once symptoms of a disease are manifested, a plethora of patient experience 
tools are available: searching related keywords on the web, specific apps for symp-
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tom checking, social media to share concerns, and tools to find specialized centers 
if necessary.
In the process of clinical decision making, the physician could base the diagnosis 
on data acquired directly by the patient using smartphone embedded sensors or con-
nected medical devices that have the potential to record possible pathologic phe-
nomena when they manifested, if symptomatic (e.g., for atrial fibrillation (Halcox 
et al., 2017), thus overcoming some existing limitations of well-established diag-
nostic Holter ECG technology).
Once the diagnosis has been established, the physician may recommend digital 
tools for condition monitoring, such as app-supported disease management pro-
grams, connected sensors for remote monitoring and rehabilitation programs, or 
apps for psychological and cognitive profiling, and for any use case across the 
patient journey. In addition, patients could share their experiences, success and fail-
ure stories in patient’s forum groups specific for the underlying pathology. In the 
context of treatment, medication management and adherence could be improved by 
utilizing digital tools, from simple reminders activated through the smartphone to 
more advanced electronic medication packaging (EMP), or solutions based on 
active patient involvement and artificial intelligence.
4.1  A Possible Scenario
Taking into account the P5 approach, such tools could be perhaps structured on the 
basis of the NICE guidelines, to be used by the patient both during the acute and the 
chronic phase of the illness. Organized in different areas, they can be used to:
 1. Fill health journal, allowing users to record their clinical parameters directly or 
from remote monitoring tools.
 2. Write diaries of life events that can have a significant impact on the individual 
well-being and quality of life. They include negative or stressful events occur-
ring in everyday working or personal life, health-related events, illness recur-
rences, and any kind of event that is perceived as negative by the individual.
 3. Collect the patient’s concerns about the treatment experience, such as treatment 
side effects, or patient’s complaints including physical or behavioral aspects 
induced by treatments.
 4. Regularly collect information about the patient’s social conditions and psycho-
logical status. Individual characteristics, such as personality traits, decision- 
making style, emotional profile, as well psychological dimensions, such as the 
presence of stress, anxiety, depression, etc, and the presence of protective or 
negative social conditions (social support or social isolation, etc.) are collected 
in this area.
All this information may be collected through monitoring tools and periodic 
remote administrations of specific questionnaires starting from the acute phase of 
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the illness (if possible) for as long a time as possible in order to provide long-term 
monitoring of the patient, from the acute to the chronic phase.
Specific algorithms are then needed to put together information obtained from 
the different areas in order to integrate physical, environmental, and psychological 
factors into explanatory and possibly predictive models.
At the same time, periodic reports for patients and physicians may be created by 
the system in order to make the patient aware of his/her condition and to alert the 
physicians when unexpected or worrying events or health changes occur.
A comprehensive monitoring program, consisting of an eHealth app collecting 
different patient information may have the potential to improve trial design, enhance 
self-management, allow for early treatment adaption to minimize side effects, 
reduce hospital admissions, and, in general, improve personalized management and 
long-term QOL. Only by integrating biological information with patient-reported 
and patient-collected information, will we be able to realize truly personalized treat-
ment, preventing clinicians from making assumptions about the patient based on 
appearance, as suggested by the fifth point of the NICE guidelines.
5  The Importance of Patient Education
Due to the availability of medical information through an incredible number of 
sources, a deep cultural change has been manifested, and described by the term of 
apomediation (Eysenbach, 2008) that is  the process of disintermediation, where 
previous intermediaries (e.g., healthcare professionals) are functionally bypassed 
by new apomediaries (i.e., the web, online groups, GoogleSearch, etc.) in guiding 
the citizens’ access to health information.
To appreciate the relevance of this phenomenon, this open access to information 
through technology could be compared to what happened after the introduction of 
movable-type printing press by Gutenberg in 1439, which led later to the era of 
mass communication in Renaissance Europe. This invention, by increasing literacy, 
permanently altered the structure of the society by the relatively unrestricted circu-
lation of information and revolutionary ideas, thus threatening the power of political 
and religious authorities and breaking the education and learning monopoly of the 
literate elite, thereby bolstering the emerging middle class.
In the medical information context, while increasing patient literacy is a positive 
factor, the chief ethical concern regarding apomediation is that incorrect ideas or 
potentially dangerous practices will take hold. As observed previously, patient edu-
cation is a lifelong program, where technology can enhance the learning process, 
but reliable content is the key. Examples of possible consequences related to these 
cultural changes are represented by the information overload while searching infor-
mation through Internet (e.g., 770 million results are returned by Google when 
searching for “cancer” and 389 million when searching for “diabetes”), or by the 
incredible proliferation of apps in the “Medical” and “Health & Fitness” categories 
in the app stores: the patient is potentially left alone in the process of choosing 
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which information to rely on, or which app to adopt that best suits her/his needs, 
with the risk of trusting unreliable sources or using apps with claims not supported 
by validation for accuracy and efficacy.
In the process of patient empowerment, defined as the acquisition of motivation and 
ability that patients might use to be involved or participate in decision making (Fumagalli 
et al., 2015), patient education becomes a critical goal for patient enablement, that is, 
the acquisition of knowledge and skills for meaningful self-management.
Patient education aims to increase the level of health literacy, defined as the abil-
ity of the patient to obtain, read, understand, and use healthcare information to make 
appropriate health decisions and follow instructions for treatment and self-care 
(Sørensen, et  al., 2012; Mårtensson and Hensing, 2012). Indeed, patient literacy 
constitutes the first step to properly understand health concepts, and it has been 
indicated by the World Health Organization as one of the social and economic fac-
tors impacting on adherence, defined as the extent to which the persons’ behavior 
corresponds with agreed recommendations from a healthcare provider (Adherence 
to long-term therapies. Evidence for action, WHO 2003). To effectively utilize 
mHealth technology, health literacy is not enough, as digital literacy, that is, the 
ability to locate, organize, understand, evaluate, and analyze information using digi-
tal technology, needs to be ensured. These two abilities have been lately summa-
rized in the concept of digital health (eHealth) literacy as the ability to seek, find, 
understand, and appraise health information from electronic sources and apply the 
knowledge gained to addressing or solving a health problem (Norman and Skinner, 
2006). As a recent EU-funded project (Health Literacy Europe) has highlighted, 
health literacy cannot be taken for granted as, of the eight countries (Austria, 
Bulgaria, Germany, Greece, Ireland, the Netherlands, Poland, Spain) surveyed, only 
the Netherlands showed less than 40% of the studied population with inadequate or 
problematic levels, while the other countries had higher values, with extremes found 
in Spain (58.5%) and Bulgaria (62.1%).
Considering that the main cause of medical errors have been attributed to 
communication- related origins (Hughes and Ortiz, 2005), the ability of the patient 
to fully understand medical recommendations given by the physician during the 
consultation appears crucial: in Kessels (2003) it was reported that from the given 
medical information, 40–80% is immediately forgotten, while half retained is incor-
rect. To improve physician–patient communication, the teach-back assessment has 
been proposed as a method to confirm patient’s understanding of medication and 
treatment recommendations (Porter et al., 2016). In this context, digital technolo-
gies provide new opportunities also for physicians to get used to this approach, with 
online learning modules freely available through the Internet (Abrams et al., 2012) 
or for the patient, with video recorded outpatient clinic sessions accessible for the 
patient via patient portal, as recently implemented at the Erasmus Medical Center in 
Rotterdam.
In order to define the baseline level for comparison after exposure to the educa-
tional interventions to determine its effectiveness, it is important to assess patient 
health literacy. In literature, different assessment tools have been proposed; for 
example, the Rapid Estimate of Adult Literacy in Medicine (REALM) (Davis et al., 
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1993), or the Test of Functional Health Literacy in Adults (TOHFLA) (Parker et al., 
1995), designed to measure both reading comprehension and numeracy to assess 
adult literacy in the healthcare setting. In the context of eHealth and health infor-
matics for patients or for the public, it is crucial to be aware of who the final user 
really is and what characteristics he/she has that might impact on eHealth design 
and implementation: digital health (eHealth) literacy needs to be assessed. The 
foundations of the eHealth literacy concept are based in part on social cognitive and 
self-efficacy theories, which promote competencies and confidence as precursors to 
behavior change and skill development. eHealth literacy includes six core skills, or 
literacies: (1) traditional literacy; (2) health literacy; (3) information literacy; (4) 
scientific literacy; (5) media literacy; (6) computer literacy. The eHealth Literacy 
Scale (eHEALS) is a self-report tool composed of eight questions that can be 
administered by a health professional and is based on an individual’s perception of 
his/her own skills and knowledge within each measured domain (Norman and 
Skinner, 2006).
6  Persuasive Design Technology
Research has proven that by means of technology, it is possible to help people to 
change their thoughts, improve their behavior and gain better health and well-being. 
Cognitive behavior psychology aims to explain, predict, and change our behavior 
using processes that are going on in the mind. In 1958, Albert Ellis developed one 
of the first cognitive behavior theories explaining how and what kind of cognitions 
(i.e., beliefs and thoughts) can change behavior. Since then, several theories for 
behavior change have been developed, thus prescribing what factors must be first 
influenced.
Behavior change is about persuasion, therefore behavior change techniques are 
often persuasive strategies as well. In the last decades, technology is used more and 
more as a vehicle for persuasion, because of its interactivity and adaptability. 
Compared to human persuasion, technology solutions present several advantages:
• Persistence: technology does not get tired of trying to persuade someone, and it 
can continue indefinitely.
• Anonymity: when talking to a human persuader, it is impossible to stay anony-
mous, while with technology this is easier, thus representing a huge advantage 
for sensitive subjects (i.e., psychological problems or substance abuse).
• Ability to manage large volumes of data: technology’s ability to process huge 
volumes of data in a short time gives more persuasive power, as technology can 
back up a certain message with the data that supports it.
• Scalability: people can only reach a limited number of other people; using tech-
nology, many more people can be reached without a large increase in cost.
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• Ubiquity: technology can be everywhere, even in places where a human per-
suader cannot be allowed to be. As for many behavior change techniques, effec-
tive timing of message delivering is crucial, so ubiquity represents a pivotal 
characteristic to modify existing behaviours;
• Multimodality: technology can present information in many different ways, 
including text, audio, and video, thus matching each person’s individual prefer-
ences to the persuasive methods it uses.
In the late 1990s, the use of technology to persuade the users to change their 
behavior was first defined by Fogg (2002), and more recently persuasive systems 
were defined as “computerized software or information systems designed to rein-
force, change or shape attitudes or behaviours or both without using coercion or 
deception” (Oinas-Kukkonen and Harjumaa 2018).
Technology can act in persuading throughout several different techniques:
• Informing: individuals have to learn the presented information, in order for this 
information to be remembered.
• Reinforcement: desired behaviour should be rewarded/reinforced as quickly as 
possible upon its performance.
• Discussing: individuals share their thinking processes and beliefs among each 
other.
• Social comparison: individuals are stimulated to compare themselves with indi-
viduals from other groups that perform the desirable behavior.
• Fear appeal: materials (i.e., images or texts that elicit fear) are presented and 
should appeal fear to individuals of the target group; typically, fear appeals are 
effective to a certain extent only, because, when reaching a high level of elicited 
fear, target users could avoid the issue instead of considering it.
• Skills training: individuals learn from practicing behavior by themselves, and 
practice improves their confidence.
In the context of the P5 approach, by using the persuasive power of technology, 
eHealth solutions can be made more effective, as people are more adherent to 
eHealth interventions when more persuasive elements are used (Kelders & Van 
Gemert-Pijnen, 2013). The Persuasive System Design (PSD) model (Oinas- 
Kukkonen and Harjumaa 2018) represents a state-of-the-art approach for designing 
and evaluating persuasive systems. It is applicable to systems that are designed to 
form, alter, or reinforce attitudes, behaviors, or an act of compliance without using 
deception, coercion, or inducements, that is, it is well suited for the design of 
eHealth technologies.
The PSD model assumes several principles common to all persuasive systems, as 
regards the ways that people can be persuaded by means of technology:
• Technology is never neutral, but has always an intention.
• People like their views and behavior to be organized and consistent: if systems 
support the making of commitments, then users are more likely to be persuaded 
to follow these commitments.
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• Persuasion is often incremental: behavior change never takes place at once, but 
in small steps.
• Direct and indirect routes: paying attention (consciously or unconsciously) is 
very important when changing behavior.
As regards the characteristics that a technology should have in order to effec-
tively persuade people, these can be listed as:
• Unobtrusive, to fit into our daily lives without requiring a big change in our daily 
routines.
• Open, to allow a person that starts using a system to clearly know its purpose 
from the beginning.
• User-friendly, as a system is more effective when it is appealing and easy-to-use; 
however, recent approaches partially challenged this assumption, because even 
tools difficult to use could generate emotions and affection that influence both 
their usage and their persuasive power (cfr. Chap. 9).
The PSD model defines four categories of elements, or software features, based 
on what technology can do to persuade its users into changing their attitude or 
behavior: (1) primary task support; (2) dialogue support; (3) credibility support; (4) 
social support. Accordingly, different software features based on psychological 
theories can be chosen and implemented to reach the aim of supporting the user’s 
primary activities, to facilitate the information flow between the computer and the 
user, to increase credibility about the presented information, or to leverage social 
influence.
In recent years, the PSD has been used both to better understand the impact of 
persuasive eHealth technology, as well as to evaluate which features are imple-
mented in an eHealth solution, and their effects on adherence and outcome. It rep-
resents a promising field in the aim of changing behavior in the domain of health 
and well-being, but more studies are needed to get more insight into which features 
and subjective factors could predict the effectiveness of eHealth technology.
Once these aspects are better defined, it will be possible to define an optimal inter-
vention for each individual, based on the selection of only those software features 
able to highly engage the subject. This could then be described by extending the P5 
approach with a sixth “p” relevant to “persuasive,” to describe the personalized pro-
cess of defining a specific persuasive technology approach that could optimize the 
desired change in behavior, paving the way for a P6 approach conceptualization.
7  Conclusion
In this chapter, we have seen how eHealth could be based on a more accurate and 
systematic consideration of the psycho-cognitive uniqueness of individuals (and 
patients). Specifically, we have presented persuasive technology as a possible 
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resource for designing technologies able to promote treatment adherence and 
healthy activities (e.g., behavioral change regarding lifestyle); however, we have to 
consider that medicine in general is a still evolving field. Although we have dis-
cussed that a consideration of psychological aspects is fundamental for the health-
care context to evolve toward patient centeredness, the research is still open to a 
complete understanding of the psycho-cognitive aspects to be included in the design 
and evaluation of technologies.
Future studies may focus on how technologies can help patients to perform deci-
sions toward their healthcare process, by identifying the influence of biases and 
misconceptions that could lead patients toward making disadvantageous choices 
toward their own health management; such technologies could be used not only to 
aid medical practice (Lucchiari, Folgieri & Pravettoni, 2014), but also to empower 
patients (Woltmann et  al., 2011); moreover, cognitive psychology would be 
included, in the form of theory-based prescriptions, in user-centered design 
approaches toward the development of health technologies, in order to take into 
consideration patients’ mindset and cognitive abilities.
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Chapter 8
Role of Next-Generation Sequencing 
Technologies in Personalized Medicine
Stefania Morganti, Paolo Tarantino, Emanuela Ferraro, Paolo D’Amico, 
Giulia Viale, Dario Trapani, Bruno Achutti Duso, and Giuseppe Curigliano
1  Historic Background of DNA Sequencing
Cancer is a genetic disease. Decades of research has led to this knowledge, showing 
that it is the accumulation of molecular alterations that is the key element of tumori-
genesis, directing the acquisition of the malignant phenotype (Vogelstein et  al. 
2013). Genes involved in oncogenesis are classified in “oncogenes,” whose activa-
tion is responsible for tumor transformation and oncosuppressors, whose inactiva-
tion leads to cellular proliferation. Mutations of oncogenes (gain of function) or 
oncosuppressors (loss of function) can be genetically inherited (germline), but they 
are mostly acquired and caused by DNA replication errors and/or exposure to car-
cinogens (Kinzler and Vogelstein 1996).
The understanding of cancer as a genetic disease, though multifactorial and non- 
Mendelian in the majority of the cases, has led researchers to focus on cancer cells 
genome, looking for the leading cause(s) of the pathological proliferation that ulti-
mately cause cancer. The identification of specific driver genomic alterations 
allowed the development of targeted therapies, more effective and less toxic com-
pared to standard chemotherapies. Trastuzumab (approved in 1998) and imatinib 
(approved in 2001) were the first two drugs to show the potential of targeted therapy, 
followed by many molecules nowadays approved for the treatment of several types 
of cancer (Fischer et al. 2003). Interestingly, the US Food and Drug Administration 
(FDA) granted an accelerated approval for imatinib for the dramatic sustained 
response of chronic myelocytic leukemia (CML) patients treated with the novel 
tailored approach (Johnson et  al. 2003), in 2001; today, both imatinib and 
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 trastuzumab are enlisted as “essential medicines” by the World Health Organization, 
for the treatment of CML and breast cancer, available as a generic and biosimilar, 
respectively.
Genetic testing soon became a standard in oncological care: in the 2000s we have 
started to stratify patients according to their tumor mutational profile, tailoring ther-
apies according to the genetic signature. However, we only aimed genetic testing at 
those few mutations known to be targetable in each specific tumor type, thus limit-
ing the information acquired in a strict disease-oriented manner. In order to better 
understand the relevance of cancer mutations across different tumour types and 
easier identify new actionable targets, a reference “normal” genome sequence was 
needed to compare with the abnormal ones. The Human Genome Project provided 
such a feature in 2003, thanks to an international effort lasting almost 15 years, the 
project was accomplished using the Sanger sequencing technique to determine the 
exact sequence of nucleotide base pairs of the human genome (Green et al. 2015). 
During the same years, researchers kept studying the basic mechanisms of cancer 
growth, identifying new oncogenes and oncosuppressors. With a complete human 
genome reference in hand, it finally became possible to confirm the pathogenic 
alterations and to discover new genetic variants linked to human diseases. Large- 
scale cancer sequencing projects, such as the American TCGA (The Cancer Genome 
Atlas) and the British Cancer Genome Project were born with this purpose, giving 
birth to the “genomic era” of cancer research, thus promoting the progressive evolu-
tion of sequencing methods: in 2004, 454 Life Sciences showcased a paralleled 
form of sequencing called pyrosequencing, decreasing sequencing expenses at six-
fold compared with Sanger sequencing. This technological implementation led to 
the birth of the first of many NGS platforms, which allowed a faster and simpler 
sequencing by employing microscopic, spatially separated DNA templates to mas-
sively parallelize the capture of data. With such platforms in hand, it became pos-
sible to sequence all the coding exons of a genome (Whole Exome Sequencing, 
WES) and even a full genome (Whole Genome Sequencing, WGS) in a short time 
and at an affordable price, providing a huge amount of data. Analyzing and inter-
preting this data promises to be the challenge of the next decades (Fig. 8.1).
1.1  The NGS Revolution in the Context of Precision Medicine
Besides improving our understanding of cancer, NGS promoted the birth of a new 
way of treating cancer patients, which we today call Precision Medicine (PM). With 
this term, we refer to the suiting of medical therapy to the individual characteristics 
of each subject and its condition (cfr. Chap. 5). In cancer care, this means tailoring 
oncological treatments to each patient’s features and each cancer genomic altera-
tions. It is not a new concept, but the use of NGS and the consequent availability of 
large-scale human genome databases have created an opportunity for significant 
onward movement of this approach.
We have already moved from a One-size-fits-all Medicine to a progressive strati-
fication of patients according to their disease subtype, clinical features, and bio-
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markers (Stratified Medicine). NGS promises to lead the shift toward Precision 
Medicine, taking into account a wide set of patient features and the cancer muta-
tional scenario to select the best therapeutic approach in oncological care (Shin 
et al. 2017) (Fig. 8.2).
PM in oncology involves identifying mutations in cancer genomes predicting 
response or resistance to therapies. In the pre-NGS era, Sanger sequencing and PCR 
(polymerase chain reaction)-based techniques allowed to obtain a limited amount of 
information on cancer mutational status; with NGS panels it is now possible instead 
to screen a broad set of genes in one comprehensive test, able to identify alterations 
even in the scarce biopsy tissue often available in the everyday practice. And in 
those frequent cases where collecting tissue for molecular testing is unsafe (e.g., 
brain, lung, peritoneal lesions), NGS allows to obtain extensive genetic information 
from simple blood draws (see “Liquid Biopsy” below). In fact, it is possible to 
obtain genetic material for sequencing from circulating tumor cells (CTCs) and 
circulating cell-free tumor DNA (ctDNA), which represents a unique instrument to 
capture the intratumoral heterogeneity, to identify prognostic and predictive factors 
and imminent resistance mechanisms (Ignatiadis and Dawson 2014). It was recently 
proposed to incorporate this instrument into cancer staging, shifting to a TNM-B 
cancer staging system to be assessed in the diagnosis of every cancer and at every 
successive stage of the disease (Yang et al. 2017).
2  Technical Aspects: From Sanger Sequencing to NGS
In 1977, Frederick Sanger and colleagues first developed a technique to sequence 
DNA (Sanger et al. 1977). Also known as “chain-termination method,” it can be 
described as a DNA replication reaction during which the random incorporation of 
dideoxynucleotides (ddNTP) causes the termination of chain elongation. This gen-
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Fig. 8.1 Timeline of major achievements in sequencing technologies
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Elements required for a classic chain-termination reaction are illustrated in 
Table 8.1.
The Sanger process is a very accurate sequencing method, giving high-quality 
sequence for relatively long fragments of DNA (up to 900 base pairs). On the other 
hand, it is a very expensive process with a low data output.
The need for simpler and faster sequencing processes led to the development of 
new technologies for DNA reading, collectively named “next-generation sequenc-
ing” (NGS). In 2005, the 454 Life Science launched on market the first NGS plat-
form (Margulies et al. 2005), and since then many other companies developed NGS 
platforms that allow for high-throughput sequencing in a cost- and time-effective 
way.
Despite the platform used, every NGS process can be summarized in three 
phases: library preparation (± amplification), sequencing, and data analysis.
Fig. 8.2 Comprehensive approach in cancer care
S. Morganti et al.
129
2.1  Library Preparation and Amplification
The sequencing library is created by random fragmentation of a DNA template. 
Fragments are then linked to platform-specific adapters and amplified by PCR 
(polymerase chain reaction) or alternative techniques (solid-phase bridge amplifica-
tion or rolling circle amplification).
2.2  Sequencing
NGS technology can be categorized into short- and long-read sequencing. The dif-
ference intuitively lies on read length: 100–600  bp for the first technique, up to 
900 Kb for the second one.
Short-read sequencing approach is the most frequently used today—it is cheaper 
and has a higher accuracy. However, the short-read length limits its capability to 
resolve complex regions with repetitive or heterozygous sequences, for which a 
long-read technique is more suitable.
Illumina, Ion Torrent, 454 Life Science, and SOLiD are the major platforms cre-
ated using a short-read technology. The first three platforms use a technique called 
sequencing “by synthesis,” whereas the SOLiD system is based on sequencing “by 
ligation.”
Table 8.1 Basic elements of a Sanger sequencing reaction
Table A single-strand DNA sample that is previously amplified by 
PCR to generate many identical copies of a DNA sequence of 
interest.
DNA polymerase The enzyme that sequentially adds nucleotides into the 
elongating chain. It catalyzes the reaction: dNTP (or ddNTP) + 
DNAn ⇌ diphosphate + DNAn+1.
Primers Short sequences of nucleotides (almost 20) that bind to the 
DNA template and act as a starter for the DNA polymerase.
Deoxynucleotides (dATP, 
dCTP, dGTP, dTTP)
Monomers that compose a DNA sequence. Each of them 




ddNTP are special, artificial nucleotides analogous to dNTP, but 
lacking the –OH group at 3’ carbon position. They act as 
chain-elongating inhibitors of DNA polymerase.
To permit automate reading, ddNTP are usually labeled.
dNTP deoxynucleotides, ddNTP dideoxynucelotides, PCR polymerase chain reaction
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The MinION system, based on nanopore sequencing, and the PacBio sequencer, 
which uses a “Single Molecule, Real-Time (SMRT)” sequencing approach, repre-
sent instead the main long-read technologies available on the market. A technical 
comparison of all these NGS platforms is given in Table 8.2.
2.3  Data Analysis
The large amount of raw data generated is then inserted into bioinformatics work-
flows in order to convert these nucleotide sequences into meaningful biological 
results.
A typical NGS data analysis pipeline can be divided into four main operations: 
base calling, read alignment, variant identification (SNVs, indels, CNAs, SVs), and 
variant annotation. Table 8.3 briefly describes these steps.
3  NGS Methods: Genomics, Transcriptomics, 
and Epigenomics
3.1  Genomics
Next-generation sequencing was first applied to genomics research, mainly to detect 
variants in DNA sequence in terms of single nucleotide variations (SNVs), insertion- 
deletions (indels), structural variations (SVs), and copy number alterations (CNAs).
NGS methodology applied to an entire genome is called “whole genome sequenc-
ing,” in which both coding and non-coding regions are sequenced. WGS generates 
huge amounts of data per sample, but usually low depth of coverage. A typical WGS 
experiment assures a 30X coverage, enough to detect most germline variants in 
human genome, but inadequate to identify all rare somatic mutations present in 
cancer genomes.
“Whole exome sequencing” is instead specifically designed to sequence only 
coding DNA. These regions are isolated before sequencing by an enrichment step, 
which targets only the exons inside the library of interest. By sequencing only 2% 
of a genome, a single region can be read many more times, ensuring a coverage of 
100X with a cheaper and faster process. WES is therefore more suitable to analyze 
cancer genome; however, the capability to detect SVs and CNVs is much lower 
when excluding non-coding regions.
An even more selective genome analysis is given by “targeted sequencing,” in 
which specific regions of interest are isolated and sequenced. Many gene panels 
have been designed specifically for this purpose, allowing to focus time and 
resources on selected genes usually sequenced with a 500–1000X coverage.
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Sanger NA 900 96 20 min–3 h 2.1 Mb 0.3%
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454
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GS FLX 
Titanium XL+
Pyro 700 1 M 23 h 700 Mb 1% indels
Illumina
Hi Seqa SBS 36 (SE) Up to 4 B 
(SE)




125 (PE) Up to 8 B 
(PE)
7 h – 6 d (Hi 
Seq 2500)
substitution
MiniSeqb SBS 150 (PE) 25 M 4–24 h 7.5 Gb <1%
substitution
NextSeq 550b SBS 75 (SE) Up to 
400 M 
(SE)
12–30 h 120 Gb <1%




MiSeq (v3) SBS 75 (PE) 25 M 
(PE)
4–55 h 15 Gb 0.1%
300 (PE) substitution
Hi SeqXa SBS 150 (PE) 5.3-6 B <3 d 1800 Gb 0.1%
substitution
NovaSeq6000c SBS 150 (PE) 20 B 36–44 h 6000 Gb NA
Ion Torrent
PGM SBS 400 (SE) 400000–
5.5 M
2.3–7.3 h 2 Gb 1% indels
Proton SBS Up to 200 
(SE)
60–80 M 2–4 h Up to 
10 Gb
1% indels
S5 SBS 600 (SE) 2–130 M 2.5–4 h 25 Gb 1% indels
SOLiD (Sequencing by Oligonucleotide Ligation and Detection)
5500xl SBL 75 (SE) ~1.4 B 10 d 240 Gb 0.01%
50 (PE) A-T bias
Third generation
PacBio (Pacific Bioscience)




30 min–4 h 1 Gb 15% indels
Sequel SMRT 30000 
(average)
~400000 30 min–20 h 10 Gb 15%
(continued)
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3.2  Transcriptomics
The transcriptome can be defined as “the complete set of transcripts in a cell or a popu-
lation of cells for a specific developmental stage or physiological condition” (Wang 
et al. 2009). Transcriptomics studies have a pivotal role in cancer research, providing 
a unique focus of what happens in neoplastic cells after DNA transcription.
RNA-sequencing (RNA-seq) is a relatively new application of NGS, which is 
gradually replacing microarrays as favorite technology for transcripts analysis. 
Differently from arrays, RNA-seq is not designed as a targeted test and does not 
require species- or transcript-specific probes. It can be used both to quantify gene 
expression and to detect novel transcripts, gene fusions, SNV, and indels at the same 
time.
Besides gene expression analysis, NGS has also been applied to small non- 
coding RNA (ncRNA) discovery and profiling through dedicated small RNA-seq 
platforms. Small non-coding RNAs are short sequences of nucleotides (≈20 bp) not 
translated into proteins. Several classes of small ncRNA exist, like transfer RNA 
(tRNA), ribosomal RNA (rRNA), microRNA (miRNA), small interfering RNA 
(siRNA), and Piwi-interacting RNA (piRNA). Between them, miRNA and siRNA 















Up to 48 h 20 Gb 5–10%
A-T adenine-thymine, B billion, bp base pairs, d days, Gb gigabase pairs, h hours, indels insertions- 
deletions, Kb kilobase pairs, M million, Mb megabase pairs, min minutes, NA not applicable, PE 
pair-end, Pyro pyrosequencing, SBL sequencing by ligation, SBS sequencing by synthesis, SE 
single-end, SMRT single-molecule-real-time
aDual flow cells; bhigh output; cdual S2 flow cells
Table 8.3 Basic steps of NGS data processing
Base calling
Signals provided during sequencing are translated into a sequence of bases, 
removing the noisy signals.
Read alignment DNA of the sequenced sample is compared/aligned to a reference genome. 
Given that NGS generally produces millions of short reads, each read needs 




Variants from sequence data are identified in this step. Four main classes of 
sequence variants exist (SNVs, indels, CNAs, and SVs), each requiring a 
different computational approach for sensitive and specific identification.
Variant 
annotation
Real variants are distinguished from sequencing artefacts, trying to identify 
which ones are potentially pathogenic and have a real clinical value.
SNVs single nucleotide variations, indels insertion/deletion, CNAs copy number alterations, SVs 
structure variants
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gene expression regulation of cancer cells (Gomes et al. 2013). Through a cellular 
process called RNA interference (RNAi), both miRNA and siRNA interact with the 
so-called RNA-induced silencing complex (RISC) to block and silence target 
mRNAs.
This powerful gene-silencing process is object of study also from a therapeutic 
point of view. RNA-based therapeutics represents a new class of anticancer drugs, 
inhibiting molecules targets that were inaccessible until now. None of these drugs is 
approved by FDA to date, but many are currently under investigation in clinical tri-
als (Barata et al. 2016).
3.3  Epigenomics
The term epigenetics refers to “the study of changes in gene function that are mitoti-
cally and/or meiotically heritable and that do not entail a change in DNA sequence” 
(Wu and Morris 2001). DNA methylation, histone-modification, and altered DNA–
protein interactions are three major epigenetic alterations involved in cancer devel-
opment and progression.
In the past years, epigenomics studies were essentially conducted through micro-
arrays technologies. The arrival of NGS signed a paradigm shift in this field, dra-
matically increasing the chance to survey epigenetic markers genomewide with 
high-throughput data output at single nucleotide resolution. Methylation sequenc-
ing (or bisulfite sequencing) (Lister et  al. 2008) and ChIP-seq (Chromatin 
Immunoprecipitation Sequencing) (Barski et al. 2007) are the NGS-based assays 
commonly employed for epigenetics studies.
4  NGS Applications for a Personalized Oncology
4.1  Detection of Driver Alterations and Resistance
The availability of next-generation sequencing technologies had literally revolu-
tionized the comprehension of cancer biology during the last decades. Massive 
genome sequencing of thousands of tumors from all major cancer types has become 
feasible, leading to identification and classification of many genetic and epigenetic 
alterations potentially involved in tumorigenesis.
By the time a cancer is diagnosed, it comprises billions of these genomic altera-
tions. Some are responsible for malignant transformation, others are acquired along 
the way. The pivotal work of Greenman and coworkers defined these two categories 
of mutations as “driver” and “passenger” (Greenman et al. 2007). The term “driver” 
is reserved for somatic mutations that, directly or indirectly, confer a selective 
growth advantage to malignancies bearing them. The term “passenger” is instead 
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referred to alterations that arise in somatic cancer genome during the progression of 
a tumor, but do not contribute to its growth.
Detection of driver alterations that results in oncogene addiction is currently the 
primary application of NGS in oncology research and discriminating between driver 
and passenger alterations is a challenge point of translational research. Several sta-
tistical and computational techniques to characterize these mutations have been 
described, including variant effect prediction, recurrence/frequency assessment, 
and pathway/network analysis. These techniques provide alternative strategies to 
filter the long list of somatic mutations, thus identifying an enriched subset of sub- 
clonal carriers who may undergo further functional validation (Gonzalez-Perez 
et al. 2013; Raphael et al. 2014; Ding et al. 2014). Given that driver mutations are 
responsible for oncogenic addiction, any targeted therapy must be based on their 
identification. The implementation of this “lock-and-key” model led to the approval 
of several specific biologic agents, targeting specific driver alterations in different 
cancer types.
Here we present the example of NGS application in clinical practice for identifi-
cation of driver and resistance mutations in lung cancer, breast cancer, and cancer of 
unknown primary origin.
4.1.1  Lung Cancer
Lung cancer represents, by far, the disease in which pathways of oncogenic addic-
tion have been characterized the most. There are, on average, more than 300 non- 
synonymous mutations per lung cancer, but only a minority of these genes can 
promote tumorigenesis, resulting in driver mutations. Large-scale genomic studies 
have recognized a variety of potential therapeutic targeting, including:
• Established targets: EGFR, ALK, ROS-1, BRAF
• Emergent target: MET, RET, NTRK, HER2, PI3KCA, AKT1, MAP 3K1, FGFR, 
DDR2
• Elusive targets: KRAS, TP53
International guidelines recommend molecular testing for these established tar-
gets in everyday clinical practice.
Detection of EGFR and BRAF mutations are classically carried out using 
RT-PCR (Real Time-PCR) or Sanger sequencing, whereas ALK and ROS1 rear-
rangements are identified through FISH (fluorescence in situ hybridization) or IHC 
(immunohistochemistry) methods. In recent years, NGS panels implementation is 
gradually replacing these techniques in clinical laboratories, allowing the analysis 
of several genes at the same time. The last MAP (Molecular Analysis for Personalised 
Therapy) consensus (Swanton et al. 2016) recommends the use of NGS panels in 
the context of clinical trials. For non-small-cell lung cancer (NSCLC), at least 20 
genes should be tested in molecular screening programs to drive patients onto thera-
peutic trials (EGFR, BRAF, HER2, KRAS, PI3KCA, NTKR, ALK, MET, AKT1, 
BRCA1/BRCA2, HRAS, NRAS; rearrangement status of ALK, ROS1, NTRK; 
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amplification of RET, MET, and EGFR; aberrations (mutations or amplifications) in 
FGFR1/2/3, NOTCH1/NOTCH2).
Profiling of EGFR, ALK, ROS1, and BRAF defines as many “subtypes” of 
NSCLC, for which specific algorithm of treatment exists. Activating EGFR muta-
tions in the tyrosine kinase (TK) domain of the EGFR gene, most frequently exon 
19 deletion mutations and the single-point substitution mutation L858R in exon 21, 
are predictive for response to the EGFR TK Inhibitors (EGFR-TKIs) gefitinib, erlo-
tinib, afatinib, osimertinib, and dacomitinib. ALK rearrangement-positive NSCLC 
are instead candidate to frontline therapy with ALK-inhibitors alectinib, crizotinib, 
or ceritinib. The last two of them are also the referred targeted drugs for ROS1- 
rearranged NSCLC, whereas cancers positive for BRAF V600E can receive the 
combination dabrafenib-trametinib (www.nccn.org/professionals/physician_gls/
pdf/nscl.pdf).
Unfortunately, almost all patients treated with targeted therapies develop second-
ary resistance. NGS can be useful to identify the implicated mechanisms of resis-
tance and to aid on following treatment choices. For instance, T790M mutation has 
been found in almost 50% of patients that progress during treatment with first- and 
second-generation EGFR-TKIs. This finding led to the development of osimertinib, 
a third-generation EGFR TKI that inhibits T790M as well as the common activating 
mutations. The AURA 3 trial (Mok et al. 2017) demonstrated the great superiority 
of osimertinib to platinum-based chemotherapy in EGFR-TKIs pretreated patients 
with T790M mutation, reporting a PFS of 10.1 months in osimetinib group versus 
4.4 months in the control group. The introduction of osimertinib has allowed pro-
longing as far as possible the chemo-free interval in EGFR-positive population.
Interestingly, the T790M mutation was documented using the Cobas EGFR 
Mutation Test v2 on ctDNA on blood and urine samples. Osimertinib is currently 
approved only for T790M-positive NSCLC, and this mutation can be indifferently 
assessed on tissue sample or liquid biopsy. In this common clinical scenario, prefer-
ring blood- over tissue-sampling is clinical practice.
4.1.2  Breast Cancer
The estrogen receptor (ER) and the HER2 signaling pathways are the dominant 
drivers of oncogenesis in breast cancer. The available arsenal of hormonal agents 
and anti-HER2 drugs has dramatically changed the natural history of metastatic 
breast cancer (MBC) during last decades, achieving a twofold increase in 5-year 
relative survival rate (Mariotto et al., 2017).
Unfortunately, ER-expression and/or HER2-amplification can well predict but 
are not secure guarantee of response to targeted therapy with endocrine therapy and 
HER2-signaling blocking agents. Many patients are resistant ab initio (de novo 
resistance), whereas others become resistant after an initial phase of therapeutic 
efficacy (acquired/secondary resistance).
ESR1 mutations in ER-positive breast cancer is a recognized cause of resistance 
to endocrine therapy, more commonly as acquired resistance. First described in cell 
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models in 1996 (Weis et al. 1996), ESR1 mutations were found to confer ER con-
stitutive activation and resistance to endocrine agents. Nevertheless, these altera-
tions were rarely found in subsequent studies (0.5% of cases), and their potential 
role remained underappreciated for several years (Koboldt et al. 2012).
With NGS technology applications, several studies renewed interest in ESR1 
mutations by demonstrating high prevalence in ER-positive MBC after aromatase 
inhibitor (AIs) therapy, suggesting a role in the endocrine resistance, both as predic-
tive and prognostic biomarker (Schiavon et  al. 2015; Jeselsohn et  al. 2014; 
Merenbakh-Lamin et al. 2013; Robinson et al. 2013).
The SOFEA trial compared exemestane alone with fulvestrant-containing regi-
mens (fulvestrant+anastrozole or fulvestrant +placebo) in patients with MBC pre-
treated with AIs (Johnston et  al., 2013). In a retrospective analysis of this trial, 
detection of ESR1 mutations (39% of patients) correlated with an improved PFS 
after taking fulvestrant compared with exemestane, whereas wild-type patients had 
similar outcomes with both treatments (Fribbens et al. 2016).
Additionally, a retrospective analysis of the BOLERO-2 trial, evaluating the ben-
efit of incorporating everolimus to AI therapy, showed longer PFS with everolimus 
only in the subgroup of patients harboring D538G ESR1 mutations (21.1%), with 
similar outcomes when compared to wild-type patients. This benefit was not 
observed for patients with Y537S mutation (alone or with D538G mutation). Despite 
the treatment arm, all patients ESR1-mutated had a worse overall survival (OS). The 
authors concluded that ESR1 mutations are not predictive of benefit with everoli-
mus, but ESR1 keeps a negative prognostic value (Chandarlapaty et al. 2016).
In the PALOMA3 trial, pre- and postmenopausal patients failing a prior ET 
within 12 months in the adjuvant and 1 month in the metastatic setting were ran-
domized to fulvestrant plus palbociclib or fulvestrant and placebo (Cristofanilli 
et al. 2016). ESR1 mutations were detected in 25% of patients, at baseline, as a 
finding related to the endocrine resistance mechanism. A significant PFS benefit 
was reported for patients treated with fulvestrant/palbociclib versus patients receiv-
ing fulvestrant alone, and this benefit was maintained in patients harboring an ESR1 
mutation. This evidence confirms a conserved selective sensitivity to fulvestrant for 
ESR1-mutant cancers, even if these mutations are commonly associated with a 
worse prognosis (Turner et al. 2016). In conclusion, the suggestion is to select the 
combination fulvestrant +/- palbociclib over AIs when ESR1 mutations are detected.
Prospective trials are needed to understand if ESR1 mutations analysis could 
impact on treatment choice and final outcome of ER-positive MBC. Specific inhibi-
tors are under investigation like AZD9496, in a refined targeted approach to endo-
crine therapy (Hamilton et al. 2018).
4.1.3  Carcinoma of Unknown Primary Site
Management of carcinoma of unknown primary (CUP) site is another field that 
made considerable steps forward since NGS availability. CUP accounts for 3–5% of 
all malignancies, the seventh for incidence and the fourth cause of cancer death 
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(Massard et al. 2011). ESMO guidelines recommend a platinum-based regimen for 
the majority of CUP patients (85–90% of cases), defined as “poor-risk” subset 
because of lacking any clinico-pathological features that provide a favorable out-
come. Their prognosis is dismal despite chemotherapy (median OS of 9 months) 
(Fizazi et al. 2015).
Thanks to NGS profiling, CUP management has radically changed. First of all, it 
has been shown that gene expression profiling can predict the tissue of origin and 
consequently allow treatment optimization, in a histology-oriented approach. A pro-
spective trial conducted by Hainsworth and colleagues at the Sarah Cannon Research 
Institute found that the primary tissue can be predicted in 98% of cases. Patients in 
this trial were subsequently treated with a site-specific regimen, reaching a median 
survival of 12.5 months (Hainsworth et al. 2012). Considering the modest benefit 
achieved with a platinum-based empiric regimen, the identification of the putative 
primary may substantially change the management and outcome of patients with 
CUP, particularly if a tumor more responsive to the best site-specific therapy is 
recognized.
Detection of actionable mutation is another promising application of the genome 
sequencing for a molecular-oriented approach to CUP management. Performing a 
sequencing panel encompassing 410 cancer-associated genes (the MSK-IMPACT 
panel), Varghese et al. analyzed 150 tissue samples of CUP. A targetable genomic 
alteration was found in 30% of cases (45 patients), and 10% of them (13 patients) 
received a targeted drug. The most common putative driver alterations detected 
were: ERBB2 amplification, BRAF V600E mutation, and PIK3CA mutations 
(Varghese et al. 2017).
“CUPISCO” is a randomized, phase II study designed to compare efficacy and 
safety of targeted therapy or immunotherapy versus platinum-based chemotherapy 
in CUP (NCT03498521). After three cycles of platinum-based induction CT, 
patients are randomized 3:1 to targeted therapy/immunotherapy or chemotherapy. A 
comprehensive genomic profiling is performed on all patients enrolled before 
receiving the induction CT, allowing a subsequent choice of the best targeted ther-
apy in the experimental arm. This trial is actually recruiting and the first results are 
expected in 2022. If positive, their results could dramatically change the manage-
ment of CUP in everyday clinical practice.
4.2  Biomarkers
In 1998, the National Institutes of Health Biomarkers Definitions Working Group 
defined a biomarker as “a characteristic that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes, or pharmaco-
logic responses to a therapeutic intervention” (Atkinson et al. 2001). A biomarker 
has a “prognostic” value when it gives information about disease outcome irrespec-
tive of treatment, whereas a “predictive” biomarker indicates the likely benefit from 
a specific treatment.
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In the era of targeted therapy, predictive biomarkers and related targeted drugs 
are commonly validated and approved in parallel. HER2 amplification/trastuzumab 
in breast cancer, BCR-ABL translocation/imatinib in chronic myeloid leukemia, 
EGFR mutation/EGFR TKI in NSCLC, and BRAF mutation/melanoma are only 
few examples of “predictive biomarker/targeted drug” pairs that commonly guide 
the therapeutic choice.
Beside the well-known biomarkers for cancer treatment response prediction, 
relatively new and more complex models are emerging. Microsatellite instability 
(MSI), homologous recombination deficiency (HRD), and tumor mutation burden 
(TMB) have the most robust data so far and will probably soon impact on clinical 
practice as predictive of response to DNA-disrupting agents, DNA repair targeting 
compounds, and immunotherapy.
4.2.1  Homologous Recombination Deficiency
Homologous recombination (HR) is a genetic recombination mechanism essential 
for repair of DNA double-strand breaks (DSBs) (Jasin and Rothstein 2013; Szostak 
et al. 1983). BRCA1 and BRCA2 genes are essential components of HR-mediated 
DNA repair, and mutations of these genes cause HR pathway failure (Moynahan 
et al. 1999; Moynahan et al. 2001). In HR-deficient cells, other mechanism of DNA 
repair must take over, such as non-homologous end joining (NHEJ) or base- excision 
repair (BER) (Hustedt and Durocher 2017). Specific agents, like poly-(ADP ribose) 
polymerase (PARP) inhibitors, have been designed to target these alternative path-
ways (Fong et al. 2009; Robson et al. 2017; Swisher et al. 2017). This therapeutic 
strategy, called “synthetic lethality,” sentences HR-deficient cells to die by 
apoptosis.
The singularity of HRD as predictive biomarker lies on its complexity. BRCA1/2 
are only two of many proteins involved in this pathway, and all of these need to be 
analyzed in parallel to make HRD a reliable biomarker. Many panels based on NGS 
sequencing are currently available to test HRD in different cancers, providing a 
quantitative score that reveals if the HR pattern is impaired or not (O’Kane et al. 
2017).
4.2.2  Microsatellite Instability
Microsatellite instability refers to hypermutability of short nucleotide sequences 
tandemly repeated (microsatellites) (Thibodeau et al. 1993). This condition is essen-
tially due to impairment of DNA mismatch repair (MMR) pathway, because of 
mutation of MMR genes (e.g., MLH1, MSH2, MSH3, MSH6, and PMS2).
MSI is observed in 15% of sporadic colorectal tumors (Vilar Gruber 2010), and 
has been reported in tumors of endometrium, ovaries, urothelium, stomach, small 
intestine, hepatobiliary tract, brain, and skin. If instead a germline mutation is 
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found, the MSI phenotype identifies a genetic disease called “hereditary non- 
polyposis colorectal cancer” (HNPCC), or Lynch syndrome (Lynch et al. 1993).
A potential role of MSI as predictive biomarker has recently been investigated, 
following the evidences that high levels of MSI seem to predict a good response to 
immune-checkpoint inhibitors (ICPI), whereas MSI stable tends not to (Le et al. 
2017). This result led to the FDA approval of pembrolizumab for MSI-H cancers in 
May 2017, the first tumor-agnostic drug approval in history.
MS instability is usually analyzed through PCR and IHC assays. Nevertheless, 
dedicated NGS panels have been recently implemented, showing feasibility and 
reliability if compared to “old” techniques (Vanderwalde et  al. 2018). The main 
advantages of NGS methodology over IHC and PCR are the unnecessity of normal 
tissue (unlike PCR), a quantitative result (instead of IHC, which is a qualitative test) 
and obviously the availability of many additional information for a therapy person-
alization at its best.
4.2.3  Tumor Mutational Burden
Tumor mutational burden is defined as the number of somatic mutations within the 
coding region of a tumor genome. A high mutational load is typically found in 
tumor associated to environmental DNA damage, like lung cancer (i.e., tobacco 
smoking, environmental pollution) or melanoma (i.e., sun exposure) (Chalmers 
et al. 2017).
TMB has recently been identified as predictive biomarker of immunotherapy 
efficacy. The rationale lies in the principle of immunotherapy itself: a TMB corre-
lates with expression of multiple neoantigens by cancer cells, and consequently to 
potential efficacy of ICPI in reactivating immunity against cancer cells.
Major evidences about a role of TMB as predictive biomarker of response to 
ICPI come from retrospective analysis of different studies, including melanoma, 
NSCLC, and urothelial cancer (Rosenberg et al. 2016; Rizvi et al. 2015; Snyder 
et al. 2014). A prospective validation in phase III trials is awaited; however, early 
phase trials suggest a predictive role for TMB. Both in NSCLC and SCLC, the first- 
line combination therapy nivolumab + ipilimimab has shown to be more effective in 
patients with high TMB, as respectively outlined in Checkmate 227 (Hellmann 
et al. 2018a, b) and 032 (Hellmann et al. 2018a, b) trials. Similar evidences come 
from trials with atezolizumab in first- (B-F1RST study (Velcheti et al. 2018) and 
second-line (POPLAR and OAK trials (Gandara et  al. 2017) treatment for 
NSCLC. Quantification of TMB was classically carried out through whole exome 
sequencing. This approach is accurate, but expensive and not suitable for routine 
use in clinical practice. For this reason, major biotechnology companies have 
designed specific targeted panels to quantify TMB in a simple and cost-effective 
way. Many independent trials have already proved their reliability if compared to 
WES (Johnson et al. 2016). Prospective trials are now necessary to validate their 
implementation in clinical practice to identify which patients are more likely to 
respond to immunotherapy.
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4.3  Liquid Biopsy
Liquid biopsies are noninvasive blood tests that detect circulating tumor cells 
(CTCs) and fragments of tumor DNA (cell-free tumor DNA – ctDNA) released into 
the bloodstream from the primary tumor and from metastatic sites.
Collection of fluid instead of classic tissue sample is gradually spreading from 
research laboratories to clinical practice. A liquid biopsy consists of a simple blood 
sampling, overcoming the issues related to the feasibility of invasive biopsy proce-
dures. For the same reason it can be repeated many times without risks or side 
effects, providing a picture of tumor evolution over time. Finally, analysis of ctDNA 
may allow a better representation of tumor heterogeneity, possibly detecting differ-
ent clones at once. Many potential applications of liquid biopsy are object of ongo-
ing clinical trials. The most promising are briefly presented below.
4.3.1  Early Diagnosis of Primary Disease
Early detection of cancer through a validated screening assay is probably the most 
ambitious purpose of liquid biopsy. Like every screening test, high sensitivity, spec-
ificity, and cost-effectiveness are essential requirements. Despite recent develop-
ment of very sensitive technologies, a reliable test for early cancer detection remains 
a challenge.
Cohen et al. (2018) launched very recently the CancerSEEK panel, developed 
for detection of the eight most common cancers (ovary, liver, stomach, pancreas, 
esophagus, colorectum, lung, and breast). This method combines the evaluation of 
eight blood biomarkers with sequencing of 16 cancer-related genes from ctDNA. On 
a sample of 1005 individuals with clinically detected non-metastatic cancers, the 
authors reported a median sensitivity of 70% (ranging from 98% in ovarian cancers 
to 33% in breast cancers), with a specificity ≥99%. Despite these encouraging 
results, some limitations to this study must be noted. Firstly, the experimental cohort 
was composed by patients with clinically detected cancers. In a real-world screen-
ing population most individuals would have less advanced disease, probably deter-
mining a minor test sensitivity. Secondly, the control cohort included only health 
individuals, without all the comorbidities that could augment the number of false 
positive results.
4.3.2  Early Detection of Relapse
Several studies have demonstrated that CTCs detection is associated with unfavor-
able prognosis in various types of solid tumors, in particular for early-stage 
diseases.
Early breast cancer (EBC) is the setting for which more evidences exist. The 
largest trial realized so far has been published by Rack and colleagues in 2014 
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(Rack et al. 2014). The authors used the CellSearch System to analyze CTCs in 
patients with EBC: 2026 women were tested before adjuvant CT and 1492 after the 
treatment. CTCs detection before CT was associated with poor outcome both in 
terms of disease-free survival and overall survival. The persistence of CTCs after 
receiving adjuvant CT was analogously linked to a negative prognosis.
Beside breast cancer, CTCs count has been evaluated as prognostic marker for 
metastatic relapse in many other tumor types, like colorectal (Yokobori et al. 2013), 
bladder (Rink et al. 2012), liver (Schulze et al. 2013), head and neck (Gröbe et al. 
2014), and testicular germ cell tumors (Nastaly et al. 2014).
Cell-free tumor DNA profiling has been similarly performed to assess its value 
in predicting metastatic relapse. In two different studies published in 2015, ctDNA 
was serially assessed for earlier detection of metastasis in patients with EBC.  In 
both cases, mutation tracking in serial samples has been shown to accurately predict 
metastatic relapse, in several instances months before clinical relapse (8–11 months 
on average) (Olsson et al. 2015; Garcia-Murillas et al. 2015). Reinert et al. (2016) 
conducted a similar trial on patients with early colorectal cancer, with analogous 
final evidences: using an NGS approach on ctDNA it was possible to detect meta-
static recurrence with a 10 months’ lead time compared to conventional follow-up.
Taken together, these evidences suggest that implementation of liquid biopsy for 
screening of patients with high risk, early-stage cancer may create a therapeutic 
window for interventions before the development of clinical metastasis.
4.3.3  Detection of Driver/Resistance Mutations and Real-Time 
Monitoring of Therapies
As previously mentioned, detection of driver- and resistance mutations is a key 
application of NGS. DNA profiling is performed on a tissue sample from a biopsy 
or a surgical specimen, usually from the primary tumor and sometimes from a meta-
static site. These samples are then archived in pathological labs, always available for 
additional analysis. Nevertheless, they may represent a “static” picture unable to 
reflect the temporal evolution under drug pressure. Moreover, metastatic relapse 
frequently happens several years after primary tumor resection, and the information 
obtained from that specimen might be outdated. Serial tissue biopsies of both pri-
mary tumors and metastatic sites are unfeasible in clinical practice. On the contrary, 
liquid biopsy allows repeated analyses over the course of treatment, providing a 
dynamic and reliable picture of tumor genome that can be used for monitoring ther-
apies in real time.
Treatment choice in metastatic breast cancer is determined by ER-expression 
and HER2-amplification. ER-positive MBCs are eligible for hormonal treatment; 
that is, commonly continued until development of resistance and disease progres-
sion. A common cause of acquired resistance to endocrine therapy is tumor hetero-
geneity: patients with ER-positive BC can harbor ER-negative CTCs, as 
demonstrated by Paoletti et al. (2015).
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Mutation of ER itself is a common cause of resistance. Chu and coworkers 
proved that somatic mutations in the ER gene (ESR1) can be readily identified in 
ctDNA, and they correlate with failure of endocrine therapy (Chu et  al. 2016). 
Liquid biopsy has been also successfully applied for analysis of ESR1 methylation, 
known to be responsible for epigenetic silencing of ESR1 (ER downregulation) and 
development of secondary endocrine resistance (Mastoraki et al. 2018).
The HER2 oncogene is another key target in MBC treatment. Also, for HER2 
status a discrepancy between CTCs and primary tumors has been found in up to 
30% of cases (Fehm et al. 2010). This evidence inspired the development of dedi-
cated interventional trials, where patients HER2-negative at primary assessment can 
receive anti-HER2 agents on the basis of HER2-status on CTCs (DETECT III 
study—NCT01619111, Treat CTC trial—NCT01548677). In colorectal cancer, 
NRAS, KRAS, and BRAF status are essential requirements for therapy optimiza-
tion. Many studies have reported a high level of concordance between mutational 
analysis on tissue samples and ctDNA (Mouliere et al. 2013; Siravegna et al. 2015). 
Moreover, liquid biopsy has shown to provide a better picture of tumor heterogene-
ity, detecting RAS mutation not found on tissue sample (Siravegna et al. 2015).
Mutational analysis of KRAS status during treatment with anti-EGFR can also 
predict disease progression several months before radiologic assessment (Misale 
et al. 2012). Longitudinal ctDNA profiling has even demonstrated that these mutant 
KRAS clones decline following anti-EGFR withdrawal, indicating that clonal evo-
lution is a continuous process (Siravegna et al. 2015).
Lung cancer is the prototype of therapy personalization based on mutational sta-
tus. Once again, liquid sequencing has proved to be a reliable surrogate of tissue 
biopsy (Kuang et al. 2009; Taniguchi et al. 2011; Nakamura et al. 2012; Douillard 
et  al. 2014; Reck et  al. 2016). On June 1, 2016, FDA approved “Cobas EGFR 
Mutation Test v2” as first liquid biopsy test available in clinical practice. It is 
licensed for the detection of exon 19 deletions or exon 21 substitutions in EGFR 
gene. If negative, guidelines recommend a routine test using tissue sample to be 
performed (www.nccn.org/professionals/physician_gls/pdf/nscl.pdf).
EGFR profiling through liquid biopsy is a useful tool also during treatment with 
TKIs, allowing for detection of EGFR mutations responsible for therapy resistance. 
Oxnard et al. analyzed plasma ctDNA in 9 patients with EGFR-mutated NSCLC 
treated with erlotinib. All patients were negative for mutation T790M before starting 
treatment, but in 2/3 of them serial ctDNA profiling showed an increasing in T790M 
EGFR mutant levels up to 16 weeks before radiologic progression, anticipating the 
clinical–radiological progression (Oxnard et al. 2014).
Androgen blockade represents the cornerstone for treatment of prostate cancer. 
Unfortunately, progression to castration-resistant prostate cancer (CRPC) occurs 
virtually in all patients. Genomic and transcriptomic alterations of androgen recep-
tor, essentially in terms of AR amplification and AR splice variants, are primarily 
responsible for progression to castration resistance.
AR-v7 is a splicing variant of AR, a truncated form of the receptor that is consti-
tutively active because of lacking the ligand-binding domain. When detected, it is 
responsible not only for resistance to classical first-line androgen-deprivation ther-
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apy, but also to second-generation anti-androgen agents commonly applied in CRPC 
(i.e., enzalutamide and abiraterone). AR-v7 is commonly tested analyzing mRNA 
from CTCs (Antonarakis et al. 2014).
A recent clinical audit published by Johns Hopkins University has confirmed the 
potentiality of AR-v7 as predictive biomarker, revealing that its knowledge can 
influence the clinical decision making in 53% of patients (Markowski et al. 2017). 
Nevertheless, (it must be pointed out that) the last St. Gallen prostate cancer confer-
ence has discouraged a routine use of AR-v7 testing in clinical practice, mainly 
because only single-center experiences are available, and a prospective, external 
validation is still lacking (Gillessen et al. 2018). Moreover, AR-V7 positivity is 3% 
(Scher et al. 2016) in patients naive to abiraterone, enzalutamide, or taxane expo-
sure, increasing only after progression on second-generation anti-androgen agents 
(19–39%) (Antonarakis et  al. 2014). For this reason, the panel concluded for its 
limited value both in first-line setting, for its low-rate detection, and in second line, 
where chemotherapy is already the treatment of choice.
4.3.4  Characterization of Tumor Heterogeneity
Genetic diversity exists between individuals with the same tumor type (intertumor 
heterogeneity), but also within a single tumor (intratumor heterogeneity). Intratumor 
heterogeneity (ITH) is both spatial, comprising different subclones inside a unique 
lesion and in distinct sites, and temporal, emerging during the evolution of a 
malignancy.
The “trunk and branch” model is commonly used to represent ITH. Into the trunk 
are found driver somatic alterations that arise very early during the natural history 
of a tumor. Since indispensable for neoplastic growth, they are detectable in every 
subclone and tumor region. Conversely, subclonal mutations that occur later during 
cancer evolution are not homogeneously localized, but present in only a subset of 
cancer cells. They make up the branches of the tree (Yap et al. 2012).
In a pivotal paper published on Science almost 40 years ago, Peter Nowell firstly 
postulated this theory of cancer as a process of clonal evolution, in which successive 
rounds of clonal selection give rise to tumor heterogeneity (Nowell 1976). However, 
this theory could find a clinical application outside the preclinical experiments only 
years later, with the emergence of NGS techniques. Serial extensive tissue sampling 
of both primary and metastatic lesions is unfeasible in clinical practice, and sam-
pling bias may occur because only limited geographical regions are analyzed.
The advent of next-generation sequencing has dramatically improved our under-
standing over tumor evolution, starting to resolve the complexity of ITH at single- 
nucleotide level. Given that ctDNA is a reliable noninvasive surrogate for tissue 
biopsies, massive parallel sequencing of ctDNA is likely to be the most powerful 
tool available to investigate ITH.
In a proof-of-concept study, De Mattos-Arruda et al. sequenced the genome of a 
primary cancer, a liver metastasis, and plasma ctDNA from a single patient with 
synchronous ER+/HER2- metastatic breast cancer. Using a targeted panel of 300 
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cancer genes, they found in ctDNA all the mutations present in the primary tumor 
and/or the liver metastasis. Conversely, not all mutated genes detected in the metas-
tasis were reliably identified in the primary. The authors successfully proved that 
ctDNA sequencing is clearly a powerful tool for heterogeneity investigation, pro-
viding an accurate representation of the complete repertoire of mutations detected 
in all tumor sites (De Mattos-Arruda et al. 2014).
Many other studies conducted on different cancer types outlined analogous 
results (Siravegna et al. 2015; Landau et al. 2013; Lebofsky et al. 2015). Based on 
this assumption, ongoing trials have been conceived to monitor disease evolution 
prospectively, from early-stage diagnosis through the different stages of tumor pro-
gression and metastatic spreading.
The TRACERx is a pioneering project in this research field. Consisting of four 
parallel observational studies (lung, renal, melanoma, prostate), it is built on the 
ambitious aim of understanding the relationships between cancer genomic evolu-
tion in metastases, immune evasion, adaptation, and clinical outcome (http://trac-
erx.co.uk/).
4.3.5  CTCs and ctDNA Analysis
CTCs and ctDNA are cancer biomarkers with complementary roles. Outlining dif-
ferent information, they can be more or less useful with regard to specific research 
needs and clinical contexts. CTCs can be isolated by several methods, using physi-
cal, immunologic, molecular, or functional assays [98]. Several platforms for CTCs 
detection are commercially available, but CellSearch® system is the only FDA- 
approved for clinical use. It is an antibody-based assay, by which CTCs are isolated 
through a double check of positive and negative selection. A cell is identified as 
CTC by CellSearch if EpCAM (Epithelial Cell Adhesion Molecule)-positive, 
cytokeratins- positive, and CD45-negative.
For many years, CTCs count has been used alone as a prognostic tumor bio-
marker. Recent advantages in isolation and sequencing technologies changed this 
perspective, paving the way to DNA, RNA, and protein analysis at single-cell level 
(Heitzer et al. 2013; Lohr et al. 2014; Perakis and Speicher 2017). However, some 
limitations exist. CTCs’ detection remains challenging, especially because of their 
very low concentration in blood. Both detection and enrichment steps require 
 sensitive and specific analytic methods, made possible only with expensive tech-
nologies (Pantel and Alix-Panabières 2013; Lowes et al. 2016).
Main technologies available for ctDNA analysis are droplet digital PCR (ddPCR) 
and next-generation sequencing. The first is a targeted-approach, mainly used for 
detection of selected mutations. It is most sensitive and cost-effective, and it allows 
for an absolute quantification of mutant and wild-type copies. Conversely, NGS can 
be both targeted (gene panels) and untargeted (WES, WGS). It is complex and 
expensive, but it has a higher throughput that renders a more comprehensive detec-
tion of all known and unknown genomic alterations (SNVs, indels, CNAs, SVs), 
without preventive selection of any gene (Perakis and Speicher 2017). Very recently, 
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the FoundationACT® assay, a 70-gene panel designed by Foundation Medicine, 
granted a Breakthrough Device designation by the FDA, likely to become the first 
liquid biopsy NGS panel to achieve regulatory approval (http://investors.foundation-
medicine.com/news-releases/news-release-details/foundation-medicines- 
new-liquid-biopsy-assay-granted).
Like CTCs, ctDNA analysis has its disadvantages. Even if technically easier and 
cheaper than CTCs’ count, a pre-analytical and analytical procedure validation is 
still lacking. A potential confounding factor is the presence of normal cell-free DNA 
that must be separated from cell-free tumoral DNA. Besides these technical consid-
erations, a more relevant conceptual question about the biological meaning of 
ctDNA must be pointed out. Little is known about the origin of ctDNA (CTCs? 
Lytic, apoptotic tumor cells?). Assuming that they are released by dying tumor cells, 
how can they provide information about therapy-resistant clones?
In conclusion, liquid biopsy has demonstrated to be a valid surrogate of tissue 
sampling. Nevertheless, a scrupulous demonstration of analytic validity, clinical 
validity, and clinical utility is essential before its introduction in clinical practice.
5  NGS Implementation in Clinical Practice: Challenges 
and Limitations
The goal of each improvement in cancer knowledge is ultimately an improvement 
in patient’s care. While the scientific value of NGS-based advancements is undoubt-
edly critical, clinical benefits deriving from them are still being discussed.
As previously mentioned, NGS allows us to obtain the entire sequence of can-
cer’s exome or even genome at a reasonable price; in medical genetics, for example, 
WES and WGS represent an important tool to diagnose genetic and inherited disor-
ders. But not all this information might have a role in determining the best diagnos-
tic and therapeutic approach for cancer patients, for which smaller targeted panels 
are more often used in clinical practice (Jennings et al. 2017).
When designing an NGS cancer-panel, it is critical to distinguish between driver 
alterations and incidental, irrelevant genetic variants. This complex process, called 
variants’ prioritization, is essentially made possible by large publicly accessible data-
bases like COSMIC (Catalogue of Somatic Mutations in Cancer), the UCSC Cancer 
Genomics Browser, or the cBioPortal. These resources have been designed as a trans-
lational bridge between researchers and clinicians, to lower the barriers of access, 
and made comprehensible the complex data sets provided by large-scale genome 
projects like the TCGA or the CGP.  In this field, the development of the GENIE 
project is certainly another step forward. This multiphase, multiyear, international 
project converges on a regularly updated registry containing all the existing CLIA-/
ISO-certified genomic data obtained during the course of routine practice at multiple 
international institutions. The information provided is certainly useful for variants’ 
prioritization, but also available for powering clinical and translational research, vali-
dating biomarkers, expanding drug labels or identifying new drug targets.
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Thanks to these efforts, many NGS-based cancer panels are currently available 
in clinical practice. One example is the 52-gene Oncomine Focus Assay, which 
includes most of the genes targeted by on-market oncology drugs and published 
evidence. The same company offers a wider panel (161 genes), and even larger 
panels have been recently validated, including the FDA-approved FoundationOne 
CDx (F1CDx), which detects mutations in 324 genes and 2 genomic signatures in 
any tumor type, and the also FDA-approved MSK-IMPACT, a 468-gene assay 
developed by Memorial Sloan Kettering Cancer Center (MSKCC).
The best panel size for clinical practice has fueled an intense debate, since for 
many of the identifiable driver alterations there is still no approved drug available, 
and performing large panels for every cancer patient is not yet affordable. However, 
the improvement in cancer knowledge provided by wide mutational panels per-
formed on a large scale might encourage such effort. Particularly helpful in this 
sense may be the recently published ESMO Scale for Clinical Actionability of 
molecular Targets (ESCAT) (Mateo et  al. 2018), which proposes a classification 
system for molecular aberrations, dividing them between six levels of actionability 
and clinical usefulness, based on the strength of evidence from clinical studies. 
Such a scale might help prioritize some alterations, in order to design “pragmatic” 
and affordable panels for everyday oncology practice. Besides the size of the panel, 
discussion is still open regarding the clinical benefit deriving from these molecular 
characterizations. Large prospective studies have been conducted and are still ongo-
ing to address this question. The SHIVA trial (Le Tourneau et al. 2015), for instance, 
studied the off-label use of targeted therapies in patients with any cancer type har-
boring matching molecular alterations; the study failed to show any benefit over 
standard treatments, arguing against the indiscriminate use of off-label molecules 
according to uncharacterized molecular alterations whose significance as driver 
mutations is unknown. This failure must be interpreted considering the aim of the 
study itself: it was not powered to evaluate if a specific drug would have any antitu-
mor activity in a selected subgroup of patients but was only able to evaluate the 
efficiency of the treatment algorithm used to allocate drugs on the basis of molecu-
lar profiling. It is not a failure for precision medicine, but a demonstration of inef-
ficacy of that treatment algorithm in improving patients’ outcome.
The MOSCATO Trial (Massard et al. 2017), instead, showed an interesting benefit 
in terms of PFS in a subgroup of patients with hard-to-treat advanced cancers where 
an actionable alteration was found and a targeted therapy was available. It must be 
noted that the MOSCATO was a not-randomized, less-powerful trial, where patients 
were taken as their own controls by using the “PFS ratio” as primary endpoint. This 
measure is assessed by comparing the PFS reached on the targeted, experimental 
treatment to the PFS achieved by the most recent therapy, retrospectively assessed.
New, promising results presented during the last 2018 ASCO Congress have 
recently relaunched the importance of Precision Medicine in cancer care. The 
IMPACT (Initiative for Molecular Profiling and Advanced Cancer Therapy) trial 
was launched more than 10 years ago to evaluate the impact of personalized therapy 
in patients with hard-to-treat cancers. Among 3743 patients tested, 1307 had at least 
one druggable genomic alteration and received a specific matched therapy. The 
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authors reported a median OS significantly longer in the matched-therapy group 
versus the nonmatched-therapy group (9.3 vs. 7.3 months), and a better median PFS 
(4 vs. 2.8 months). Interestingly, in the multivariate analysis the matched-targeted 
therapy was found to be an independent factor of longer OS, whereas mutations in 
the PI3K/AKT/motor pathway were an independent factor of shorter OS if com-
pared to other alterations (NCT00851032 (Tsimberidou et al. 2018)).
A prospective validation of these results is expected by the IMPACT 2 trial, a 
randomized phase II study comparing the PFS achieved by patients receiving 
molecular-matched targeted therapy to PFS reached by patients treated with a 
molecular-unselected strategy (NCT02152254).
Beside this great potential, the implementation of Precision Medicine in the real-
world of cancer care has several limitations. First of all, costs of NGS-based tests 
are still prohibitive and largely not reimbursed, representing a patient’s effort as 
out-of-pocket expense. Costs of targeted gene panels vary widely, mainly depend-
ing on the numbers of genes sequenced. For example, a recently published nation-
wide French study reported a cost ranging between €376 and €968 (Marino et al. 
2018), whereas the cost-effective analysis conducted on 10 studies by Tan et  al. 
calculated an average cost of $1609 USD per sample (range: $488–$3443 USD) 
(Tan et al. 2018). The authors observed that cost of sequencing is generally lower if 
performed in-house compared to outsourcing to a service provider.
Many concerns have been raised about the impact of these costs in terms of clinical 
benefit. Even if evidences for cost-effectiveness are still lacking for many cancer types, in 
NSCLC an upfront mutational analysis based on NGS demonstrated to be less costly and 
faster than a single-gene test approach. Presented at ASCO 2018, this economic model 
showed a saving of 2 billion dollars for US Medicare reimbursement (Pennell et al. 2018).
Accessibility to tests and drugs is another obstacle that needs to be overcome. In 
recent years, many national projects have been launched to facilitate test accessibil-
ity. “France Medecine Genomiques 2025” (https://www.gouvernement.fr/sites/
default/files/document/document/2016/06/22.06.2016_remise_du_rapport_dyves_
levy_-_france_medecine_genomique_2025.pdf) and the “100k Genomes Project 
from UK” (https://www.genomicsengland.co.uk/the-100000-genomes-project/) are 
two such examples, born to transfer resources and results of genomic medicine from 
clinical trials to clinical care. On the other hand, even if a patient is found to harbor 
a druggable mutation, the accessibility to a specific target therapy is not guaranteed 
outside clinical trials. Targeted agents are approved by regulatory agency more 
often in histology-oriented settings, being the tumor-agnostic approval of pembroli-
zumab is still an exception for microsatellite-unstable tumors. To solve this ques-
tion, predicting biomarkers, molecular tests, and targeted drugs should be ideally 
developed and approved in parallel. Innovative and clever study designs have 
emerged with this purpose: basket, umbrella, and adaptive enrichment are state-of-
the-art approaches conceived for a personalization of treatment at its best.
During the last 2018 ASCO Congress, Otis Brawley, MD and ASCO chief medi-
cal officer said: “Precision medicine has given us some things, but it has promised 
a lot, which it has yet to deliver.” Instead of interpreting this sentence as a criticism, 
we want to read it as a promise. The best is yet to come.
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As seen throughout this book, the P5 approach to healthcare technology calls for 
devices that are preventive, predictive, personalized, participatory, and sensitive to 
psycho-cognitive aspects of both interaction with technology itself and health issues 
(Gorini and Pravettoni 2011; Pravettoni and Gorini 2011). The previous contribu-
tions have deepened these concepts through historical, theoretical, and methodolog-
ical information: for example, it has been said that innovative devices (e.g., wearable 
technology, and/or Ambient Intelligence applications) may help to detect and ana-
lyze not only the progress of disease, but also patients’ state in terms of emotional 
activation, observable behavior, and subjectively reported preferences. Moreover, 
previous contributions explained how technological devices can be based on per-
sonal characteristics, both in their interactive physical properties (i.e., to promote 
effective ergonomics) and in the content of digital stimuli (Vergani et al. 2019).
In general, it has been said that eHealth tools should be tailored on patients’ 
characteristics in order to be deeply effective and obtain desirable results in an 
acceptable amount of time (cf. Chap. 1). Such a message could be difficult to under-
stand or to translate into practice for those stakeholders who are interested in the 
development of eHealth tools, but who are not expert in the design of technology. 
The idea of “tailoring technology on users” may just look like a “way of saying” 
with no actual impact (or no practical one) on health technology development and 
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implementation. What does it actually mean to tailor technology on its users? There 
are at least four possible answers readers could have considered while reading this 
book and considering the P5 approach to eHealth:
 1. Technology developers should keep in mind the fundamental characteristics of 
the diagnosis and of its consequences on everyday life (both physical and psy-
chological), in order to design tools that could be used effectively and causing no 
harm.
 2. The eHealth tools of the future should include personalization features and 
pleasant/engaging aspects so the users could develop a positive attitude toward 
use and possibly be driven toward a higher rate of acceptance and adoption in the 
long term (cf. Chap. 4).
 3. The eHealth tools of the future should be developed with features allowing mod-
ifications at later stages of interventions, according to users’ feedback.
 4. Technology developers should keep themselves up-to-date with scientific litera-
ture on development and effectiveness of eHealth solutions, in order to address 
issues that are known within the literature, especially for what regards factors 
that may promote or hinder acceptance and adoption among users.
All these possible answers feature directions that are very important and certainly 
deserve eHealth developers’ and stakeholders’ consideration; however, none of 
them could be considered sufficient from the point of view expressed by the P5 
eHealth approach and its indications for technology design.
Specifically, the first response has merit because it considers the medical charac-
teristics of chronic diseases and the fact that they could have important influences 
on everyday life, both physical and psychological; however, it is not only the pathol-
ogy that influences effective human–technology interaction, neither acceptance nor 
adoption in the long term; patients are not “only patients”; despite an eHealth tool/
technology could be designed in order to be used by patients’ whose lifestyle is 
influenced by the onset and continuous presence of a chronic disease, also personal 
preferences, habits and behaviors could get in the way of effective usage, or the 
technology could be inadequate to contextual factors that have nothing to do with 
users’ health status. Moreover, at an organizational level, it is not possible to expect 
that technology designers would develop health professionals’ specific knowledge 
and competences, and neither that health professionals would be fully employed in 
the design and development of technology.
The second response values psychological aspects of interaction more, but fails 
in giving specific guidelines to include these in the design/development process; 
moreover, it seems to not consider that psychological aspects such as preferences 
and positive emotions are transient and could change over the course of time, pos-
sibly making eHealth solutions no more adequate to users in the long term.
The third response takes some steps further by acknowledging the iterative 
nature that an evolved conception of technology design often features: certainly, 
eHealth design should take into consideration that modifications could be necessary 
at every step of implementation and interaction, so that the design process does not 
end with the final prototype. However, this response does not provide specifications 
on which kind of information one should consider for modifying or redesigning 
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technology; is “users’ feedback” sufficient? The next pages will show that the 
response to this last question could not be so simple.
Finally, the fourth answer points out one very important aspect, that is, eHealth 
development should be based on scientific information, not only on the designers’ 
skills and creativity; however, it is important to appreciate that not even scientific 
literature is sufficient to inform design; indeed, scientific results are necessarily 
based on samples that tend to oversee individual characteristics and differences. Of 
course, eHealth development needs to be based on general guidelines but, in order 
to be very effective and to augment its possibilities to be adopted, it should be able 
to consider specific cases and fine-grained practice information that often could be 
not included in scientific reports.
In conclusion, “tailoring technologies on users” is a guiding concept that possi-
bly includes all the considerations outlined above, but should go beyond these 
including specific guidelines for practice. Therefore, this chapter is aimed at outlin-
ing methodological consideration to translate such concept into practice, and to give 
specific information on how this “tailoring” could be enacted in the eHealth project, 
from the very first steps of design to final implementation. More specifically, the 
proposal of this chapter relies on the methods of so-called User-Centered Design.
2  From Ergonomics to User-Centered Design
In our opinion, the best way to introduce the concept of User-Centered Design is to 
locate it in the history of technology evaluation. Indeed, technologies (especially 
those designed to be used in the healthcare context) always need to be evaluated, 
which means, it should be demonstrated whether they are able to (help human users 
to) achieve their aims, or not.
Historically, the so-called Scientific Study of Work emerged during the Industrial 
Revolution, which can be considered the first organized way to evaluate technolo-
gies (Nickerson 1999; Triberti and Brivio 2017): its aims were to analyze human 
work (often mediated by industrial technologies) in order to divide it in simple 
actions that could be taught to the workers in order to improve productivity.
Subsequently, ergonomics (mostly in Europe) and Human Factors (mostly in the 
United States) emerged in 1900, as disciplines devoted to improve physical/ana-
tomical and cognitive aspects of technology-mediated work in order to improve 
product quality and productivity but also safety and possibly subjective satisfaction 
(Karwowski 2012; Sharit 2006; Wilson 2000).
In the 1980s, Usability arose as a “simplified” form of ergonomics focused on 
Industrial Design, namely, as a discipline interested in empowering the interface of 
common-use objects, products and services so to make it easy to use and immedi-
ately comprehensible for customers, stakeholders, and users (Triberti and Brivio 
2017): usability experts such as Jakob Nielsen and Donald Norman set the basis for 
the evaluation of the “things” and tools all of us use every day, and generated the 
idea that easiness of use is more important for artifacts than other properties such as 
originality and aesthetic beauty (Nielsen 1999, 2003; Norman 2002).
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However, more recent development of the disciplines and methods associated to 
tools and technologies highlighted that easiness-of-use is not the sole criterion to be 
taken into consideration when evaluating technology: User Experience (UX) is the 
umbrella term used nowadays to identify methodological approaches that recognize 
the role of additional factors such as emotion/affection/pleasure (e.g., people can 
use nonusable objects if they “love” them) and context (e.g., besides usability of 
interfaces, tools can be more or less adequate to physical, social, or cultural features 
of situations of use) (Benyon et al. 2005; Hassenzahl 2008; Lee et al. 2008; Triberti 
and Brivio 2017).
This development led to the global recognition that evaluation of technology 
should not take into account “functioning” only, but a multiplicity of criteria to 
quantify effectiveness: these are at least quality, safety, easiness-of-use, emotions 
(positive, or if necessarily negative, possible to manage for users), adequacy to con-
text (physical, social, cultural), accessibility (e.g., technology could be used by vari-
ous populations, people with disability included).
Obviously, evaluating all of these characteristics in technology, taking into 
account that partial or total redesign could be called for when one or more of the 
criteria appear insufficient, could be very costly in terms of time and resources 
(Herstatt and Von Hippel 1992; Pavelin et al. 2012); however, designers, developers, 
and stakeholders could consider important criteria for technology effectiveness in 
advance, which means, the design itself could be based on user research data, so not 
only on preexistent ideas (about users, contexts, related activities, and the issue to 
be addressed by technology) or the creativity and intelligence of the designers. 
Exactly this concept is at the core of User-Centered Design (UCD henceforth) 
(Garrett 2010; Lowdermilk 2013; Triberti and Brivio 2017; Triberti and Liberati 
2014), a broad term that encompasses any design project in which users and users 
research influence how the design itself takes place. According to Garrett (2010), 
UCD could be depicted as a strategy that (in a “perfect” scenario) allows for any 
possible issue or variable to not escape the designer’s awareness. In other words, 
implementing UCD means that users should be involved from the very steps of 
design in order to provide valuable information for the design itself, not just in the 
last steps of implementation to evaluate some already-developed prototype (Abras 
et al. 2004). Although the term UCD is relatively old (Norman and Draper used it 
for the first time in the 1980s already) (Norman and Draper 1986), it developed into 
a discipline in more recent times, consistently with the semi-standardization of 
methods and tools devoted to analyze users’ needs before design.
The next section would be devoted to introduce some typical UCD tools/tech-
niques that could be adapted to serve eHealth design and development: taking into 
account the importance of the other aspects highlighted by the answers above (i.e., 
attention to literature, consideration of disease/illness-related issues, user engage-
ment, iterative prototyping), the application of such techniques could help eHealth 
developers to tailor technologies on their users, in order to assure not only positive 
functioning, but also the implementation of the P5 as described in this book.
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2.1  Interaction Factors
As Hesse and Shneiderman say (Hesse and Shneiderman 2007), during the pioneer-
ing days of eHealth, the question was often about what the computer could do; 
eHealth pioneers posed technical questions about computers, the Internet, and soft-
ware’s capability to help patients keep trace of their own medications/therapy and 
of their disease. During the next phase, crucial questions concern what people can 
do (and, we would add, what they cannot).
This concept is true in many senses, but in this section we focus on interaction 
aspects only. As previously said, the history of technology evaluation featured 
Usability as a discipline interested in developing interfaces that are easy to under-
stand and to use for the final users. Certainly, usability is a very important charac-
teristic that is currently taken into consideration when evaluating the adequacy and 
effectiveness of eHealth solutions: a number of studies have been published focus-
ing on methods and results about medical informatics usability (Gerdes et al. 2014; 
Goldberg et al. 2011; Vorderstrasse et al. 2016). However, many studies just employ 
usability questionnaires with final users when the technology is already designed 
(as a prototype, or even as a final version) and it is often not clear whether these data 
will influence actual modification or redesign of the evaluated platforms.
Usability questionnaires (such as, e.g., the SUS (Brooke 1996)) certainly are use-
ful tools to get, as the author says, a “quick and dirty” index about the easiness-of- 
use of some system or application; nevertheless, they are not conceived to give a 
“full” usability evaluation. Let us say, for example, one obtains a average-to-high 
value of usability basing on participants filling in a given questionnaire: what does 
this mean? This is only a general evaluation participants performed by responding 
to general questions, but no information has been provided about specific, more or 
less serious, more or less frequent system usage issues. Indeed, typical questions of 
such usability questionnaires are: “Were you able to use the system without effort?” 
or “State on a scale from 1 to 10 how much you felt to be able to obtain the system 
goal by using the system”; obviously, responses to such questions refer to a general 
evaluation but do not account for specific issues that could prevent users to achieve 
their own objectives in real-life contexts.
For this reason, the correct way to examine usability is to implement specific 
research methods, which typically are divided into two categories, namely, usability 
inspection and testing methods.
Usability inspection refers to those methods performed by evaluators, without 
the involvement of final users; these are constituted by guidelines and rules to ana-
lyze interfaces systematically, in order to account for usability problems that may 
escape a general, nonspecialized exploration. Currently, the main usability inspec-
tion methods still used are the cognitive walkthrough (which is based on exploring 
each function of the interface in sequence, reporting any possible problems encoun-
tered by a hypothetical user) and heuristics analysis (which is a global, holistic 
analysis of interface).
Cognitive walkthrough (Kushniruk et al. 2015) entails a checklist to be followed by 
evaluators who put themselves in the shoes of users, accounting for each possible 
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action that the user would take with the interface and signaling any possible mistake 
or interaction issue. Differently, heuristic evaluation is based on a list of general crite-
ria interfaces should respect in order to guarantee effective usage. A number of heuris-
tics lists are available, such as the generic (and probably most used) by Nielsen (1995) 
and others for specific technologies or domains (Hermawati and Lawson 2016).
Another option (that could be also used in conjunction with inspection methods) 
is usability testing, which constitutes any technique for evaluation that involves final 
users who interact with the interface in systematic and more or less controlled con-
texts, in order to identify usability issues by a critical evaluation of actual interaction; 
usability testing could employ a number of methods and tools for registering usabil-
ity issues, ranging from physiological signals to interviewing the participants to 
observation of behavior (e.g., counting the number of errors) (Smilowitz et al. 1994).
With regard to the evaluation of interaction factors, the main suggestion coming 
from the P5 approach is not to “resolve” such issues by basic evaluations such as 
using a usability questionnaire alone; on the contrary, evaluators should be activated 
in any phase of the development process. Specifically, usability inspection and test-
ing methods can be applied at different phases of conceptualization of the interface 
and prototyping, in order to modify interaction issue in itinere.
2.2  Motivation and Emotion
User experience is not limited to usability. As explained in the sections above, User 
Experience (as a discipline) emerged when the role of additional factors was explic-
itly recognized. Indeed, it is not enough for an interface to be easy to use, especially 
if what is expected is to promote long-term usage. If one would plan to use tech-
nologies to change patients’ everyday life, in order to positively influence their own 
lifestyle and care process, then eHealth resources should be also engaging, pleasant, 
or even self-actualizing.
According to the Positive Technology paradigm (Riva et al. 2016), technologies 
can be used to structure, augment, or replace users’ experience with digital resources, 
in order to improve their well-being in terms of emotion, connections, and meaning. 
More generally, in order to advance technologies’ ability in this sense, it is important 
to consider motivational and emotional factors. Indeed, it is more frequent for users to 
use (even at a long term) technologies that are not easy to use but that they love, than 
the contrary. The following sections will explore motivation and emotional factors as 
important aspects to be considered both when evaluating and designing technology.
2.2.1  Motivation in Design
“Motivation” generally refers to any mental feature that guides and promotes human 
goal-directed behavior. Assessing motivation to use technology requires going 
beyond traditional conceptions of motivation that held that people give more value 
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to strictly physical or safety needs, and only after satisfying them consider relational 
or self-actualizing motives (e.g., having friends, succeed in one’s own passions, 
spirituality, etc.). On the contrary, depending on current situations and personal 
goals, people may put high-level needs before basic ones. According to Self 
Determination Theory (Ryan and Deci 2000), fundamental life “nutrients” regard 
creating and maintaining positive relationships with others, feeling competent and 
autonomous. Hassenzahl and colleagues (Hassenzahl et  al. 2010) developed 
motivation- focused interviewees in order to consider users’ important motivation 
when designing or evaluating products and artifacts. In the field of user-centered 
design for eHealth interventions, one should consider that users’ needs may vary 
depending on the experience and perception of the long-lasting illness, and so do 
life projects and everyday activities (Triberti and Barello 2016). It is not advisable 
to design eHealth technologies just considering therapy outcomes and/or desired 
health states; on the contrary, if technologies are designed to be used effectively, 
they should be able to communicate their scope as useful in terms of patients’ per-
sonal objectives (Triberti and Riva 2016).
2.2.2  Emotion in Design
“Emotional design” is an expression typically used to refer to that design which is 
implemented to promote a pleasurable sensation in users. Two main approaches can 
be found in the literature, one more focused on pleasant, funny, creative features 
added to interfaces or external appearance (Jordan 2002), and the other related to 
engaging and fluent interaction (Hancock et al. 2005). Recent studies (Triberti et al. 
2017) proposed to develop the concept of emotional design through three main 
lines:
• The assessment of discrete emotions in ongoing interaction with technology to 
provide on-line modifications of interfaces (affective computing/affective 
design).
• The focus on emotions as discrete cognitive processes instead of generic pleasant 
states, to promote even complex emotions or emotional nuances.
• The analysis of users’ “emotional profiles” to tailor technologies on their preex-
isting emotional traits.
In other words, emotions should not be considered as simply by-products of 
stimuli, rather they could actively participate in the interaction and influence it. 
Also, not only positive emotions should be taken into consideration by designers; 
for example, if one has to design a eHealth platform feature that is meant to signal 
dangerous situations to the patient (e.g., the need for insulin administration for 
 diabetes), it is not expected to transform an urgent signal into a “positive” experi-
ence, which it is not. On the contrary, if previous emotion-focused research is avail-
able, designers and evaluators can have important information on how to realize 
such an alarm so to be recognized, understood, and managed as more effectively as 
possible by the patient/user.
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Emotion aspects research can certainly be conducted by making use of psycho-
physiological measures, but also qualitative methods are important in order to cap-
ture the personal emotional experience of patients, regarding both the illness/
treatment experience and the technology itself.
2.3  Context
P5 eHealth must consider context as an important variable for UX and delivery of 
care. In particular, psycho-social aspects of the P5 approach are involved in this 
process. Any technological artifact related to eHealth, or otherwise, is made to be 
used by someone for a particular context, in a particular environment. The user’s 
purpose guides the artifact’s design first and later its use, which is situated in a pre-
cise space-time moment. The user experience is therefore—and perhaps above all—
linked to the places and moments in which the user uses the artifact “in vivo.” In this 
sense, for the purposes of the design and evaluation of the user experience, the 
context of use must be taken into account.
Context is a difficult concept to define and can indicate: material elements of the 
environment in which the use takes place; relational elements, when artifacts medi-
ate the relationships between people directly or indirectly; and semiotic and cultural 
elements (Galimberti 2011). Several of these aspects must be taken into consider-
ation in the design phase; others, on the other hand, are more unpredictable and 
emerge from the interaction between artifact–user–context (Nardi 1996), and once 
these aspects are detected, they could be corrected and/or integrated into subsequent 
releases of the artifact to improve the users’ UX.
The Situated Action Theory (SAT) (Mantovani 1995, 1996; Suchman 1987, 
1993) helps understand that behavior, cognition, and higher-level contextual ele-
ments, such as cultural, organizational, and group settings, contribute to the interac-
tional process between user and technology—and thus affect UX—at different 
levels: context of use depends on social context, interpretation of the situation, and 
local interaction with artifacts. The first level, the social context, is seen as a reper-
toire of social norms, within which actors must act. The second level considers daily 
experience, where the social context refers to specific situations in which the inter-
ests of social actors interact with the opportunities presented by the environment. 
The last level relates to local interaction between man and artifact, which occurs in 
everyday situations, whenever the user uses the artifact to achieve their goals.
eHealth technologies are considered technological artifacts, therefore they are 
bound by cultural and social rules, the situation in which they are used, and by how 
the aims and scopes of the users interweave with the previously mentioned aspects 
and the material feature of the artifact itself (e.g., the interface).
Norman (1993) wrote that it is not enough to focus individually on the situation, 
artifact, environment, or person: the users are not in a vacuum, but are located in a 
specific context. The symbolic order is achieved through action, which allows the 
interpretation of the situation, which in turn allows actors to use certain artifacts in 
certain situations. Context is built on a cultural and symbolic order (rules, laws, 
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social habits, cultural norms) that preexists the user in interaction, but also contrib-
utes to the users’ activities and directs their goals: context helps the users make 
sense of their actions and interactions. Within a context, users are not alone, but 
interact with other actors and artifacts in order to accomplish their goals and plans. 
New meaning is generated by the interaction between subjects and artifacts. These 
meanings become part of and they partially modify the symbolic order, generating 
new meanings.
Material artifacts—such as objects, technologies, etc.—are readily available to 
people, but they are not exempt from important psychological and signification pro-
cesses: if a technological artifact is inadequate for use within the rules governing the 
context, and does not meet the objectives of the users, it will produce an unsatisfac-
tory user experience and will soon be abandoned; it is almost impossible to deter-
mine in advance in a univocal way the use that users will make of an artifact, it will 
therefore be necessary to carry out in-progress checks in order, if possible, to adapt 
the artifact to the emerging practices resulting from the interaction with social actors.
Robinson (1994) postulated the existence of three reference frameworks that 
people use to interpret artifacts. This interpretative process involves a user’s assump-
tion, knowledge, bias, and past experiences shaping their understanding of the 
world. There are three frameworks that drive this process (Robinson 1994): (a) indi-
vidual level: frameworks constitute, at this level, personal constructs: our way of 
being has an influence on the way we interface with and interpret the world; (b) 
social level: our interpretative schemes are built with the people we interact with, in 
the different contexts (e.g., work, family) and these references also contribute to our 
understanding of artifacts; (c) cultural level: this level refers to language, religion, 
visions of science and the world, conceptions of space and time (e.g., seasons, cycli-
cality), which permeate our way of interacting with people and objects around us.
In conclusion, context can be defined by three dimensions that can be ascribed to 
both Robinson’s frameworks and to the Situated Action Theory: individual and 
psycho-social aspects, cultural and relational aspects, material/physical aspects. 
The following paragraphs outline each of these dimensions and how eHealth may 
be affected.
2.3.1  Individual and Psychosocial Dimensions of Context
Gender, age, and culture are aspects that affect the user’s acceptance—in terms of 
adoption and speed of adoption—of technological artifacts. The Technology 
Acceptance Model (TAM) (Davis 1989) theorizes the process from the user’s inten-
tion to use the technology to its final adoption. The TAM explains the intention to 
use an artifact on the basis of perceived utility (i.e., the perception of obtaining a 
benefit from the use of that artifact) and perceived ease of use (i.e., the perception 
that using that artifact will require few resources). If there is a high level of per-
ceived utility and a high level of perceived ease of use, the user will be likely to 
develop the intention to adopt that particular artifact. External variables such as 
system characteristics, training, etc. do not affect directly on the intention to adopt 
the system, but their effect is mediated by the two variables previously explained. 
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Utility is influenced by perceived ease of use: the easier the artifact is to use, the 
more useful it is perceived to be (Venkatesh and Davis 2000). More recently, other 
factors have been added as antecedents to the intention of adoption and to the vari-
ables of perceived utility and ease of use, such as social influence (subjective norms, 
image, etc.), cognitive processes (relevance of the task, quality of the outputs, 
demonstrability of the results), and experience (Venkatesh and Davis 2000).
There are clear differences in gender with regard to the TAM. Venkatesh and 
Morris (2000) found that men and women differ in decision-making processes for 
adoption and use of technologies (cf. Chap. 4); in particular, the perceived user- 
friendliness variable is more important for women, despite identical initial training 
and identical experience with technology.
Men and women also differ in access and use, interest and ease of use of techno-
logical artifacts (Anderson et al. 1995), even though this gap is rapidly closing. One 
of the most important gender differences is related to the perceived self-efficacy 
(Bandura 1997) in the use of technologies, that is, the belief of being able to use a 
technology to perform a certain action (Durndell and Haag 2002; Vekiri and 
Chronaki 2008): in particular, even in the simple use of computers, males, com-
pared to females, feel more secure and able to address the problems that may arise 
during the use of technology in a flexible and creative way (Brivio and Ibarra 2010). 
It can therefore be assumed that in the event of a technology breakdown, men and 
women will have very different experiences, and experience different emotions, 
with effects on their self-esteem and self-efficacy. The processes of breakdown and 
consequent troubleshooting for the recovery of technology functionality should 
probably be investigated in more detail from a gender point of view, to make them 
more accessible to all. In other respects, the user experience between men and 
women does not differ, although there are sometimes artifacts that try to exaggerate 
these differences. Self-efficacy (along with the variables of TAM) affects the use of 
technologies by older people, who have never had to deal with complex technolo-
gies (e.g., smartphone and tablet), and often do not feel confident in interacting with 
these artifacts, which very often are not designed with the elderly in mind, which 
makes the interaction difficult and the experience sometimes frustrating (Brivio 
et al. 2016; Strada et al. 2013).
Research with eHealth technologies show that age can still impact adoption and 
use, especially with middle-old (66–84 year olds) and old-old (85 years and over) 
people, who need more training and support (Hunsaker and Hargittai 2018; Millard 
and Fintak 2002); only after training and support are they more likely to adopt and 
use eHealth systems, as the interactional experience is less frustrating. Young old 
people (55–65 year old) have fewer issues with use and adoption (Tavares and 
Oliveira 2016). The gender gap in eHealth adoption seems to be slowly closing 
(Tavares and Oliveira 2016). A variable specific to adoption and use of eHealth 
technologies is self-perception, that is, the awareness of having a health problem: if 
a person is aware that they have a health issue they are more likely to use eHealth 
technologies (Tavares and Oliveira 2016; Yuan et al. 2015; Venkatesh et al. 2012). 
eHealth applications and technologies should therefore include in-system trainings 
for target populations, and enhance self-perception, in order to provide a good UX, 
which in turn ensures higher levels of intention to use, adoption, and sustained use.
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2.3.2  Cultural and Relational Dimensions of Context
A cultural aspect that influences the User Experience is the semiotic dimension that 
underlies the artifacts. Semiotics deals with the study of signs and how they take on 
meaning. Every aspect of an interface can be considered a representation of a cer-
tain functionality to which it gives access: both the interface and the functionality to 
which it refers are systems of signs (Goguen 1999). Sustained use of an artifact 
depends on the user’s understanding of the metaphor underlying the design of an 
artifact (Barr et al. 2005): designers must choose a sign system that helps the user 
understand the artifact’s functionalities. If there is no correspondence between the 
systems of signs of the artifact and that of the user, the artifact will not be under-
standable and will provide an insufficient UX.
The most general distinction between cultural contexts that has proved to be 
relevant to UX is the one between Western and Eastern, individualistic or collectiv-
istic cultures. Culture is “the collective programming of the mind that distinguishes 
the members of one group from another” (Hofstede 1991, 2001): the term “collec-
tive planning of the mind” suggests that culture can be conceived as a set of shared 
characteristics within a group, whose members behave similarly because of the 
shared norms. User Experience is also influenced by these shared characteristics: 
for an artifact to be successful at an international level, it is necessary to have an 
excellent knowledge of the variability of the cultures of the target markets, since 
sometimes an international version of an artifact may not be sufficient or may not 
work at all in terms of needs and cultural appropriateness (Marcus and Gould 2000). 
To have artifacts that adapt to different cultures, two aspects must be taken into 
account (Honold 1999, in Walsh et al. 2010): (1) objective aspects: language, date 
and time format, numbers, direction of written text, etc.; (2) subjective aspects: 
value, behavioral, and intellectual systems of the groups that use technological arti-
facts in the different cultural contexts. These aspects can be integrated into the 
design of artifacts from the beginning, using the studies and tables (created by coun-
try) of Hofstede (1991), taking into account that the indications given are always 
trends and always relative. Not all aspects of interaction with a technological arti-
fact are, however, subject to cultural differences: for example, it seems that ges-
tures—spontaneously generated to obtain a result on a portable device—are not 
culturally connoted and resemble each other for all cultures (Mauney et al. 2010).
To provide excellent UX and delivery of care, eHealth technologies and applica-
tion must take these aspects into consideration, and go through a cultural and con-
textual adaptation process for “culturally sensitive elements” (e.g., language, values, 
concepts, content) (Lal et  al. 2018). For the relational dimension—as Battarbee 
points out (2003)—the User Experience models used often focus on individual expe-
rience and its constituent elements; most people though experience collective, not 
individual, contexts and thus create experiences with artifacts together with other 
users (Battarbee 2003, 2004; Battarbee and Koskinen 2005). Artifacts must of course 
be functional, usable, and provide a good individual user experience; but, with the 
advent of personal ICT, it is important that these artifacts give users the opportunity 
to have optimal user experiences together, or to have a co-experience. Battarbee 
identifies some characteristics that the co-experience given by an artifact must have:
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• Social: co-experience is based on communication, which allows proposals, opin-
ions, evaluations to be put into play, agreements to be negotiated, ideas modified, 
etc. These communicative exchanges give meaning to the experience. It is there-
fore essential that the artifacts support agile communication exchanges and that 
they reflect the communication needs of users in a given context.
• Multimodal: co-experience can be augmented by technology, which provides 
different modes of interaction (e.g., audio, video, image, text) and allows switch-
ing between them seamlessly, while continuing to have the same experience with 
the same people or with different people.
• Creative: when people use technological artifacts together, they get more inter-
esting and creative results than those obtained with individual use. Co- experience 
is a resource of social and symbolic innovation, because interaction generates 
new meanings, both related to technology and not.
• Fun: co-experience is a source of fun and pleasure, as well as it strengthens 
social ties. Fun promotes the use of artifacts. For designers, therefore, it is essen-
tial to think about the dimension of enjoyment and pleasure in social terms, 
because it is a fundamental motivation for the adoption and sustained use of an 
artifact.
Any environment that involves co-presence of multiple people needs individuals 
to feel that the other is present: in other words, to perceive a good sense of social 
presence, which is “the degree of salience of the other person in the interaction and 
the consequent salience of the interpersonal relationship” (Short et al. 1976). An 
adequate level of social presence allows higher levels of involvement with the arti-
fact, that is, the user experience will be more satisfying and positive (Gunawardena 
and Zittle 1997). According to Riva and colleagues (2008), social presence depends 
on the fact that the information available within the context, even if limited, allows 
the users to grasp the others’ intentions and actions (Riva 2008).
In eHealth, several technologies and applications successfully harnessed social 
communications and exchange between users to deliver their intervention, for exam-
ple in smoking cessation (Khalil et al. 2017) and in psychosis recovery (Williams 
et al. 2018). This made possible not only delivery of care, but also a good UX that 
could potentially support adherence and sustained use of the eHealth system.
2.3.3  Physical and Material Dimension of Context
In designing or evaluating an artifact, technological or otherwise, it is important to 
know where the user will use the artifact itself. The physical environment produces 
effects on UX in different ways. For example, placement of a technology within a 
busy and noisy environment may influence the user’s ability to hear acoustic feedback 
(Lowdermilk 2013). Mobile technologies complicate this matter further: they allow 
user to cross different contexts; and indeed, the use of some applications persists from 
one context—digital and material—to another, and therefore the experience persists 
across contexts, and designers must take these contextual changes into consideration.
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Literature is lacking in identifying and describing the effect of the physical con-
textual elements on eHealth delivery and UX. One possible concern is related to 
privacy: mHealth makes it easier to access health services and care, but at the same 
time make it easier for private and sensitive information to be available, accessible 
or overheard by non-authorized people, or to use the technology in inappropriate 
settings for delivery of care (e.g., a patient using a telepsychotherapy service in a 
public setting). Consequence of accidental sharing of information and/or use in 
appropriate settings may be an inefficient delivery of care and/or a reduced UX, 
which in turn may push people to abandon the eHealth service.
3  User-Centered Design and P5 eHealth
As hinted at in the introduction, User-Centered Design should be a fundamental 
methodological approach within P5 eHealth: in order to design health technologies 
that are really able to help people, it is paramount to analyze users/patients’ needs, 
intentions, abilities, and contexts in advance, and use these data as the main source 
for design ideas and implementation.
As a conclusion, it is interesting to consider the utility of a UCD mindset when 
designing the P5 properties within health technologies:
• For designing technologies with prevention features, developers should be 
informed not only about healthy behaviors to be promoted in the users, but also 
of users’ own habits, preferences, characteristics, and typical behaviors in order 
to identify risks and/or opportunities.
• Personalized technology requires up-to-date information about users’ character-
istics; the exact concept of personalization of application features implies to con-
sider and understand users, instead of basing on prototypical representations.
• The predictive power of any computational model programmed within software 
is notably empowered by adding information on users’ preferences and behav-
iors; not only medical/diagnostical data should be used.
• Participatory technologies require a deep understanding of users’ social con-
text; going beyond the mere analysis of users, methods should be able to capture 
important social relations (e.g., caregivers, different health professionals) to be 
assigned a role within the technology-based intervention.
• Psycho-cognitive technologies, as previously said, are able to consider users’ 
cognitive abilities, decision making, and behavior; this could be done by imple-
menting the UCD mindset/approach within the technology itself, which means, 
the technology should be responsive to users’ actions in order to tailor its out-
comes (feedback) on individual characteristics.
With this background, P5 eHealth could develop as a truly patient-centered 
approach, by basing its own design on the application of research methods to the 
measurement and understanding of final users’ irreducible characteristics.
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Chapter 10




In spite of its promise to significantly ameliorate health and care practices, the 
momentous rise of eHealth technologies—an umbrella term that refers to a varied 
set of tools and resources such as health information networks, electronic health 
records, telemedicine and monitoring services, wearable systems, as well as online 
health self-management tools—has been fraught with significant ethical and soci-
etal concerns. Thriving out of the extensive use of (sensitive) personal data (i.e., Big 
Data approach), while also representing a major driver for reconfiguring entrenched 
social practices and relations within health and care systems, eHealth has been the 
focus, in recent years, of increased ethical, legal, and sociological scrutiny.
Aimed at providing an overview of the data protection regime and the main ethi-
cal issues associated with the emergence and progressive stabilization of eHealth 
within the context of the European Union (EU), this chapter is structured as follows. 
First, innovation in eHealth as a core policy objective of the EU is presented; then, 
regulatory issues related to eHealth research and innovation are discussed; notably, 
our attention will be devoted to the discussion of eHealth technologies in light of the 
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regulatory regime unfolding in Europe following the enforceability of the new 
 legislation on data protection, Regulation (EU) 2016/679, also known as the General 
Data Protection Regulation. Finally, the second part of the chapter will provide an 
overview of the main ethical challenges raised by the development and implementa-
tion of novel eHealth technologies.
2  eHealth in the European Union: From Advancement 
of Innovation to Data Protection Concerns
Ever increasingly since the launch of the Lisbon Agenda at the turn of the millen-
nium, the European Union (EU) has targeted the acceleration of scientific and tech-
nological innovation as a key policy objective. Emphasized as one of the privileged 
means to steer the EU out of its current economic and political gridlock, the accel-
eration of innovation has also been envisaged as a prominent lever to relaunch the 
promise of the European project and to promote the further consolidation of the 
fragile European polity (Marelli and Testa 2017).
Notably, innovation in eHealth, which thrives out of advances in fields such 
as  personalized medicine, Artificial Intelligence, Big Data Analytics and mobile 
Health (mHealth) technologies, has emerged, in recent years, as a major recipient of 
knowledge and material investments from the part of the Union, geared to 
“strengthen[ing] the resilience and sustainability of Europe’s health and care sys-
tems” and “maximiz[ing] the potential of the digital internal market with a wider 
deployment of digital products and services” (EC 2018: 4). Specifically, the latest 
Communication from the European Commission on Enabling the digital transfor-
mation of health and care in the Digital Single Market (EC 2018) has identified 
three key objectives to be accomplished through the full-fledged digitization of 
health and care systems and the (yet-to-be-achieved) completion of the Digital 
Single Market—a policy cornerstone of the European Commission under the presi-
dency of Jean-Claude Juncker—in the health and care domains.
Firstly, the Commission set out its intention to enhance the sharing of health data 
across borders, by “supporting the development and adoption of a European elec-
tronic health record exchange format” (EC 2018, p. 5), predicated on the interoper-
ability of standards across Member States, the development of EU-wide standards 
for data quality, reliability and cybersecurity, as well as potential (re)use of data for 
research and other purposes. A second envisaged objective is represented by the 
“pooling of genomic and other health data to advance research and personalized 
medicine” (EC 2018, p. 7). Specifically, against the backdrop of a flurry of initia-
tives having mushroomed throughout European Member States in recent years, 
the EU is tasked with “linking national and regional banks of -omics data, biobanks 
and other registries,” with the aim of “provid[ing] access to at least 1 million 
sequenced genomes in the EU by 2022” (EC 2018, p. 8). Thirdly—and most rele-
vantly for the purposes of this chapter—the digitization of health and care through 
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the integration of eHealth technologies and practices in health and care systems is 
framed as directed toward the enactment of “citizen empowerment and person- 
centered care” (EC 2018, p. 10). Indeed, ageing of the population together with the 
growing burden of chronic conditions and multi-morbidity are said to require pro-
found changes in health and care systems (cf. Chap. 1). As contended by the 
Commission, what is required is, in particular, a “shift from treatment to health 
promotion and disease prevention, from focus to disease to a focus on well-being 
and individuals, and from service fragmentation to the integration and coordination 
of services along the continuum of care” (EC 2018, p. 10).
Notwithstanding the emphasis placed on the advancement of innovation in the 
eHealth sector, poised to the creation of a “Europe-wide ecosystem for data-driven 
healthcare” (Smith 2018), EU policymakers have been equally alerted to the privacy 
and data protection concerns European citizens maintain when confronted with 
these new technologies and practices (Mager 2017). Accordingly, following tri-
logue (and extensively lobbied) negotiations started in 2012, in 2016 the European 
Parliament has approved Regulation (EU) 2016/679 on data protection, also known 
as the General Data Protection Regulation (GDPR). As remarked by its rapporteur, 
German MEP Jan Albrecht, the GDPR is intended to provide “the right balance 
between the fundamental right to data protection as well as strong consumer rights 
in the digital age, on the one side, and the need to create a fair and functioning digi-
tal market, with a real chance for growth and innovation, on the other side” 
(Albrecht 2016).
In what follows, we will explore the impact of the GDPR on the European 
eHealth sector. In particular, our focus is directed at charting some of the key provi-
sions of the GDPR that affect research and innovation processes in the eHealth sec-
tor. Besides, we will probe the implications of the Regulation as to the balancing of 
the interests and fundamental rights of individuals and the advancement of eHealth 
innovation.
3  The GDPR and Its Impact on eHealth Research 
and Innovation
The GDPR, which repeals the previous European legislation on data protection, 
Directive 95/46/EC, has become applicable since May 25, 2018. Differently from 
the previous Directive, which required adoption in national legislations, the GDPR 
is directly enforceable across all Member States, and is thus geared to achieve 
immediate and thorough legislative harmonization across the EU. Besides provid-
ing regulatory support for the establishment of a full-fledged digital single market, 
its entry into effect is bound to impact the eHealth sector very significantly, in the 
EU and possibly beyond. How, and to what effect, is what we aim to chart in the 
following sections.
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At its core, as enshrined in the “data protection by design and by default” prin-
ciple (art. 25), the GDPR adopts a risk-based approach to data protection, geared to 
ensure that appropriate data protection measures are designed and implemented 
throughout the entirety of the data processing activities. Additionally, it confers 
novel rights to data subjects, such as the right to data portability (art. 20) and the 
so-called right to be forgotten (art. 17). While the former bestows on individuals the 
right to require that data concerning them be standardized and made portable across 
companies or service providers of their choice, the latter empowers data subjects to 
obtain from data controllers the prompt erasure of relevant personal data. Moreover, 
the GDPR prescribes the adoption of specific provisions for the processing of sensi-
tive data (art. 9) for scientific research purposes (art. 89), such as technical and 
organizational measures (e.g., pseudonymization), which are meant to provide ade-
quate safeguards to the rights and freedoms of data subjects. Such provisions—
which we will explore more in detail below—are poised to have a great impact on 
the development and commercialization of novel eHealth tools and technologies. 
Relevantly, the GDPR also endows Member States with the prerogative to maintain 
or introduce further conditions, including limitations, with regard to the processing 
of genetic data, biometric data or data concerning health (art. 9(4)).
3.1  The Accountability Principle and its Implications
In general terms, the axiomatic cornerstone of the GDPR can be said to be repre-
sented by the “accountability principle” (art. 5(2), art. 24), which requires data con-
trollers (i.e., the persons, companies, associations, or other entities that are factually 
in control of personal-data processing) to adopt a proactive approach toward data 
protection compliance. Notably, data controllers are made responsible to assess, 
implement, and verify the adoption of appropriate technical and organizational 
measures to ensure, and be able to demonstrate, that data processing complies with 
the GDPR (art. 24). The GDPR itself provides coarse-grained guidance as to what 
measures actually fulfill a controller’s obligations, and in fact makes the determina-
tion of those measures dependent on the contingent “nature, scope, context and 
purposes” of the relevant processing (art. 24). Accordingly, it can be argued that the 
GDPR is bound to promote a “controller-based,” “case-sensitive,” and eminently 
“context–specific” approach to data protection (Marelli and Testa 2018).
Such decentralized, flexible, and accountability-based approach rises to signifi-
cance with respect to two aspects that are of key importance in the development and 
adoption phase of eHealth technologies, namely, consent and secondary use of data 
(further processing). With regard to consent, the GDPR requires the “specific [and] 
informed” consent of the data subject (art. 6(1)(a) and recital 32). However, when it 
comes to the processing of personal data within research—as can be the case in the 
developmental phase of eHealth technologies, such as mHealth apps, telemedical or 
Ambient Intelligence tools—it recognizes that it may not be possible to fully iden-
tify all potential future research purposes at the time of data collection. Accordingly, 
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as per recital 33, it states that, if too specific a consent would impinge on the pur-
pose of research, “data subjects should be allowed to give their consent to certain 
areas of scientific research when in keeping with recognized ethical standards for 
scientific research.” Otherwise put, such provision lends the full legislative weight 
of the GDPR in support of broad consent, whenever the criterion of specific consent 
for specific research use at the moment of data collection proves impossible to sat-
isfy (Marelli and Testa 2018).
As for the further use of previously collected and processed data—a key require-
ment for Big Data processing—article 5(1)(b) of the GDPR mandates that personal 
data should be “collected for specified, explicit and legitimate purposes and not 
further processed in a manner that is incompatible with those purposes.” Additionally, 
it specifies that further processing for scientific research purposes “shall […] not be 
considered to be incompatible with the initial purposes” for which personal data 
have been collected. More specifically, the GDPR requires controllers to carry out, 
on a case-by-case and context-dependent basis, a “test” for compatibility assess-
ment, geared at ascertaining whether the further processing of personal data without 
data subject’s consent is compatible with the initial purpose for which data were 
originally collected (art. 6(4)). Factors such as the “the reasonable expectations of 
data subjects based on their relationship with the controller as to their further use” 
(recital 50), and “the context in which the personal data have been collected,” are 
among the key elements to be taken into account for assessing the compatibility of 
the intended further processing (art. 6(4)).
3.2  Pseudonymization and Anonymization of Sensitive Data
An important distinction introduced by the GDPR is the one between pseudony-
mized and anonymous data. Art. 4(5) defines “pseudonymization” as “the process-
ing of personal data in such a manner that the personal data can no longer be 
attributed to a specific data subject without the use of additional information, pro-
vided that such additional information is kept separately and is subject to technical 
and organizational measures to ensure that the personal data are not attributed to 
an identified or identifiable natural person.” On the contrary, anonymous data are 
defined, as per recital 26, as “information which does not relate to an identified or 
identifiable natural person or to personal data rendered anonymous in such a man-
ner that the data subject is not or no longer identifiable.” This difference has signifi-
cant implications. On the one hand, pseudonymized data—insofar as they can be 
attributed to the data subject through the use of “additional information”—are con-
sidered as personal data whose processing should comply with the GDPR. On the 
other hand, the provisions of the GDPR “do not concern the processing of anony-
mous information, including for statistical or research purposes” (recital 26). In 
other words, whereas the processing of pseudonymized information should be sub-
jected to the full spectrum of provisions contained in the GDPR, individuals will not 
be entitled to data protection rights if their data are processed anonymously.
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But what does constitute “anonymous” processing (or, better phrased, processing 
of “anonymous” data) in light of the GDPR? Interestingly, the GDPR differs 
 conspicuously, in this respect, from other major data protection legislations world-
wide, such as the Health Insurance Portability and Accountability Act (HIPAA) 
Privacy Rule in the USA (Shabani et al. 2018). Within the Privacy Rule, the Safe 
Harbor standard for achieving the de-identification of personal data singles out 18 
distinct identifiers, the removal of which is said to make the resulting information 
“not individually identifiable,” and thus anonymous. Differently from this, recital 
26 of the GDPR states that personal data should be considered anonymous insofar 
as the data subject cannot be identified “by any means reasonably likely to be used 
[…] either by the controller or by any other person” (GDPR recital 26; see also 
Article 29 Working Party,18 opinion 05/2014). To ascertain whether means are rea-
sonably likely to be used to identify the natural person, the GDPR further states that 
“account should be taken of all objective factors, such as the costs of and the amount 
of time required for identification, taking into consideration the available technol-
ogy at the time of the processing and technological developments” (recital 26).
As such, and in line with the overall decentralized thrust of the Regulation, the 
GDPR can be said to adopt a context-based criterion to determine whether personal 
data should be considered as irreversibly de-identified (and thus anonymous), while 
devolving to controllers the responsibility to address such a question (is there a 
“reasonable likelihood” that reidentification techniques can be effectively used to 
de-anonymize my given dataset?) in the context of their concrete processing 
activities.
Moreover, the definition of “anonymous data” advanced by the GDPR seems to 
create a “catch-22” situation (Shabani and Marelli 2019). On the one hand, as we 
have seen, the processing of anonymous data is not subjected to the safeguards 
entailed by the GDPR, and this represents an implicit incentive to the processing 
and sharing of anonymous information. On the other hand, however, precisely the 
absence of said safeguards, as well as the enhanced circulation of data, are factors 
that, in themselves, are bound to increase the likelihood of reidentification of the 
data subject, which, in turn, can lead to the de-anonymization of the dataset. Thus, 
the very approach toward anonymous data processing adopted by the GDPR can be 
said to set a high legal bar for achieving anonymization of data (Quinn and Quinn 
2018)—especially in the context of the processing of genetic data (Shabani and 
Marelli 2019).
3.3  The “Right Balance” Between Innovation and Protection 
of Individuals’ Rights and Interests?
As explicitly stated in the Regulation, the adoption of the GDPR has been under-
pinned by the aim to accomplish, at once, two seemingly contrasting objectives, 
namely, the protection of the fundamental rights and freedoms of individuals with 
regard to the processing of personal data (i.e., data protection), and the enhancement 
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of the free movement of personal data within the EU, in view of the creation of a 
full-fledged Digital Single Market poised to foster digital innovation (i.e., data util-
ity). For such “data protection–versus–data utility” conundrum, the implementation 
of a controller-based and decentralized approach to data protection, in place of rigid 
and detailed provisions, can be assessed ambivalently.
On the one hand, beside the introduction of novel rights for data subjects, the 
flexibility entailed by mechanisms such as the “compatibility test,” as well as the 
enhanced role assigned to institutionalized ethics in defining the scope of data pro-
cessing in Research & Innovation programs (on this aspect, cf. Marelli and Testa 
2018), could be said to increase data subjects’ protection while affording patients 
and/or research participants a substantive rather than mere formalistic engagement 
in the development and use of novel eHealth technologies.
On the other hand, however, in addition to the controllers’ discretionary preroga-
tives, the GDPR upholds a far-reaching “research exemption” to the strict limita-
tions otherwise imposed on the processing of sensitive data (art. 9(1)), for instance 
relaxing requirements for consent (recital 33) and limitations in data storage (art. 
5(1)(e)). In addition, as per recital 159, the GDPR provides a remarkably broad defi-
nition of activities falling under the rubric of “scientific research,” including “tech-
nological development and demonstration,” “applied research,” and “privately 
funded research.” As a consequence, eHealth and mHealth companies (such as app 
providers, telemedical companies, AI companies, etc.), claiming to conduct “scien-
tific research” activities with data gathered from individuals, stand to benefit directly 
from the regulatory leeway deriving from these combined provisions—with an 
arguably significant shift of the balance of interests in favor of data controllers over 
data subjects (Pormeister 2017; Marelli and Testa 2018).
In the final analysis, whether the GDPR will achieve the stated aim of ensuring 
the “right balance” between providing appropriate safeguards to individuals—thus 
allaying still widespread privacy and data protection concerns surrounding eHealth 
technologies (Powles and Hodson 2017)—and creating the conditions for a thriving 
Digital Single Market in domains such as health and care, is something that only its 
implementation in the coming months and years will be able to tell.
4  Ethical Issues in eHealth Technologies
Notwithstanding the similar data protection concerns raised,  the expression 
“eHealth” (cf. Eysenbach 2001) connotes a vast array of different technologies (as 
well as their related social practices), each of which raises distinct ethical issues. In 
what follows, eHealth technologies will be divided into three broad families:
• Online eHealth (self-management tools)
• Monitoring techniques
• New and unconventional eHealth technologies
The respective ethical aspects will be discussed separately.
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4.1  Online eHealth (Self-Management) Tools
One of the most widespread forms of eHealth is represented by consumers’ demand 
for online health information, which remains “one of the most important subjects 
that internet users research online” (Fox 2011a). Besides dedicated websites, health- 
related information is increasingly being accessed through blogs and social media. 
According to Fox, the information most commonly searched for within this broad 
category is that referring to diseases and/or medical problems, medical treatment 
and/or medical procedure, or information regarding doctors or other health-care 
professionals (Fox 2011a). The same study has also shown that the vast majority of 
online eHealth consumers consists of people affected by chronic diseases, whose 
primary aim is not only that of broadening the information at their disposal but also 
finding “peers,” that is, people affected by their same condition, with whom they 
can share their experiences and from whom they could receive advice and/or sup-
port.1 Giving rise to distinct forms of “biosociality” (a term coined by renowned 
anthropologist Paul Rabinow (1996) to capture the emergence of new collectivities, 
social networks, and social interactions forming around shared biological—espe-
cially genetic—and medical characteristics), the so-called peer-to-peer health care 
(cf. Chap. 3) is rapidly expanding, in the USA and beyond (Fox 2011b).
By helping acquiring information with respect to health and health-related issues, 
eHealth technologies are said to provide individuals—independently of their liter-
acy and/or economic status—with the opportunity “to become more informed and 
thus better prepared to discuss treatment plans with their physicians” (Czaja et al. 
2013, p. 31; Taha et al. 2009). In particular, by facilitating peer-to-peer interactions 
and by allowing patients to get in touch with medical expert networks and/or patient 
associations, online eHealth technologies contribute to patients’ acquaintance with 
health-related issues, thus promoting their improvement of medical literacy.
What has been just depicted as an emancipatory affordance of online eHealth 
tools may, however, give rise to a number of pitfalls. Firstly, the much too informed 
online individual may become a distrustful patient, unwilling to adhere to medical 
advices provided in conventional face-to-face settings (Czaja et al. 2013). Secondly, 
such individual may equally turn into a consumer of online commercialized prod-
ucts lacking clear medical or preventive benefits without adequate medical over-
sight—something that has been shown to occur, for instance, in the case of unproven 
stem cell therapies as well as Direct-to-Consumer genetic tests (cf., e.g., 
Wallace 2011).
Another criticality ascribed to online eHealth self-management tools concerns 
the way in which online eHealth information is presented and its tools are designed. 
1 Other sets of people who are likely to engage in online searches for people sharing their same 
health concerns include “internet users who are caring for a loved one; internet users who experi-
enced a medical crisis in the past year; and internet users who have experienced a significant 
change in their physical health, such as weight loss or gain, pregnancy, or quitting smoking” (Fox, 
2011b).
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Indeed, despite its promise of improving access to health information, “to date 
many Internet-based health applications have been designed without consideration 
for needs, capabilities, and preferences of user group[s]” (Czaja et al. 2013, p. 31). 
Although it should be recalled that the group of users looking for health information 
online is rather heterogeneous—spanning from adults to older adults, affected by 
chronic as well as nonchronic conditions—these tools and platforms are often 
devised without considering the potential difficulties that users may encounter in 
navigating this information and understanding its content.
To summarize, two main sets of criticalities may be ascribed to eHealth online 
technologies: while the former—distrust toward medical experts, patients-turned- 
consumers without adequate medical oversight—represents a potential negative 
impact of the aforementioned technologies on online consumers, the latter—inade-
quacy of eHealth online tools with respect to target users—questions the appropri-
ateness of technologies themselves to comply with the expectations set forth by 
their deployment.
A fruitful strategy for partially overcoming such issues may be found in the 
notion of patient engagement (cf. Chap. 1), defined as the act of involving patients—
as well as the latter’s availability of being involved—in their health and care pro-
cesses (Gruman et  al. 2010; Hibbard and Mahoney 2010; Clancy 2011; Barello 
et  al. 2012; Menichetti et  al. 2016). In broad terms, engaging patients has been 
considered as a key priority for contemporary health care and a policy objective in 
many countries (Thompson 2007). Besides fostering patients’ capacity to signifi-
cantly impact on the orientation, management, and evaluation of research programs 
concerning their diseases, “patient activation” has been associated with better 
adherence to treatments and improved treatment outcomes (Greene and Hibbard 
2012; Vahdat et al. 2014).
In the context of the eHealth technologies under investigation here, patient 
engagement may lead to the design of technologies that more closely match users’ 
preferences. Indeed, patients have been shown to adopt new technologies “if the 
tools are felt to be relevant to their own health-care problems, are engaging and easy 
to use, and are effective at achieving behaviour change” (Birnbaum et  al. 2015, 
p. 754). As such, “without considering the patient as an active agent in the health-
care environment,” eHealth solutions run the risk “to be substantially ineffective in 
the end” (Triberti and Barello 2016,  p. 151). As a consequence, “user-centered 
design” has been advanced as the “gold standard” for developing the eHealth tools 
of the future (cf. Chap. 9).
In addition, an engaged role from the part of the patients from the very onset of 
technological development can also reduce the risk that perceived harm related to 
technology usage (e.g., uncertainty about privacy rights, or about the management 
of one’s own health data) would negatively influence users’ acceptance at a later 
time. Indeed, despite the initial enthusiasm for eHealth technologies, some evidence 
exists that patients remain skeptical toward technological tools if these do not evolve 
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in line with their changes, renewed attitudes, and needs (Currie et al. 2015; Gaul and 
Ziefle 2009).2
4.2  Monitoring Techniques
A second family of eHealth technologies is the so-called monitoring techniques, 
that is, the set of techniques allowing a continuous observation of one’s own condi-
tion (physiological and physical) performed through body and/or home sensors. 
Monitoring techniques were originally developed for improving health care locally, 
in those contexts in which geographical distances would have precluded regular 
health measures. Additionally, they have been typically devised for monitoring the 
behavior of chronic patients and/or the elderly, while communicating relevant health 
and/or behavioral information in real time to health-care professionals and/or their 
reference family member. Amongst the broad set of monitoring techniques, an 
important difference exists between more conventional monitoring techniques, such 
as telemedicine, and rather new and unconventional monitoring techniques, such as 
those labeled under the rubric of “Ambient Intelligence.” These two sets of monitor-
ing systems differ profoundly not only in terms of their technological capacities and 
impact on patients’ health, but also in terms of ethical threats potentially related to 
their (ab)use.
Telemedicine, which literally means “healing at a distance” (Strehle and Shabde 
2006), has been defined by the World Health Organization (WHO) as “the delivery 
of health-care services, where distance is a critical factor, by all health-care profes-
sionals using information and communication technologies for the exchange of 
valid information for diagnosis, treatment and prevention of disease and injuries, 
research and evaluation, and for the continuing education of health care providers, 
all in the interests of advancing the health of individuals and their communities” 
(WHO 1998). According to this definition, telemedicine comprises sets of tech-
niques aimed at overcoming the obstacles that may arise in providing assistance 
and/or care to a patient, using advanced telecommunication devices able to transmit 
medical information from the patient herself to the healthcare facility and vice 
versa, thus actively contributing to the improvement of health-care services. Despite 
their differences, the WHO has suggested to include, under the label “telemedicine,” 
all those interventions (i) whose aim is to provide clinical support; (ii) which are 
intended to overcome geographical barriers, connecting users who are not in the 
same physical location; (iii) which involve the use of various types of information 
and communication technologies; (iv) whose broad goal is to improve health 
2 Actually, it is noteworthy to point out that the patient who let herself be engaged is neither a rep-
resentative nor an average patient, but she is clearly a more active individual, with a better access 
to health care. Social determinants of health such as income, housing, social environments, and 
education have a real impact not only on health outcomes, but also on the opportunity to become a 
fully engaged patient.
V. Sanchini and L. Marelli
183
 outcomes (Ryu 2012, p.  9). Telemedicine applications are further classified in 
“store- and- forward” (or “asynchronous”) interventions, in those instances in which 
telemedicine involves the exchange of prerecorded data between two or more indi-
viduals at different times, and “real time” (or “synchronous”) interventions, when 
the involved individuals are simultaneously present for immediate exchange of 
information, as in the case of videoconferencing. Moreover, the interaction between 
the individuals involved may occur in the form of exchange between health-care 
professional and patient (“health professional-to-patient”), or between two or more 
health-care professionals (“health professional-to-health professional”) (Ryu 
2012, p. 10).
Traditional eHealth monitoring systems such as telemedicine in its different 
instantiations present several sets of advantages, among which the following are 
also ethically relevant. Firstly (cf. Chap. 4), they may improve health outcomes and 
allow patients to be assisted and/or cured in their home environments, while also 
reducing costs and inconveniences for patients due to prolonged admissions and 
hospital-based commuting. Additionally, they may enable the provision of high- 
quality home services, while prolonging as much as possible patients’ indepen-
dence—thus positively impacting on patients’ quality of life. Thirdly, eHealth 
monitoring systems hold potential for improving health-care professionals’ daily 
activities. Indeed, telemedicine is able to make available to the attending physician 
all the existing information related to the single patient and to send it, for consulting 
purposes, to specialists from all over the world; moreover, it contributes to reduce 
unnecessary administrative work, while at the same time enabling a more secure 
and organized management of information. Finally, by reducing prolonged and/or 
unnecessary hospitalizations, eHealth monitoring systems can also increase the effi-
ciency and productivity of health services (Bauer 2001; Stanberry 2006). Monitoring 
technologies can therefore enable progress in the management and care of the 
chronic patient as well as of the elderly—leading to the identification of potential 
health problems before they become serious (cf. Chap. 5).
However, despite providing high data quality that may help ensure correct pro-
cessing and interpretation of information, as well as the appropriate intervention of 
medical services, serious ethical concerns exist with respect to potential misuse of 
patients’ information. In particular, the use of these technologies is usually accom-
panied with concerns related to informational privacy, that is, regarding what type 
of information is recorded, how it is recorded, and with whom it is shared. This 
appears particularly controversial in case of new and unconventional aforemen-
tioned monitoring systems, such as Ambient Intelligence.
Ambient Intelligence refers to the sets of different physical environments—such 
as homes, offices, meeting rooms, schools, hospitals, control centers, vehicles, tour-
ist attractions, stores, and sports facilities (Ramos et al. 2008)—that “intelligently 
and unobtrusively” interact with people, through a “world of ubiquitous computing 
devices” (Ramos et al. 2008, p. 15), such as micro-computers and different types of 
sensors, in order to systematically monitor the daily activities of the target users. 
Despite referring to different kinds of environments, Ambient Intelligence has been 
bound, in recent literature (Ramos et al. 2008; Cook et al. 2009; Acampora et al. 
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2013), to the presence of some distinctive features: “it is context aware (it makes use 
of information drawn on the here-and-now situation); personalized (it is tailored on 
the individual user’s needs); anticipatory (it develops the capacity of predicting 
user’s needs); adaptive (it is able to modify its own functions/behavior on the basis 
of the user’s habits); ubiquitous (it is embedded and distributed among the environ-
ment); transparent (it is able to function without direct action, nor perception, nor 
knowledge by the human user)” (Triberti and Barello 2016, p. 151).
As embedded in environments structurally and inherently devised to monitor 
human behavior, Ambient Intelligence raises at least three kinds of ethical concerns 
with respect to the target user that need to be considered and properly handled.
Firstly, and as already mentioned, the most relevant ethical concern regards infor-
mational privacy. In the case of Ambient Intelligence, as some scholars have 
noticed, almost any kind of data gathering may potentially represent a privacy 
violation. As an example, the use of image processing through video cameras as 
a potential kind of sensor has been deemed “a controversial area” (Cook et al. 
2009, p. 287), as cameras filming users in specific conditions and/or while per-
forming certain activities may appear as a violation of the individual personal 
sphere. In line with this observation, it is interesting to notice that, according to 
empirical evidence collected (Beach et al. 2009, 2010), requests for greater con-
fidentiality exist with respect to information acquired in certain specific house 
areas (such as the bathroom and bedroom) where privacy violation is intuitively 
perceived as more serious by the side of the target user. Besides implementation 
of the GDPR’s accountability-based approach described in the first part of this 
chapter, solutions exist in order to limit privacy concerns, such as limiting cam-
eras registration to specific environments and in space obscuring bodies, but, as 
it has been pointed out, even seemingly innocuous ones such as walking patterns 
and eating habits can be combined to provide very detailed information on a 
person’s identify and lifestyle (Bohn et al. 2005).
Secondly, and relatedly, the so-called big brother syndrome (Dwight and Feigelson 
2000), that is, the negative feeling of being observed by the technology itself, 
may have an impact on personal behavior, inasmuch as individuals may modify 
their behaviors precisely as a consequence of knowing of being registered, thus 
limiting de facto their personal liberties. Ambient Intelligence technologies, in 
this respect, may shape individual behaviors, leading to the self-disciplining of 
the individual.
Finally, concerns related to the actual validity of users’ authorization toward these 
techniques have been raised. Indeed, despite the rhetoric of transparency with 
respect to Ambient Intelligence systems, several doubts exist with respect to the 
validity of target users’ consent, as the latter may be based on user’s misconcep-
tions and/or partial misrepresentation of the system and its functioning, based 
upon preliminary explanations that may hardly convene adequate representa-
tions of the system in which the user will be embedded. In addition to enriching 
the oral explanation of Ambient Intelligence systems with videos and figurative 
representations, a possible solution may be that of envisaging a “multistep 
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 consent” to be provided at different time points, not only before, but also in 
between distinct set up phases of the system.
4.3  New and Unconventional eHealth Technologies
In addition to the aforementioned and more conventional eHealth technologies, a 
set of novel and less conventional eHealth technologies has recently emerged and/
or developed in the health and medical domains, raising distinct sets of ethical issues.
Artificial Intelligence. A first domain in which eHealth technologies are rapidly 
evolving revolves around the adoption of Artificial Intelligence (AI) within the 
medical context and, in particular, as a clinical care tool. Inasmuch as some areas 
of medicine, such as radiology, pathology, and dermatology, find themselves 
dealing with increasing amount of data, they are likely to adopt AI tools, in order 
to “extract fine information about issues invisible to the human eye and process 
those data quickly and accurately” (Jha and Topol 2016). In this context, such 
emerging technology may run the risk of impacting on the epistemic and social 
authority of physicians and medical specialists. At the same time, however, the 
idea that the AI will inevitably displace medical expertise and reconfigure 
entrenched epistemic and social relations between doctors and patients seems 
largely far-fetched. As analysts have noted, “given that artificial intelligence has 
a 50-year history of promising to revolutionize medicine and failing to do so, it 
is important to avoid overinterpreting these new results” (Beam and Kohane 
2016, p. E2).
Virtual Reality. Virtual reality (or environment) is defined as a “spatial (usually 3D) 
world seen from a first person’s point of view” where the view “is under the real- 
time control of the user” (Lányi 2006, 87). In recent years, virtual reality has 
rapidly emerged as a promising technology in the health-care domain, in particu-
lar in diverse sensitive settings such as aged care, clinical rehabilitation, and 
mental health (Valmaggia et al. 2016; Moyle et al. 2017). With regard to this 
latter domain, some scholars have recently observed that, because of its power to 
simulate the environmental conditions that trigger problems, it may be used to 
treat phobias, posttraumatic stress disorders, and to induce empathy and other 
altruistic-based behaviors in patients (Freeman et al. 2017). Moreover, inasmuch 
as it is an immersive technology, virtual reality has the potential to be introduced 
effectively in pain management, distracting chronic patients from their experi-
ence of pain (Gromala et al. 2015). In addition to some practical challenges in 
implementing virtual reality technologies, for example, the costs of implementa-
tion and the need for one-on-one assistance from care staff (Waycott et al. 2018), 
some ethical challenges may also arise. First, due to the novelty of the technol-
ogy itself, possible system failures may happen, which may be interpreted by 
vulnerable participants as signs of failure on their part (Waycott et  al. 2018, 
p.  412). Secondly, and more importantly, inasmuch as virtual reality involves 
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being immersed in an alternate reality, it may amplify people’s experience, creat-
ing experiences of confusions and even trauma, which may be particularly prob-
lematic for those vulnerable categories of individuals for which these techniques 
are deployed (Vines et al. 2017).
Virtual Worlds. A further development of virtual reality is represented by virtual 
worlds, consisting of technologies devised so as to provide users with the possi-
bility to share the experience of an interactive virtual environment through the 
creation, customization, and use of avatars (Morie and Chance 2011), thus com-
bining the advantages of virtual realities environments with the connectivity 
offered by social networks. Despite their potential impressive impact in health 
care, particularly as tools promoting a high level of education for health-care 
professionals, some doubts have been raised with respect to the involvement of 
patients in these settings. Indeed, inasmuch as the virtual worlds are contexts 
where different individuals are simultaneously present, it is not always possible 
to predict the (ab)use and the impact these systems will have on patients them-
selves (Triberti and Chirico 2017).
5  Conclusions
This contribution has explored the regulatory landscape that, after the entry into 
effect of the GDPR, underpins the unfolding of eHealth research and innovation in 
the EU. As we have observed in the chapter, the GDPR promotes a decentralized 
approach to data protection—centered on the accountability of data controllers. 
Whether this approach will be effective in achieving an effective balance between 
protection of the rights and interests of individuals (data subjects) and the promo-
tion of innovation in the eHealth sector is, at the time of writing, still a major open 
question.
Moreover, this contribution has provided an overview of the societal and ethical 
challenges raised by the development of novel digital technologies, examining some 
important ethical issues that may arise when developing and implementing eHealth 
solutions for health management in the context of medical (e.g., chronic) condi-
tions. In conclusion, we stress that, regarding the psycho-cognitive factors in P5 
eHealth technologies, it is still paramount to develop a set of psychometric instru-
ments able to capture the important psychological characteristics that would allow 
(1) the user (patient)-centered design of devices and interfaces, in order to tailor 
eHealth solutions on users’ needs, and (2) the adequate technology-mediated analy-
sis of patients’ characteristics to be considered within the field of chronic illness 
management.
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